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I Introduction to musculoskeletal infection
Infections of the musculoskeletal system , or orthopaedic infections  are
terms that are used in literature to lump together infections of bone, cartilage
and soft tissues, like muscle, tendon and synovium. Such infections, whether
these occur as a complication of surgery, mechanical injury or due to other
causes, can seriously affect the quality of life of patients. The major impact of
musculoskeletal infection on healthcare, also in terms of financial costs, has
led to great scientific effort to improve the management of these infections,
by studying their nature and strategies for prevention and treatment.
Nevertheless, many strategies related to this complication in orthopaedics can
and need to be further optimized. This is partially due to the fact that medi-
cine is evolving and new techniques and products for medical use have to be
and are constantly being evaluated. But another major factor that makes
research difficult in the field of musculoskeletal infection - of which
osteomyelitis and septic arthritis are the main representatives - is the multi-
factorial aspect of these diseases. Since this thesis is based on studies of the
treatment and prevention of orthopaedic infections, including the diagnostic
approach, it is important to outline the multifactorial aspect of the problem,
that may determine the outcome of such studies. This chapter gives an
overview of several aspects of musculoskeletal infections, and discusses their
relevance and implications for research on the management of these diseases.
I Infection mechanism
The spectrum of associated pathogens of musculoskeletal infection changes
with host age, infection site, entrance route, underlying systemic or local
pathologic conditions and the presence of foreign bodies, such as a joint pros-
thesis and osteosynthesis material. All these host-related factors that may
decrease the ability of the patient s immune system to fight the infection, can
play a role in the initial stages of development of an infection, but can also
determine to some extent the course and outcome of the infection. A variety
of characteristics of the microorganisms are known to act/counteract with
these host factors. These include the genetically driven assembly of virulence
substances like adherence receptors and toxins, and the capability to pheno-
2
hoofdstuk 01  07-05-2001  12:44  Pagina 2
typically alter the growth rate.
The response of the musculoskeletal tissues to the presence of these bacteria
can show a great variation, depending on the host and microbial factors men-
tioned above. Some pathogens and infection sites are known to predispose
for a fulminant onset of the infection, resulting eventually in a full-blown
pyogenic infection, such as in the case of Staphylococcus aureus septic arthri-
tis. Other species or even strains of the same species may, in contrast, cause
an indolent osteomyelitis at for instance the site of an orthopaedic implant,
presenting with few clinical or laboratory signs of an inflammatory response
to these pathogens.
The multitude of factors related to the prevention of osteomyelitis reflects the
multifactorial aspect of musculoskeletal infection. To illustrate this, the vari-
ety of risk factors that has been associated with musculoskeletal infection is
discussed below, and the prophylactic measures which can be undertaken to
minimize these risks.
I Risk factors for musculoskeletal infection
The concept of the triad of bacteria, host and wound  can be used to visualize
the relationship between the risk-factors and to differentiate the prophylactic
approach [Hanssen, 1997]. In Table 1, an overview of the many risk factors
for orthopaedic surgical infections as reported in literature is presented, and
categorized by effect on the three components of the triad. Clearly, these
components and factors are closely related to each other and some overlap
exists: Decreased wound healing itself can affect the number of bacteria in a
wound. Malnutrition, diabetes mellitus and rheumatoid arthritis have been
correlated with not only a delayed wound healing, but also with a decrease in
immunocompetence due to lower lymphocyte counts and decreased neu-
trophil function respectively [England, 1990, Gherini, 1993, Jensen, 1982,
Wilson, 1990b]. Both a delayed wound healing and a decrease in immuno-
competence may attribute to a higher risk of infection. Furthermore, ulcers of
the skin and recurrent breakdown of the skin may pose the rheumatoid and
diabetic patient at risk for delayed haematogenous infection after arthroplas-
ty [Papagelopoulos, 1996, Wilson, 1990b]. The relationship between the risk
factors makes it difficult to point out single risk factors and to estimate their
potential to contribute to infection rate. Indeed, some studies could demon-
3
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strate a significant difference among various risk factors, whereas others
could not. Multicenter prospective studies should provide more extensive
data to rationalize our choices in patient care.
Certainly, these studies have underscored the importance of identifying, and,
when possible, eliminating any risk factor for infection in a patient undergo-
ing arthroplasty surgery. However, full proof of the efficacy of some prophy-
lactic measures may be marginal [Gillespie, 1997]. Furthermore, questions of
generalizability of some results remain, and in addition it is difficult to esti-
mate the additional benefit of each prophylactic technique when used in
combination with others. The latter was illustrated by a study of Lidwell et al.
in which he showed that ultraclean air could positively affect the infection
rate after surgery [Lidwell, 1982]. However, these and other authors recog-
nized the lack of randomization on use of antibiotics in that study, and it
appeared that the same effect could be achieved without ultraclean air when
antibiotics were used for infection prophylaxis [Garvin, 1995, Hanssen, 1997,
Lidwell, 1986].
In addition to existing prophylactic measures, the design of new techniques
and materials to optimize infection prophylaxis in orthopaedics is ongoing.
4
Table 1. Summary of risk factors of orthopaedic surgical infection, based on the
Bacteria, host and wound  triad.
Bacteria - factors that influence the number or virulence of bacteria introduced into a wound
Foreign bodies (biomaterials) Joint prosthesis or osteosynthesis material, especially when previously
infected  [Cherney, 1983, Gristina, 1985, Naylor, 1990, Poss, 1984,
Schmalzried, 1992]
Bone graft  [Schutzer, 1988]
Operating room Number and traffic of theatre personnel  [Borst, 1986, Nelson, 1987, Ritter,
1987]
Operation time  [Chan, 1998, Charnley, 1972, Fitzgerald, 1977]
Airflow in theatre  [Brady, 1975, Charnley, 1972, Fitzgerald, 1992, Glynn,
1983, Hanssen, 1994, Lidwell, 1986, Lidwell, 1982, Marotte, 1987, Nelson,
1980, Salvati, 1982b]
Early shaving of the operation site  [Mishriki, 1990, Seropian, 1971]
Permeable surgical dress and drapes  [Blomgren, 1990, French, 1976,
Johnston, 1987, Whyte, 1983]
Use of a suction tip  [Greenough, 1986, Meals, 1978, Strange-Vognsen, 1988]
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For instance, it can be expected that a wider range of antibiotics in various
release systems or carriers will become available in the future. Biodegradable
materials are increasingly used for this purpose. Obviously, studies that evalu-
5
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Continued
Host - factors that influence the host’s capability to response to the infection
Integrity of skin and mucosa distant Vascular catheter  [Friedman, 1988, Wilkins, 1990]
from operation site (bacteremia)
Urinary catheters  [Maderazo, 1988, Michelson, 1988, Ritter, 1989, Stamm,
1991, Wroblewski, 1980]
Major dental procedure  [Drangsholt, 1998, Sandhu, 1997, Segreti, 1999,
Thyne, 1991, Waldman, 1997]
Decubitus ulcer  [Deacon, 1996, Wilson, 1990b]
Psoriasis  [Beyer, 1991, Menon, 1983b]
Hospital stay Time in hospital  [Cruse, 1973]
Time on intensive care  [Vincent, 1995]
Systemic disorders or altered general Rheumatoid arthritis  [Deacon, 1996, Poss, 1984, Wilson, 1990b]
state of health
Insulin-dependent (type 1) diabetes mellitus  [England, 1990, Menon, 1983a,
Papagelopoulos, 1996]
Hemophilia  [Goldberg, 1981, Lachiewicz, 1996, Luck, 1989, McCollough,
1979]
Malnourishment  [Gherini, 1993, Greene, 1991, Jensen, 1982, Puskarich,
1990, Smith, 1991] 
Use of immunosuppressive drugs  [Wilson, 1990b]
Obesity  [Stern, 1990, Wilson, 1990b]
Allogeneic blood transfusion  [Fernandez, 1992, Murphy, 1991]
Wound - Factors that influence wound healing and viability
Compromized bone or soft tissue Devascularization, dead space and hematoma  [Fitzgerald, 1977, Glynn,
1983, Nelson, 1987, Nelson, 1980]
Previous operation on the affected joint  [Fitzgerald, 1977, Nelson, 1980,
Rand, 1989, Surin, 1983, Windsor, 1990]
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ate release characteristics of antibiotic-loaded carriers should reveal their
potency to be of use in infection management. Likewise, the biocompatibility
of such new (biodegradable) implants, determined by their composition, is
important. New or modified antibiotic-containing implants, to be used in the
management of (orthopaedic) infection, should indeed be non-toxic and non-
allergenic. In addition, inflammatory components should not be present,
which may otherwise influence the healing of tissue defects, especially in
areas of infection. Thus, not only the release characteristics and eventually
the degradation rate of an antibiotic-loaded carrier, but also its biocompati-
bility are important aspects in the design of such an implant [Garvin, 1994].
Subsequently, in vitro and experimental efficacy tests may demonstrate their
bacterial inhibitory properties. Finally, some of these implants will be studied
clinically, and approved for clinical use in the management of orthopaedic
infection. Continuous monitoring of such biomaterials, or any other method
used clinically for the management of orthopaedic infection, is vital for an
adequate evaluation of their efficacy and safety. Governmental bodies like the
Federal Drug Agency and (inter-)national societies for research in
orthopaedic or biomaterials contribute to this process of objective evaluation
of new and existing techniques. Orthopaedic surgeons play an important role
in this process because they can judge clinical outcome in their patients.
Especially when they participate in ventures such as the Scandinavian or
other arthroplasty registries, clinical data become available for objective eval-
uation [Berry, 1997, Fender, 1997, Havelin, 2000, Herberts, 2000, Malchau,
2000, Paavolainen, 1991, Rothwell, 1999, Sarungi, 2000]. However, as a
consequence of the many variables in orthopaedic infections and related risk
factors, the approach to infection prophylaxis in orthopaedics is and should
be multidisciplinary. Not only the orthopaedic surgeon is involved in this
process, but also other medical specialties, theatre staff, personnel on the
intensive care and hospital wards, the microbiologist, hospital committees for
hygiene and infection prevention, and the general practitioner. As a result of
an increased awareness of risk factors and development of new prophylactic
techniques, infection rates should decrease. Indeed, recent data show that
infection incidence has decreased over the years, presumably due to the
many prophylactic measures that are now widely applied [Malchau, 2000].
The latest annual report of the Swedish National Hip Arthroplasty Registry
states that the 10-years cumulative frequency of revision due to infection of
total hip prostheses inserted in 1979 was 0.8-0.9%, and this had decreased to
0.3% for hip prostheses that were implanted in 1988 [Malchau, 2000].
6
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I Outline of this thesis
This thesis represents the multifactorial approach to the clinical problem of
musculoskeletal infection. Management of this infection does not only
include prevention, but also deals with difficulties in diagnosis and treatment
of the disease. Certainly, the fact that many diagnostic modalities and treat-
ment options for musculoskeletal infection exist, indicates that none of these
are fully accurate or effective in all patients [Elgazzar, 1995]. Therefore, the
search for new and better tools for diagnosis and treatment of orthopaedic
infection is ongoing, just as it is for prophylaxis of it. In part I of this thesis,
new techniques have been investigated for the diagnosis of musculoskeletal
infection. These include the use of radiopharmaceuticals for the imaging of
musculoskeletal infection, and a new molecular technique, which might
enable the detection of bacterial DNA in tissue samples of patients, suspected
for infection. Part II of this thesis consists of experimental studies investigat-
ing a new pre-mixed tobramycin-containing bone cement. The in vivo release
of tobramycin and the efficacy of this cement in prevention and treatment of
prosthesis-related infection were studied.
7
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Introduction to new diagnostic
techniques
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I Introduction
The management of infection in orthopaedics, such as osteomyelitis, soft tis-
sue infection, infectious arthritis and arthroplasty infection, remains a chal-
lenging clinical problem. A high index of suspicion, early intervention, and
aggressive treatment are important in order to clear the infection [Tetsworth,
1999]. Early intervention requires an early diagnosis of infection. Aggressive
treatment can not be complete without the full knowledge of the pathogen,
severity and extent of the infectious process. Especially in chronic
osteomyelitis and in arthroplasty infection, problems in the diagnosis of
infection are frequently encountered. In contrast to a full-blown acute
osteomyelitis, symptoms and signs of infection may be minimal in chronic
osteomyelitis. Becker described how the pathogenesis of diabetic foot can
contribute to difficulties in diagnosis of chronic osteomyelitis in these
patients [Becker, 1999]:  Pedal osteomyelitis in the diabetic foot often results
from continuous spread from skin ulcers, secondary to neuropathy and
macroangiopathy. Inhibition of bone resorption, periosteal new bone forma-
tion, and healing due to ischemia may lead to atypical changes of
osteomyelitis. The sequela osteomyelitic bone resorption, pathological frac-
ture, diminished intraosseous blood vascularity, and osteonecrosis can pre-
cede chronic osteomyelitis in the diabetic foot. Chronic pedal osteomyelitis
combined with the absence of pain and proprioceptive sensation leads to
pathologic fractures, bone sclerosis and subluxations, findings that can mimic
pure neuroarthropathy. The absence of fever, bacteremia and elevated ery-
throcyte sedimentation rate may hamper the early diagnosis of diabetic pedal
osteomyelitis even more. Undiagnosed, the ongoing osteomyelitic process in
these and other patients with chronic osteomyelitis can result in considerable
disability and morbidity.
In arthroplasty, two major complications - loosening and infection of the
implant - can sometimes be difficult to distinguish. Both can present them-
selves clinically as painful joints, with equivocal or nonconclusive follow-up.
Furthermore, growth characteristics of bacteria embedded on the surface of a
foreign body can change, contributing even more to the insidious nature of
implant infections. When the causative organism cannot be detected and/or
the spread of infection cannot be visualized, the surgical and/or antibiotic
treatment cannot be facilitated and optimized. It can therefore be concluded
that diagnosis of bone and prosthesis infections remains a difficult challenge,
and many have focused and will focus on improvement of diagnosis. During
10
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the last years, improvements have been made in the use of nuclear medicine
techniques, and in molecular biological techniques. In part I of this thesis,
some of these new modalities in nuclear medicine for the imaging of
orthopaedic infections were explored, as well as new tools in molecular biolo-
gy for the detection of the pathogens of these infections.
I Scintigraphic imaging of musculoskeletal
infection
For imaging of either implant related or other forms of musculoskeletal infec-
tions, different diagnostic modalities are available, including conventional
radiography, computed tomography, magnetic resonance imaging and scinti-
graphic techniques. On radiographs, local nonspecific (swelling, thickening or
elevation of the periosteal and cortical erosions) and more specific (sequester,
Brodie s abscess) bone and soft tissue responses to infection can be seen. It
can take more than two weeks for these changes to become visible on radi-
ographs [Al-Sheikh, 1985, Norden, 1980]. Anatomic changes due to the
infection have to be present as well in order to be visualized by computed
tomography. A previously distorted anatomy may hinder image interpreta-
tion. The direction of the CT-plane is usually transversal, which makes it diffi-
cult to determine the extent of the infection [Wegener, 1991]. Magnetic reso-
nance imaging can depict infection due to the shift of water from local
edema, hyperemia and ischemia. The high resolution that can be obtained
using this technique facilitates differentiation of bone and soft tissue, and
subsequently of osteomyelitis and soft tissue infection [Boutin, 1998, Totty,
1989]. However, artifacts due to ferromagnetic properties of implants can
hamper MRI image interpretation [Wegener, 1991]. This is, of course, partic-
ularly relevant in diagnosis of prosthesis related infections.
Radioisotopes play an important role in the imaging of infectious and nonin-
fectious disorders in orthopaedics, because radioisotopes or radiolabeled
compounds can detect alterations in physiologic activity of tissues. Gamma
cameras are used to detect emitted gamma irradiation of intravenously or, for
some indications, intraarticularly injected radiopharmaceuticals. Whole body
images can be obtained, which might detect a remote focus of arthroplasty
infection or can be useful in screening purposes like in fever of unknown ori-
gin (FUO). Spot images provide better resolution for depicting focal sites of
11
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infection. Different radiopharmaceutical have been developed that can be
used for imaging musculoskeletal infection (Table 1).
In 1971, technetium-(99mTc)-labeled phosphate complexes were introduced
as an agent for skeletal imaging [Subramanian, 1971]. Nowadays, methylene
diphosphonate (MDP) or hydroxymethane diphosphonates (HMDP) are used
for the bone scan. The mechanism of localization of these complexes is proba-
bly driven by the absorption of the phosphonate complex to the bony crystal
surface and subsequent slow transport into the bone. Uptake of these
radionuclides is partially dependent on blood flow, however increased bone
turnover like in fracture or osteomyelitis is thought to be the most important
factor in the uptake process [Schneider, 1999]. The radiopharmaceutical is
excreted via the urine. Bone scans can be acquired at subsequent time points
after intravenous injection of 99mTc-labeled diphosphonate in a 3- or 4-phase
imaging procedure. A series of images obtained in the first phase, one to two
minutes after injection gives information about blood flow and vascularity of
the lesion. Accumulation of the radionuclide in the extravascular space can
be visualized on the blood pool scan in the second phase early (few minutes)
after the dynamic flow scan. The third phase of the bone scan includes static
images obtained from different directions, 2 to 4 hours after injection, and
shows uptake of the 99mTc-compound by the bone. Eventually, the bone scan
can be completed by a fourth stage done 24 hours after injection, which
might improve target to background ratio. Three-phase bone scanning with
99mTc-methylene diphosphonate (MDP) is an excellent tool for the initial
12
Table 1. Radiopharmaceuticals for scintigraphy in musculoskeletal infection
Vehicle Radionuclide
Methylene diphosphonate 99mTc
No vehicle 67Ga-citrate 
Leukocytes 99mTc or 111In
Nonspecific human IgG antibody 99mTc or 111In
Antigranulocyte monoclonal IgG antibody 99mTc
Antigranulocyte Fab’ antibody fragment 99mTc
Deoxyglucose 18F
Liposomes 99mTc
Ciprofloxacin analogue 99mTc
Antimicrobial peptide 99mTc
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evaluation of bone infection because of its high sensitivity [Elgazzar, 1995].
The three-phase bone scan can be used to differentiate between soft tissue
infection and osteomyelitis. Osteomyelitis can manifest itself with increased
accumulation due to hyperemia and increased vascular permeability on the
first two images, and, in contrast to soft tissue infection, also with delayed
uptake on the 2-4 hours image [Wegener, 1991]. The specificity of 99mTc-
MDP to detect osteomyelitis, however, is rather low because high uptake is
seen in any area of increased bone turnover. The specificity of 99mTc-MDP is
clearly limited when infection is suspected in previously fractured bone or
after surgical intervention [Palestro, 1995]. In addition, the bone scan may
be unsuitable for evaluation of installed therapy, as it may remain positive for
months after clinical healing has occurred [Scoles, 1980]. Sequential 99mTc-
MDP and gallium-(67Ga)-citrate scintigraphy has been reported to improve
specificity in the diagnosis of chronic osteomyelitis [Palestro, 1994, Tumeh,
1986]. Gallium-67 is an analogue of iron that binds to transferrin in blood
and extravasates at the site of inflammation [Corstens, 1999, Elgazzar,
1999]. It binds strongly to leukocyte lactoferrins and bacterial siderophores
[Tsan, 1985, Wegener, 1991]. After initial excretion by the kidneys, the prin-
ciple route of excretion after 24 hours is the colon [Palestro, 1994]. 67Ga-cit-
rate - originally developed for bone scanning purposes - can accumulate in
bone, which hampers image interpretation in patients with osteomyelitis
[Palestro, 1994, Schelstraete, 1992]. Sequential 99mTc-MDP and 67Ga-citrate
scintigraphy has its drawbacks too, especially in patients with sites of
increased bone turnover after violation of the bone [Elgazzar, 1995, Palestro,
1995, Sammak, 1999]. 67Ga-citrate imaging with single photon emission
computed tomography (SPECT) has recently been reported to offer identical
information as that obtained by dual-tracer imaging in patients with spinal
osteomyelitis, suggesting that costs and imaging time could be reduced
[Love, 2000].
The use of indium-(111In)-labeled leukocytes is nowadays, more than twenty
years after it was first reported for clinical application, still considered the
gold standard for imaging of infection and inflammation [Corstens, 1999,
Thakur, 1977]. However, it requires a relatively cumbersome preparation of
labeled autologous leukocytes, which includes the withdrawal and handling
of blood. Typically, an image is acquired at 24 hours following injection,
which will show normal accumulation in liver, spleen and bone marrow
[Sammak, 1999, Wegener, 1991]. Inflammatory or infectious foci attract cir-
culating leukocytes. The role of 111In-leukocytes in the diagnosis of chronic
osteomyelitis or prosthesis infection has been debated, because the radiola-
13
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beled leukocytes are mostly polymorphonuclear [Elgazzar, 1999, Oyen,
1991a]. Whereas some authors found only minimal uptake of labeled leuko-
cytes in chronic, low grade infection, others consider the technique to be the
method of choice when bone scanning is equivocal [Elgazzar, 1995, Johnson,
1988, Propst-Proctor, 1982, Schauwecker, 1989]. To differentiate normal
uptake of labeled leukocytes in marrow from pathologic uptake in infection,
combined scintigraphy with labeled leukocytes and marrow tracers like
99mTc-labeled sulfur-colloid is often necessary [Palestro, 1990, Sammak,
1999]. Unwanted red marrow uptake has also been reported when 99mTc is
used as the radionuclide in leukocyte scintigraphy [Wegener, 1991].
However, 99mTc linked via hexamethylpropylene amine oxime (HMPAO) to
leukocytes, offers several advantages over 111In-leukocytes, such as cost,
availability and dosimetry [Corstens, 1999, Sammak, 1999]. A retrospective
study on imaging of bone and joint infection in 116 patients suggested that
99mTc-HMPAO-leukocytes scintigraphy gives results comparable to those
obtained with 111In-leukocytes [Devillers, 1995]. In contrast with the in vitro
radiolabeling of leukocytes, granulocytes can also be radioactively tagged in
vivo, using a radiolabeled antigranulocyte monoclonal antibody or its Fab
fragment. The latter techniques (using technetium-99m as the radionuclide)
might improve sensitivity for infection compared to the white blood cell scan
[Hakki, 1997, Reuland, 1991]. Rapid imaging within several hours after
injection has been reported to be possible with the 99mTc-labeled antibody
fragment (known as LeukoScan), in contrast to whole antibody scintigraphy
[Becker, 1999, Becker, 1996]. False-negative imaging of LeukoScan has been
reported in patients with chronic osteomyelitis, an involucrum-like formation
of a sheath of sclerotic new bone around the infected bone, and leukopenia in
an HIV positive patient [Becker, 1996, Hakki, 1997]. Nonspecific, antigen
unrelated uptake of antibody due to increase vascular permeability might
account for false positive LeukoScan results. This is for instance seen after
loosening of a prosthesis, fractured bone and periprosthetic calcification
[Becker, 1996, Hakki, 1997]. Again, nonpathological LeukoScan uptake in
bone marrow islands might be excluded with sequential 99mTc-labeled sulfur-
colloid scanning [Becker, 1996, Palestro, 1991b].
Positron emission tomography (PET) with fluor-18-deoxyglucose (18FDG) can
be used for scintigraphic imaging of cancer, but also for detection of inflam-
matory and infectious processes. Increased glucose metabolism in inflamma-
tory cells account for the accumulation of 18FDG in the latter. Zhuang et al.
showed increased accumulation of 18FDG in chronic osteomyelitis on the PET
scan, and these authors claimed that this technique was likely to be more
14
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cost-effective than labeled leukocyte scintigraphy for this indication [Zhuang,
2000]. However, other sites of musculoskeletal inflammation like postsurgical
inflammatory changes have been shown to cause false-positive results in
18FDG-PET scans for as long as 6 months after the operation.
In view of the problems with existing radiopharmaceuticals, new radiophar-
maceuticals have been proposed for imaging of infection such as radiolabeled
nonspecific human immunoglobulin (IgG) and radiolabeled liposomes. IgG is
a large protein that accumulates in inflammatory tissue by virtue of increased
vascular permeability [Rubin, 1994]. Several studies suggest the utility of
111In-IgG scintigraphy for the detection of various types of focal infection,
including those located in the bone or joints [Oyen, 1992b, Oyen, 1992d,
Rubin, 1989]. Preliminary data suggested that this imaging modality is very
useful in the detection of infected arthroplasties [Oyen, 1991b]. Therefore,
we evaluated in Chapter 3 the efficacy of 111In-IgG scintigraphy to detect
musculoskeletal infection.
Radiolabeled liposomes (artificial phospholipid vesicles) can also be used for
imaging of infection [Boerman, 1995, Goins, 1993, Oyen, 1996a]. Studies
suggested that locally enhanced vascular permeability and a local uptake that
is driven by high concentration of liposomes, contribute to the mechanism of
accumulation of liposomes [Awasthi, 1998, Laverman, 2000, Oyen, 1996b].
Long-circulating characteristics of currently developed liposomes prevent
these from rapid clearance by the reticuloendothelial system [Bakker-
Woudenberg, 1993, Woodle, 1992]. These so-called sterically stabilized lipo-
somes, coated with polyethyleneglycol (PEG) and radiolabeled with 111In or
99mTc, showed favorable performance compared to routine agents in various
experimental models of acute infection [Boerman, 1995, Oyen, 1996a]. A
recent clinical study suggested better visualization of musculoskeletal infec-
tion with 99mTc-labeled PEG liposomes, compared with 111In-IgG [Dams,
2000]. This was attributed to the smaller size of IgG that would result in less
retention of the molecule at the site of the infection. A new 99mTc-labeling
method, using hydrazinonicotinamide (HYNIC) as the chelator, was recently
shown to improve the in vivo and in vitro characteristics of radiolabeled PEG-
liposomes as compared to the conventional 99mTc-HMPAO labeling method
[Laverman, 1999]. Nonspecific human immunoglobulin (IgG) can also be
labeled with 99mTc, which is to be preferred over the use of the 111In radionu-
clide, because of better imaging properties and lower radiation dose. Dams et
al. recently showed that 99mTc-HYNIC-IgG performed equally well as 111In-
IgG in patients with non-acute infection, including some patients with chron-
ic osteomyelitis [Dams, 1998a].
15
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In Chapter 4, the performance of 99mTc-HYNIC-PEG-liposomes and 99mTc-
HYNIC-IgG to detect chronic osteomyelitis was evaluated in a rabbit model.
These agents were compared with 99mTc-MDP, 67Ga-citrate and 111In-granulo-
cytes.
Technetium-99m-labeled ciprofloxacin derivate (Infecton) and antimicrobial
peptides are other examples of newly develop radiopharmaceuticals, which
can be used for the imaging of musculoskeletal infection [Vinjamuri, 1996,
Welling, 2000]. Supposedly, these substances bind preferentially to bacteria
over host cells, thereby distinguishing sterile inflammation from infection.
As molecular insights in medicine are expanding, it is tempting to speculate
about the role DNA based techniques in nuclear medicine in the next future.
Antisense oligonucleotides have been used for the imaging of cancer
[Hildebrandt, 1996, Tavitian, 1998]. In theory, a parallel can be drawn to the
imaging of bacterial infections, when such antisense oligonucleotides are
directed against specific bacterial gene sequences. Stability, biodistribution
and intracellular uptake of oligonucleotide probes might pose major draw-
backs for such application [Hildebrandt, 1996].
I Molecular techniques for diagnosis of muscu-
loskeletal infection
Not only the imaging of the infectious process can be met with difficulties;
also the detection and identification of the pathogen of musculoskeletal infec-
tion can be difficult and/or laborious. Rapid identification, isolation and sub-
sequent determination of antimicrobial susceptibility are particularly impor-
tant for the tailoring of adequate antimicrobial therapy. However,
conventional methods that can identify pathogens of infection have their lim-
itations. Speedy screening methods like Gram staining or acid fast staining
characterize microorganisms by their appearance, but their accuracy is low
[Krogstad, 1989]. Culture is an important tool for identification of microor-
ganisms and allows for further sensitivity studies. Nevertheless, some short-
comings of culture are recognized that can decrease the chance of successful
outcome of all kinds of infection, including musculoskeletal ones [Hoeffel,
1999]. These shortcomings concern the diagnostic delay and sensitivity of
culture. Some bacterial species are easily cultured in three days, but especial-
ly culture of anaerobic and slow growing organisms like mycobacteria can be
16
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delayed for 2-8 weeks [Krogstad, 1989]. Not infrequently, previous or concur-
rent antimicrobial treatment in patients with an orthopaedic implant or
chronic osteomyelitis disturbs the outcome of microbiology testing. In addi-
tion, the capability of some bacterial species to change their phenotype and
adapt to the microenvironment on the surface of a foreign body may hamper
full recovery of all isolates [Gristina, 1985]. Orthopaedic infections are often
associated with foreign bodies or biomaterials, like joint prostheses, osteosyn-
thesis-hardware or allografts [Musher, 1977]. The local release of antibiotics
may further enhance the production of so called small colony variants of bac-
terial strains in polymer associated orthopaedic infections, as shown by von
Eiff et al. [von Eiff, 1997]. Two decades earlier, Musher et al. had demon-
strated that variant forms of S. aureus emerged after in vitro exposure to gen-
tamicin [Musher, 1977]. Although less virulent than their parent strains,
these variant strains were shown to readily induce infection in experimental
animals. Growth of small colony variant strains can be considerable reduced,
resulting in failure to recognize the bacteria by personnel in the microbiology
laboratory [Proctor, 1995, Roggenkamp, 1998, von Eiff, 1998]. Alternatively,
other specific growth requirements of microorganisms like anaerobic growth
are also difficult to predict. The failure to detect pathogens in revision arthro-
plasty may be the result of this problem, but may also explain some beneficial
effects of antimicrobial therapy in noninfected loosened implants, since it is
likely that some of these patients have unrecognized infected implants
[Espehaug, 1997, Tunney, 1999].
So there is a need for detection techniques, which can bypass these draw-
backs in the diagnosis of orthopaedic infections. This might be accomplished
with new molecular tools that have been advocated for and are currently
under investigation [Garvin, 1995, Hoeffel, 1999, Mariani, 1996, Mariani,
1998, Rantakokko-Jalava, 2000, Tunney, 1999]. These techniques are aimed
to detect (amplified) bacterial DNA directly, independently of specific growth
characteristics of bacteria. Commonly, most procedures involve polymerase
chain reaction (PCR) to amplify DNA. PCR, first described by Mullis et al. in
1986, is based on the repetition of a 3-step process: [Loutit, 1995, Mullis,
1986, Mullis, 1987]. (1) denaturing double-stranded DNA into single-strand-
ed DNA by heating the sample; (2) annealing primers (specific synthetic
oligonucleotides that determine which part of the gene is amplified) by cool-
ing the sample; and (3) extension of the primers complementary to the sin-
gle-stranded DNA templates by the DNA polymerase enzyme, thereby dou-
bling the amount of specific DNA present. Repetition of these steps enables
PCR to copy one piece of DNA one million times in only 3 hours. 
17
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In Chapter 5, the development and preliminary clinical results of a new
technique for the identification of bacterial PCR products is described. This
technique, reverse line blot hybridization (RLB), uses different oligonu-
cleotide probes attached on a membrane to screen for reactivity on clinical
specimens after a broad-range PCR on the gene encoding for the 16S-subunit
of ribosomal RNA (16S rRNA). Broad-range primers in 16S rRNA PCR are
directed against the two ends of a large part (consisting of about 550 base
pairs) of the 16S rRNA gene. PCR with these primers will typically result in
amplification of only bacterial DNA, since eukaryotic cells do not contain the
16S subunit of rRNA. Within this amplified DNA, several sequences can be
identified that are specific to one or more bacterial species. On the internet,
large databases are available that contain information on DNA sequences.
This information can be used to find the specific sequences, which can be
used to design oligonucleotide probes of about 15-20 base pairs in length for
identification purposes. Since our aim was to use RLB for the diagnosis of
musculoskeletal infections, we designed species-, genus- and group-specific
oligonucleotide probes to identify bacteria that are frequently seen in these
infections. An additional eubacterial probe screens for other possible bacterial
species in the specimen. Accuracy and clinical feasibility of RLB were tested
using intraoperative tissue specimens of orthopaedic patients.
I Aims of Part 1 of this thesis
¥ To evaluate the feasibility of 111In-IgG scintigraphy of musculoskeletal
infections in patients (Chapter 3);
¥ To evaluate the performance of 99mTc-HYNIC-PEG-liposomes and 99mTc-
HYNIC-IgG for scintigraphy in a rabbit model of chronic osteomyelitis as
compared to the agents 99mTc-MDP, 67Ga-citrate and 111In-leukocytes
(Chapter 4);
¥ To develop and evaluate the reverse line blot technique for the diagnosis
of orthopaedic infections (Chapter 5).
18
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The evaluation of musculoskeletal
infections with indium-111-labeled
human IgG scintigraphy
3Chapter
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I Introduction
Infection and inflammation of the musculoskeletal system is a common con-
dition in clinical practice. Adequate diagnostic modalities are necessary for
optimal planning of treatment. A specific diagnostic challenge is encountered
in the group of patients with a painful total joint arthroplasty, since it can be
cumbersome to differentiate between two main complications of total joint
arthroplasty, i.e. loosening and infection of the implant. Both can present
themselves clinically as painful joints, with equivocal or inconclusive follow-
up. In the last decades, a wide variety of procedures have been proposed for
the diagnosis of either implant-related or other types of musculoskeletal
infection. Conventional radiography remains the first-step procedure for this
group of patients. Radiographs form the basis of the diagnostic work-up,
since bone and joint pathology, other than infection, can be identified at rela-
tively low cost without the need for scintigraphic imaging. However, radi-
ographs alone are seldom diagnostic. Therefore, more sophisticated modali-
ties, such as computerized tomography (CT), magnetic resonance imaging
(MRI) and nuclear medicine techniques are used. Focusing on the latter, bone
scanning with technetium-99m (99mTc) diphosphonate is the oldest and most
widely used [Wegener, 1991]. Although these agents have superior sensitivi-
ty, specificity is low [Elgazzar, 1995, Palestro, 1995, Wegener, 1991]. This is
caused by high uptake in areas of increased bone turnover of any cause. This
is particularly a problem for differential diagnosis in violated bone, for exam-
ple after arthroplasty or surgery. Similar problems have been reported for gal-
lium-67 (67Ga) citrate scintigraphy [Elgazzar, 1995, Palestro, 1994]. Labeled
leukocyte scintigraphy is currently the most commonly used scintigraphic
technique for evaluation of infectious and inflammatory disease, especially
when combined with bone marrow seeking tracers, like 99mTc-labeled sulfur-
colloid, in areas where normal bone marrow uptake may be a confusing fac-
tor in image interpretation [Palestro, 1990]. However, preparation of labeled
leukocytes is relatively cumbersome and requires the handling of patients
blood. Moreover, sensitivity in areas of low-grade infection may be decreased
[Schauwecker, 1989]. In view of the problems with 67Ga and labeled leuko-
cytes, many new agents are currently being evaluated in clinical practice. One
of those agents is indium-111-labeled nonspecific polyclonal human
immunoglobulin G (111In-IgG), a labeled large protein that accumulates in
inflammatory tissue by virtue of increased vascular permeability [Rubin,
1994]. Several studies suggest the utility of 111In-IgG scintigraphy for the
20
hoofdstuk 03  07-05-2001  13:11  Pagina 20
detection of various types of focal infection, including those located in the
bone or joints [Oyen, 1990, Oyen, 1992d, Rubin, 1989]. A preliminary study
of Oyen et al. showed promising results for the detection of arthroplasty
infections [Oyen, 1991b]. In the present study, we evaluated the usefulness
of 111In-IgG scintigraphy in routine clinical practice.
I Materials and methods
Patients
The studies of 243 patients, obtained over a period of four years, were
reviewed. Of those 243 patients, 226 patients (108 male and 118 female;
mean age 54.3 years, with a range of 5-90 years) suspected of 232 possible
foci of infection could be evaluated. Previously published patient data, which
were obtained before patients were recruited for the present study were not
included [Oyen, 1990, Oyen, 1992d]. The patients were categorized on the
basis of the suspected focus: total hip arthroplasty (n=87; 38%), total knee
arthroplasty (n=17; 7%), chronic osteomyelitis (n=43; 18%), diabetic foot
osteomyelitis (n=22; 9%), pseudarthrosis (n=11; 5%), septic arthritis
(n=16; 7%), noninfectious arthritis (n=13; 6%), soft-tissue infection (n=7;
3%) or spondylodiscitis (n=16; 7%). Acute osteomyelitis was defined as evi-
dence of infection for one or several days, chronic osteomyelitis as evidence
of infection for weeks, months or even years.
Radiopharmaceuticals
DTPA-conjugated human nonspecific polyclonal IgG was obtained as a
lyophilized kit containing 2 mg IgG per vial (MacroScint, RW Johnson
Pharmaceutical Research Institute, Spring House, PA). The kit was radiola-
beled with 111In (indium-111 chloride, Mallinckrodt Medical, Petten, The
Netherlands) in a 15-minutes, one-step procedure according to the manufac-
turer s instructions. The radiochemical purity as determined by instant thin
layer chromatography was always higher than 95%. A dose of approximately
2 mg IgG, labeled with 75 MBq 111In was injected intravenously.
Within 1 month of the 111In-IgG scintigraphy, two- or three- phase skeletal
scintigraphy was performed in 135 patients after intravenous injection of
methylene diphosphonate labeled with 600 MBq 99mTc. The maximum time
interval was only considered in chronic cases and only when no invasive
21
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diagnostic or therapeutic interventions were performed. In acute cases, the
studies were all performed within a few days.
Imaging procedure and image interpretation
Scintigraphic imaging was performed as reported earlier [Oyen, 1992d]. In
brief, digital images were obtained with a Siemens Orbiter gammacamera con-
nected to a Scintiview image processor (Siemens Inc., Hoffman Estates, IL).
Indium-111-IgG images were acquired at 4, 18-24 and 42-48 hours postinjec-
tion. All images were interpreted by 3 observers. The observers were not blinded
for pretest clinical information. A definite judgment of the scintigraphic images
was reached before any of the verification procedures was performed. The 111In-
IgG images were interpreted with the corresponding bone scintigraphy, when
available. A 111In-IgG scan was interpreted as positive, if focal, continuously
increasing accumulation could be noted over time. Nonvisualization of the
lesion detected by bone scan and/or plain radiographs, or failure to show
increasing accumulation, was considered to be a negative 111In-IgG scintigraphy
result. A bone scan was considered positive when there was increased activity in
at least two phases (blood pool and late phase) in the area of interest.
Verification
The scintigraphic results were verified by culture, obtained surgically (n=98,
42%) or by puncture (n=43, 19%) or long-term clinical and roentgenological
follow-up (n=91, 39%). The latter was mainly used in patients with negative
diagnostic work-up, including negative scintigraphic imaging.
I Results
The overall infection prevalence was 27% (62 foci). Staphylococcus species
were cultured from 17 foci (38%), Streptococcus species from 13 foci (29%),
Pseudomonas aeruginosa from 3 foci (7%) and a variety of other microorgan-
isms or mixed flora from 12 foci (27%). 
Nineteen patients received antibiotics before 111In-IgG scintigraphy, including
β-lactam antibiotics, (n=17), tetracycline (n=1), and fluorochinolon (n=1).
Twelve scintigrams of these patients were scored true-positive, 5 true-nega-
tive, one false-positive and one false-negative. Table 1 summarizes the results
of 111In-IgG scintigraphy in various patient categories.
22
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Total hip arthroplasty (n=87)
All 21 infected total hip arthroplasties showed increased 111In-IgG uptake on
scintigraphy (Figure 1a-b). None of the 54 hip arthroplasties demonstrating
normal distribution of 111In-IgG were infected. Most (10 of 11) noninfected
cementless hip arthroplasties demonstrating normal 111In-IgG uptake were 
23
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Figure 1. (a) 111In-IgG-scintigram of a 69-year-old man showing focal accumula-
tion (arrow) of the radionuclide 15 month after implantation of a left total hip
arthroplasty (cemented stem, cementless cup). Intraoperative cultures grew
group G β-hemolytic Streptococcus. (b) Plain radiograph showing a small radi-
olucent zone in the calcar region and some scalloping around the stem.
a
b
hoofdstuk 03  07-05-2001  13:11  Pagina 24
25
CHAPTER 3  I  DIAGNOSIS OF MUSCULOSKELETAL INFECTION USING 111IN-IGG SCINTIGRAPHY
implanted 16 months or longer before scintigraphy, whereas cemented hip
arthroplasties were recorded as true-negative as early as 6 weeks after
implantation. Twelve hip arthroplasties were recorded as false-positive,
including 9 cementless implants. Six of the latter had been implanted within
a 14-months period before 111In-IgG scintigraphy. In 6 patients with false-
positive scintigraphy, histological specimens were available and all showed
signs of chronic inflammation near the hip arthroplasty. Other causes of false-
positives included foreign body response after wear of the polyethylene sock-
et (n=1), and periarticular ossification (n=1). 
One patient with increased 111In-IgG uptake on scintigraphy 6 months after
hip arthroplasty still had a wound with signs of inflammation (redness,
induration,) at time of imaging. One month later however, this patient was
free of complaints. In 4 of 7 hip arthroplasties with increased 111In-IgG
uptake located around the neck of the femoral component, no infection was
found (Figure 2a-b).
Total knee arthroplasties (n=17)
All three infected knee arthroplasties showed increased 111In-IgG uptake on
scintigraphy. Seven of 14 noninfected knee arthroplasties were scored false-
positive. In one patient, infection was less likely since 1 month after scintigra-
phy knee pain decreased and the sedimentation rate of erythrocytes dropped
without specific treatment. The positive 111In-IgG scintigraphy in this patient,
performed 7 weeks after arthroplasty, remained unexplained, other than
being caused by the surgical procedure itself. One false-positive result consist-
ed of increased 111In-IgG uptake on scintigraphy 11 months after total knee
arthroplasty, which was caused by calcifications in the knee capsule seen on
radiography. Three false-positive results consisted of scintigrams with clear
focal 111In-IgG accumulation, but the location of this uptake was noted to be
probably caused by noninfectious inflammation of soft tissues rather than
infection located in bone around the arthroplasty itself (Figure 3).
Five false-positive results were scored based on negative cultures from needle
aspirations (n=4) and arthroscopy (n=1). However, in all four available his-
tological specimens signs of inflammation were seen.
Chronic osteomyelitis (n=43)
All 15 patients with proven chronic osteomyelitis showed increased focal
accumulation on 111In-IgG scintigraphy (Figure 4). Two of the 28 foci that
were proven to be noninfected were scored as false-positives. The first patient
suffered from severe decubitus on the lateral side of her right hip. Soft-tissue
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Figure 2. (a) 111In-IgG-scintigram of a 46-year-old woman with a cemented right
total hip arthroplasty, 2 years after implantation. Cultures obtained intraopera-
tively and from puncture grew no bacteria. Focal accumulation of 111In-IgG
due to aseptic inflammation (histology) is seen around the neck of the femoral
component of the arthroplasty (arrow). (b) Plain radiograph showing protru-
sion of the right total hip arthroplasty, a radiolucent zone medial to the stem
of the femoral component and periarticular ossifications.
a
b
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Figure 3. (a) 111In-IgG-scintigram of a 71-year-old woman with a painful swollen
right knee, 1 year after total knee arthroplasty. Puncture showed no infection.
The focal accumulation of 111In-IgG (arrow) was seen to be located in soft-tis-
sues around the arthroplasty and probably caused by aseptic inflammation of
soft tissues. Nevertheless the scintigram was interpreted as false-positive for
infection. (b) Plain radiography showing no radiolucency, only some ossifica-
tions in the soft tissues.
a
b
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cultures grew Escherichia coli and Enterococcus faecalis. Within 1 month, the
wound healed and resection of the head of the hip was not performed. In this
case, it was not possible to differentiate between increased 111In-IgG uptake
in soft tissue or bone. In the second patient, an above-knee amputation was
performed 10 months before scintigraphy due to a late complication of dia-
betes mellitus. 
A fistula at the amputation side existed for several months. Culture of the pus
revealed S. aureus in low counts. No evident signs of osteomyelitis were seen
on plain radiography. Indium-111-IgG scintigraphy was scored as false-posi-
tive because the wound healed within 4 weeks after scintigraphy, 3 weeks
after oral antibiotics only (amoxicillin-clavulanic acid).
28
Figure 4. 111In-IgG-scintigram of a 23-year-old man showing focal accumulation
in his distal left tibia, which was painful and swollen for 7 years.
Intraoperative cultures proved infection (S. aureus), and histological speci-
mens showed chronic active osteomyelitis.
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Diabetic foot osteomyelitis (n=22)
Seventeen foci in patients with a diabetic foot were adequately evaluated
with 111In-IgG scintigraphy: 7 osteomyelitis, 10 no osteomyelitis (normal
scan or soft-tissue inflammation only). Five foci in patients with a diabetic
foot were recorded false-positive. Two of those patients had deep ulcers on
the heel, culture revealed S. aureus and Proteus vulgaris. In the first patient
histological specimens from the ulcer showed no signs of osteomyelitis,
whereas in the other patient the ulcer was healing rapidly 2 weeks after
scintigraphy with oral flucloxacillin (4 g/day). Three false-positive results
were from patients with Charcot joints with recent fractures, who responded
well to conservative treatment.
Pseudarthrosis (n=11)
In only 2 patients, a positive 111In-IgG scintigram could be confirmed as posi-
tive for infection. Surgically obtained cultures proved infection in one patient
with positive 111In-IgG scintigraphy 3 months after removal of osteosynthesis
material from his tibia. In the other patient infection was evident based on a
continuing producing fistula for several months from an internal fixator of
the femur, being 1 year in situ at the time of imaging.
One pseudarthrosis in a tibia with an external fixator placed 16 months before
imaging was true-negative, and subsequently proven by a negative culture.
Eight patients with pseudarthrosis showed false-positive focal accumulation
of 111In-IgG on scintigraphy. Surgically obtained cultures were negative and
no histological evidence for infection was found in these patients. Five out of
8 patients had undergone removal of internal (n=4) or external (n=1) fixa-
tors from femur (n=3) or tibia (n=2), at least 3 months before scintigraphy.
In the remaining 3 patients the following surgical procedures had been per-
formed: implantation of a dynamic hipscrew one year before imaging,
osteotomy of a tibia 5 months and arthrodesis of an ankle 14 months before
scintigraphy, respectively.
Arthritis (n=29)
In 13 out of 29 patients the arthritis consisted of noninfectious inflammation
in one or more joints. This included gout, severe progressive osteoarthritis,
necrosis of the head of the femur, reactive arthritis in response to Crohn s dis-
ease and intestinal infection, paraneoplastic polyarthritis and seronegative
symmetric polyarthritis. Those joints showed an increased accumulation on
111In-IgG scintigraphy, but with a different distribution-pattern compared to
septic arthritis as seen in five other patients. In infectious arthritis, diffuse,
29
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intense uptake is seen in the joint, whereas in sterile arthritis typically the
synovial lining is visualized.
In 2 out of 7 patients with 111In-IgG scintigraphy scored positive for infection
no septic arthritis could be proven ( false-positives ). Histological specimens
from both joints (knee and ankle) showed mild, chronic synovitis. No signs of
infection could be detected in all 9 patients with normal uptake of 111In-IgG
in their joints.
Soft-tissue infection (n=7)
The soft-tissue infections consisted of abscess in the psoas muscle region
(n=2), abscess in the thigh (n=2), abscess in the calf (n=1) and infection in
a Girdlestone-hip (n=2). Six infections were proven by culture and histology
and showed increased 111In-IgG uptake on scintigraphy, including 2 patients
with AIDS and one patient with leukopenia due to chemotherapy. One
Girdlestone-hip with a negative 111In-IgG scintigram was proven to be nonin-
fected by surgically obtained culture.
Spondylodiscitis (n=16)
Spondylodiscitis was proven twice by puncture (lumbar spine), culture
revealed Kingella denitrificans and kingae (Figure 5). Both patients showed
focal 111In-IgG accumulation on scintigraphy. In 13 patients with negative
111In-IgG scintigraphy, no spondylodiscitis was detected by long-term follow-
up. In one patient, blood cultures revealed Brucella species, after which
antibiotic therapy was started, 4 days before scintigraphy. Indium-111-IgG
scintigraphy showed no increased uptake. MRI showed at this time only early
epiduritis, no spondylitis, whereas no signs of infection were seen on CT.
Lumbar puncture revealed an acute infection of the central nervous system.
Doxycycline (1 dd 200 mg) and rifampicine (1 dd 100 mg) was continued for
4 months. Two and 5 weeks later, MRI showed both epiduritis and spondylitis
at L3-L4. Indium-111-IgG scintigraphy was scored as false-negative.
30
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99mTc-MDP bone scintigraphy
The results of 99mTc-MDP bone scintigraphy are summarized in Table 2. In all
but one patient-category, this imaging technique showed an excellent sensi-
tivity. In the patient with false-negative 111In-IgG scintigraphy for spondylitis,
the 99mTc-MDP bone scintigraphy was also false-negative. Specificity of 99mTc-
MDP bone scintigraphy for osteomyelitis is considerable lower than sensitivi-
ty. The 99mTc-MDP bone scintigraphy remained positive up to 7 months after
cemented total hip arthroplasty and 9 months after total knee arthroplasty.
All 17 cementless total hip arthroplasties showed increased 99mTc-MDP on
scintigraphy.
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Figure 5. 111In-IgG-scintigram of a 35-year-old man with low back pain. Focal
111In-IgG accumulation is seen on the ventral side of the vertebrae L3-L4.
Biopsy proved infection (K. denitrificans).
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Table 2. R
esults of 99m
Tc-M
D
P bone scintigraphy for detection of infection in various patients
n 
TP 
FP 
TN 
FN 
Sensitivity
Specificity
PPV
NPV
Total hip arthroplasty
60
13
40
7
0
100%
15%
25%
100%
Total knee arthroplasty
7
2
4
1
0
100%
20%
33%
100%
Chronic osteom
yelitis
26
9
11
6
0
100%
35%
45%
100%
Diabetic foot infection
21
7
13
1
0
100%
7%
35%
100%
Pseudarthrosis
5
1
4
0
0
100%
0%
20%
—
Septic arthritis
9
1
7
1
0
100%
13%
13%
100%
Soft-tissue infection
2
1
0
1
0
100%
100%
100%
100%
Spondylodiscitis
5
2
2
0
1
67%
0%
50%
—
TP =
 true-positive, FP =
 false-positive, TN =
 true-negative, FN =
 false-negative, PPV =
 positive predictive value, NPV =
 negative predictive value
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I Discussion
This study shows that 111In-IgG scintigraphy is a very sensitive imaging tech-
nique for musculoskeletal infection. In most patient-categories, the sensitivity
for infection was optimal, only one patient with spondylitis in the lumbar
spine did not show increased 111In-IgG accumulation on scintigraphy.
Specificity varies between different patient categories. Specificity is high in
patients with total hip arthroplasty, chronic osteomyelitis, arthritis, soft-tissue
infection and spondylodiscitis (82%, 93%, 82%, 100% and 100%, respective-
ly), moderate in patients with total knee arthroplasty and diabetic foot
pathology (50% and 67%), and low in patients with pseudarthrosis (11%).
The high negative predictive value is important for planning, e.g. in prosthe-
sis revision, given the significant extra time and costs of adequate infection
treatment. In all foci scored as false-positive with 111In-IgG scintigraphy, signs
of sterile inflammation were present. This confirms the present concepts of
the mechanism of 111In-IgG accumulation, being not specific for infection,
but occurring in any inflammatory focus [Oyen, 1992b, Oyen, 1992d]. In all
categories, though, specificity of 111In-IgG scintigraphy is higher compared
with 99mTc-MDP scintigraphy. Indium-111-IgG does not, like 99mTc-MDP,
accumulate in metabolic active bone. Therefore, previous pathologic changes
of the bones, like arthroplasty and chronic osteomyelitis, compromise image-
interpretation of 111In-IgG scintigraphy less than that of 99mTc-MDP scintigra-
phy. An additional advantage of all scintigraphic techniques is that, unlike
conventional radiography, CT and MR imaging, altered anatomy itself and
metal parts of arthroplasties or osteosynthesis material do not interfere with
image interpretation.
Comparing cemented with cementless total hip arthroplasties shows that the
period for 111In-IgG scintigraphy to become negative after arthroplasty is con-
siderably longer for cementless total hip arthroplasties. Noninfected cement-
ed hip arthroplasties showed no increase uptake scintigraphy from 6 weeks
after implantation, whereas all but one noninfected cementless hip arthro-
plasties showed false-positive 111In-IgG accumulation on scintigraphy when
recorded within a 14 months period after arthroplasty. Therefore, differentia-
tion between cemented and cementless total hip arthroplasty is important for
image interpretation of 111In-IgG scintigraphy in the first year after arthro-
plasty. Prolonged focal uptake of radiolabels in noninfected cementless hip
arthroplasties has also been shown in other scintigraphic image modalities.
Oswald et al. showed increased 99mTc-MDP and 111In-labeled leukocytes
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uptake up to 2 years after cementless hip arthroplasty [Oswald, 1989,
Oswald, 1990]. In our study, all cementless hip arthroplasties showed focal
accumulation of 99mTc-MDP on scintigraphy. Wegener and Alavi hypothesized
that ingrowth of bone and fibrous tissue in the porous coating of the cement-
less prosthesis caused this prolonged uptake of the tracer on scintigraphy
[Wegener, 1991]. The finding of nonpathologic increased 99mTc-MDP uptake
on bone scintigrams of cemented arthroplasties up to 7 months or even
longer after implantation confirms data in literature [Utz, 1986]. In general,
aseptic loosening of an arthroplasty caused increased uptake of 99mTc-MDP,
but not of 111In-IgG, indicating the usefulness of the latter technique in differ-
ential diagnosis. The main benefit of bone scintigraphy in patients with
arthroplasties is to exclude infection [Elgazzar, 1995]. However, the present
study indicates that this is relevant in only a minority of patients, in whom no
increased accumulation of 99mTc-MDP is observed. Nevertheless, this imaging
technique remains helpful in evaluating infected arthroplasties, because it is
widely available, relatively inexpensive and useful to detect aseptic loosening
and to localize osseous structures, thus facilitating interpretation of 111In-IgG
scintigraphy. Gallium-67 scintigraphy lacks specificity in patients with arthro-
plasties as well, since gallium-67 can accumulate in areas of noninfected
increased bone turnover [Elgazzar, 1995]. Combined bone and 67Ga-scintigra-
phy increases the specificity of either technique, resulting in an accuracy
between 60% and 80% [Palestro, 1995]. To increase specificity of labeled-
leukocyte scintigraphy, combined imaging with 99mTc-labeled sulfur-colloid
has been proposed [Palestro, 1990]. This combined technique can differentiate
between normal and pathologic uptake of labeled leukocytes in marrow.
Reported specificity for this dual-tracer technique ranges between 85% and
100% [Palestro, 1990]. However, dual tracer imaging is less efficient than sin-
gle tracer imaging, like 111In-IgG scintigraphy [Love, 2000, Palestro, 1995].
Periarticular ossification and debris formed by polyethylene socket wear, both
clearly visualized on plain radiography, are other causes of sterile inflamma-
tion after total hip arthroplasty [Oyen, 1992d]. However, in most cases,
image interpretation does not need to be impaired when the 111In-IgG images
are read in conjunction with radiographs. Despite our impression that non-
bone-marrow uptake of 111In-IgG around the neck of the femoral component
of a hip arthroplasty (outside the osseous structures) could be caused by such
noninfectious reaction after socket wear, the scintigraphy was scored positive,
since uptake was clearly elevated. Only 3 of 7 total hip arthroplasties proved
to be infected, when this pattern of uptake was seen.
Due to the high prevalence of noninfectious inflammation after total knee
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arthroplasty, the specificity of 111In-IgG scintigraphy is relatively low in this
patient category. It seems possible to increase this specificity to 71% by differ-
entiating between increased 111In-IgG uptake around the knee arthroplasty
due to noninfectious inflammation of soft tissues (horseshoe shaped, mild
uptake in the suprapatellar bursa above the prosthesis) and uptake due to
infection of the knee arthroplasty itself (diffuse uptake, also located in bone).
Persistent periprosthetic 99mTc-MDP uptake for several years like in total hip
arthroplasties limits the role of this scintigraphic technique in total knee
arthroplasties even more [Rosenthall, 1987]. Little has been reported on
other scintigraphic imaging techniques of knee arthroplasty. One study
reported a 95% accuracy of combined leukocytes and sulfur colloid imaging
in these patients [Palestro, 1991b].
These results are in accordance with a previous study, which showed that
111In-IgG scintigraphy is accurate for evaluating chronic osteomyelitis [Oyen,
1992d]. Controversy exists about the usefulness of leukocyte (neutrophil)-
labeled scintigraphy in diagnosing chronic osteomyelitis, with predominant
infiltration of mononuclear cells [Elgazzar, 1995, Datz, 1994]. As stated
above, previous pathologic changes of bone, like chronic osteomyelitis, do not
reduce specificity of 111In-IgG scintigraphy. Not surprisingly, specificity of
99mTc-MDP scintigraphy is considerably lower in this group of patients (55%
versus 93%).
It was difficult to distinguish infection in soft tissue from osteomyelitis with
111In-IgG scintigraphy, particularly in diabetic foot patients with deep ulcers
on the heel and in patients with decubitus and a deep fistula . Although bone
scanning is essential for localizing osseous structures, separating bone from
soft-tissue infection was not possible in these patients. As indicated by
Ezuddin et al., SPECT imaging may be helpful to differentiate these two con-
ditions [Ezuddin, 1992]. The ability of MRI to separate bone from soft-tissue
infection is a major advantage of this technique for diagnosing osteomyelitis
in diabetic foot patients. Yuh et al., in a study of 24 diabetic foot patients,
found a 100%-specificity of MRI for osteomyelitis [Yuh, 1989]. Indium-111-
labeled leukocyte studies as well reported good results in this patient catego-
ry, although sensitivity and specificity varied from 79% to 100% and from
68% to 95% respectively [Keenan, 1989, Kolindou, 1996, Larcos, 1991]. A
Charcot joint with a recent fracture can be the cause of a false-positive result
of 111In-IgG scintigraphy, as was reported in an earlier study of 16 diabetic
foot patients [Oyen, 1992c].
Specificity of 111In-IgG scintigraphy for infection in pseudarthrosis is very low
(11%). Nepola et al. reported an 82%-specificity (59/70) of combined
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labeled leukocyte and bone scintigraphy for infections of delayed unions or
nonunions [Nepola, 1993]. Their explanation for the false-positive results in
unstable fractures was that these were caused by continued irritation from
motion at the unstable sites. This is probably true as well for the nonspecific
111In-IgG uptake on scintigraphy in pseudarthrosis.
Indium-111-IgG scintigraphy visualizes septic arthritis as well as noninfec-
tious inflammatory pathology of the joints, such as metabolic, reactive and
autoimmune arthritis. As indicated above, in most patients, the pattern of
111In-IgG uptake on scintigraphy is different for septic and noninfectious
inflammatory arthritis. Detailed clinical information is helpful for a correct
image interpretation of 111In-IgG scintigraphy of these patients. An advantage
of the use of this and other radiopharmaceuticals in the detection of (poly-
)arthritis activity is that it allows direct imaging of joints by means of whole-
body scintigraphy and of joints that are difficult to assess clinically or radi-
ographically [de Bois, 1995]. The true-positive-scored 111In-IgG scintigraphy
in this study of three immunocompromized patients (AIDS and leukopenia
due to chemotherapy) with soft-tissue infections confirm that it is possible to
detect infections in these patients with this imaging-technique [Oyen, 1992a,
Rubin, 1994]. Because these patients are very susceptible for infection and
infection often presents atypically in these patients, reliable diagnostic tech-
niques are needed. Some disagreement exists over whether labeled leukocyte
scintigraphy is sensitive enough for this purpose [Datz, 1991, Datz, 1994].
The only case of bone infection missed by 111In-IgG scintigraphy in present
study concerned a patient with early, low-grade spondylodiscitis. Lower sen-
sitivity for osteomyelitis of the spine has been reported in studies using other
scintigraphic techniques as well, including labeled leukocyte and 99mTc-IgG
scintigraphy [Goh, 1990, Palestro, 1991a, Sciuk, 1991, Whalen, 1991].
Modic et al. reported a 96% sensitivity using MRI to detect vertebral
osteomyelitis [Modic, 1985]. MRI is more useful than CT scanning in this
group of patients because it provides better anatomic detail and can differen-
tiate between vertebral and soft-tissue infections [Totty, 1989, Unger, 1988].
In conclusion, 111In-IgG imaging is a sensitive technique for evaluation of
infections and inflammatory bone and joint disease. Specificity is increased
over 99mTc-MDP bone scintigraphy, which in most cases is the first procedure
performed on these patients except for those with recently violated bone.
Specificity of 111In-IgG scintigraphy for infection can be increased even more
when considering particular patterns of increased uptake that are frequently
caused by sterile inflammatory processes (e.g., uptake around the neck of a
total hip arthroplasty or uptake in the synovial lining only).
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Scintigraphic evaluation of
experimental chronic osteomyelitis
4Chapter
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I Introduction
Chronic osteomyelitis is a disabling disease which may have a substantial
impact on the quality of life [Lew, 1997]. Accurate assessment of the severity
and extent of the disease is essential to facilitate and optimize surgical
and/or antibiotic treatment. For this purpose, different diagnostic modalities
are available, including conventional radiographs, CT, MRI and scintigraphic
techniques. Three-phase bone scanning with 99mTc-methylene diphosphonate
(MDP) is an excellent tool for the initial evaluation of bone infection because
of its high sensitivity [Elgazzar, 1995]. Its specificity, however, is rather low
because the agent accumulates in any area of increased bone turnover. This is
particularly a problem when an additional pathological condition is present,
e.g., a fracture or an orthopedic device. In addition, the bone scan may be
unsuitable for evaluation of installed therapy, as it may remain positive for
months after clinical healing has occured [Scoles, 1980]. Sequential 99mTc-
MDP and 67Ga-citrate scintigraphy has been reported to improve specificity in
the diagnosis of chronic osteomyelitis [Palestro, 1994, Tumeh, 1986].
Unfortunately, 67Ga-citrate also accumulates at sites of increased bone
turnover, hampering correct interpretation in patients with violated bone.
The role of 111In-leukocytes in the diagnosis of chronic osteomyelitis is still
controversial. Although some authors found only minimal uptake of labeled
leukocytes in chronic, low grade infection, others consider the technique to
be the method of choice when bone scanning is equivocal [Elgazzar, 1995,
Johnson, 1988, Propst-Proctor, 1982]. Major disadvantages of radiolabeled
leukocytes are the laborious procedure and the need to handle potentially
contaminated blood.
New radiopharmaceuticals proposed for imaging of infection are radiolabeled
nonspecific human immunoglobulin and radiolabeled liposomes. 111In-
immunoglobulin G (IgG) has been extensively studied in patients with mus-
culoskeletal infections, and the agent has shown high accuracy in chronic
osteomyelitis [Oyen, 1992d]. Recently, it has been showed that IgG labeled to
99mTc via hydrazino nicotinamide (99mTc-HYNIC-IgG) performed equally well
as 111In-IgG in patients with non-acute infection, including some patients
with chronic osteomyelitis [Dams, 1998a]. The application of radiolabeled
liposomes for imaging purposes has regained interest with the development
of liposomes with long-circulating characteristics [Bakker-Woudenberg, 1993,
Woodle, 1992]. These so-called sterically stabilized liposomes, coated with
polyethyleneglycol (PEG) and radiolabeled with 111In or 99mTc, showed
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favorable performance compared to routine agents in various experimental
models of acute infection [Boerman, 1995, Oyen, 1996a]. A new 99mTc label-
ing method, using HYNIC as the chelator, was recently introduced and
showed improved in vivo and in vitro characteristics of radiolabeled PEG-lipo-
somes compared with the conventional 99mTc-hexamethyl propylene oxime
labeling method [Laverman, 1999]. However, the performance of radiola-
beled liposomes has not been evaluated in a model of chronic infection. As a
99mTc-label is preferred over 111In, on account of better imaging properties
and lower radiation dose, we evaluated 99mTc-HYNIC-PEG-liposomes and
99mTc-HYNIC-IgG in a rabbit model of chronic osteomyelitis. For comparison,
we included the agents 99mTc-MDP, 67Ga-citrate and 111In-granulocytes.
I Materials and methods
Animal model
Adult female New Zealand White rabbits ranging in weight from 2.8 to 3.2 kg
were caged individually, and fed with regular rabbit diet and water ad libitum.
The experiments described in this paper were carried out in accordance with
the guidelines of the local animal welfare committee. Chronic osteomyelitis
was induced in nine rabbits as described previously with minor modifications
[Nijhof, 1999]. Briefly, the rabbits were anesthetized with a mixture of
halothane, nitrous oxide and oxygen, and placed prone on the operation
table. Both hind legs were shaved, disinfected with a 2% tincture of iodine
and isolated by sterile drapes. The trochanter tertius was exposed bilaterally
and the cortex was penetrated using an air-pressured AO minidrill. The hole
was widened and the femoral canal was reamed with drills and fraises. The
medullary canal was washed with sterile saline solution and suctioned. A
small syringe with a 2-cm long silicone tube (outer diameter 3.0 mm)
attached to it was filled with bone cement (Simplex P; Stryker-Howmedica-
Osteonics, Rutherford, NJ), placed in an applicator gun and approximately
1.2 ml cement was injected gently into the right femoral canal. The left
femoral canal was then inoculated with 106 CFU Staphylococcus aureus, and
closed with bone cement as described above. After polymerization of the
cement, the wounds were cleaned with sterile saline solution and closed.
Clinical examination was performed regularly with special attention to
wound healing, activity level and body temperature and body weight.
39
CHAPTER 4  I  SCINTIGRAPHIC IMAGING OF CHRONIC OSTEOMYELITIS
hoofdstuk 04  07-05-2001  13:26  Pagina 39
Radiopharmaceuticals
99mTc-PEG-HYNIC-liposomes. PEG-HYNIC-liposomes were prepared as
described previously [Laverman, 1999]. The liposomes were composed of the
polyethyleneglycol-2000 derivative of distearoylphosphatidyl-ethanolamine
(PEG-DSPE), partially hydrogenated egg-phosphatidylcholine, cholesterol
and the hydrazino-nicotinamide derivative of distearoylphosphatidyl-ethalon-
amine (HYNIC-DSPE) in a molar ratio of 0.15:1.85:1:0.07. The particle size
distribution was determined by dynamic light scattering with a Malvern 2000
system equipped with a 25-mW Neon laser (Malvern Instruments Ltd,
Malvern, United Kingdom). As a measure of particle size distribution of the
dispersion, the polydispersity index was determined. This index ranges from
0.0 for an entirely monodisperse dispersion to 1.0 for a completely polydis-
perse dispersion. The mean size of the liposome preparations was 85 nm with
a polydispersity index of 0.1. Preformed HYNIC-PEG liposomes were labeled
with 99mTc as previously described [Laverman, 1999]. 99mTc-labeded HYNIC
liposomes have been shown to be highly stable. No significant release of radi-
olabel was observed after incubation with high concentrations of diethylene-
triamine pentaacetic acid, cystine, or glutathione or after 48 hours of incuba-
tion in serum at 37¡C [Laverman, 1999]. The radiochemical purity of the PEG
liposomes was determined using instant thin-layer chromatography (ITLC)
on ITLC-SG strips (Gelman Sciences, Inc., Ann Arbor, MI) with 0.15 mol/l
sodium citrate (pH, 5.0) as the mobile phase and verified by elution on a PD-
10 column. Labeling efficiency exceeded 95%, and the 99mTc-liposomes were
administered without any further purification (37 MBq per rabbit).
99mTc-HYNIC-IgG. HYNIC was synthesized and conjugated to human polyclon-
al IgG (Gammagard; Baxter/Hyland, Lessines, Belgium) according to the
method described by Abrams et al [Abrams, 1990]. The purified HYNIC-con-
jugated IgG was diluted to 4 mg/ml in 0.15 Mol/l acetate (pH, 5.85), steril-
ized by membrane filtration and stored at -20¡C in 0.5-ml aliquots. After
thawing of 0.5 ml of the HYNIC-IgG-conjugate, the conjugate was radiola-
beled with 99mTc by adding 0.1 mg N-[Tris(hydroxymethyl)methyl]glycine
(Fluka, Buchs, Switzerland), 0.01 mg SnSO4 and 400 MBq 
99mTc pertechne-
tate. The mixture was incubated for 15 minutes at room temperature. The
radiochemical purity of the radiolabeled IgG was determined by ITLC on sili-
ca gel strips with 0.15 mol/l sodium acetate (pH, 5.85) as the mobile phase.
High-performance liquid chromatography analysis of the 99mTc-HYNIC-IgG
preparation on a size-exclusion column (Protein Pak 300 SW; Waters
Associates, Milford, MA) revealed that the preparation migrated as a
monomeric 150-kDa peak (<5% aggregrates) as has been described
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[Claessens, 1996]. Labeling efficiency was always >95%. Each rabbit
received a dose of 0.2 mg IgG labeled with approximately 37 MBq 99mTc.
67Ga-citrate. 67Ga-citrate (DRN 3103) was purchased from Mallinckrodt, Inc.
(Petten, The Netherlands). A dose of approximately 18 MBq 67Ga-citrate per
rabbit was injected intravenously.
111mIn-granulocytes. Carotid artery canulation was performed on 2 anes-
thetized donor rabbits. A total of 100 ml of blood was drawn into acid citrate
dextrose-coated tubes. The total leukocyte count of the donor rabbits was 6.4
and 6.8x109/l, respectively, with approximately 50% granulocytes.
Separation of granulocytes was performed according to the method described
by Lillevang et al. with minor modifications [Dams, 1998b, Lillevang, 1994].
As we have shown previously, this separation procedure did not affect granu-
locyte function [Dams, 1998b]. Morphological integrity of the granulocytes
was checked by light microscopy. Granulocyte purity (Giemsa-stained slides)
was >90%. Functional integrity of the labeled granulocytes was checked by
trypan blue staining, indicating that cell viability exceeded 98%. In addition,
granulocyte function was evaluated by in vivo performance, including transit
through the lungs and recovery of labeled granulocytes in the blood. The
labeling efficiency was 86%. A dose of 18 MBq 111In-granulocytes was admin-
istered intravenously.
99mTc-MDP. A kit containing methylenediphosphonate and stannous chloride
was labeled with 99mTc, with a labeling efficiency > 95% as determined by
ITLC. A dose of 18 MBq 99mTc-MDP was administered intravenously.
Study design
All rabbits underwent studies with 99mTc-liposomes, 99mTc-IgG and 99mTc-
MDP to minimize bias caused by variation in the degree of infection. The rel-
atively long half-lives of 111In and 67Ga precluded serial injection. Therefore,
the animals were then randomized into two groups to receive either 67Ga-cit-
rate or 111In-leukocytes. Scintigraphic studies were started 4 weeks after sur-
gery. The radiopharmaceuticals were injected in a fixed order. On day 1 of the
imaging experiment, 99mTc-liposomes were injected. 99mTc-IgG was adminis-
tered on day 2, followed one day later by 99mTc-MDP. On day 4, one group of
rabbits received 111In-granulocytes and the other group 67Ga-citrate. The rab-
bits were slightly sedated by a subcutaneous injection of 0.2 ml Hypnorm
(fentanyl, 0.315 mg/ml and fluanisone, 10 mg/ml; Janssen Pharmaceutical,
Oxford, UK). After sedation, the rabbits were immobilized in a mold and
placed prone on a gamma camera equiped with a parallel-hole, low-energy
collimator (Orbiter, Siemens Medical Systems Inc., Hoffman Estate, IL) for
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the 99mTc studies and a medium-energy collimator for the 67Ga and 111In
studies. Imaging was performed at 5 minutes, 1, 4, 10, 22 and 44 hours after
injection of 111In or 67Ga. Imaging with 99mTc-MDP was performed at 3 min-
utes after injection (blood-pool image), and 1 and 4 hours after injection
(delayed images). Images (250,000 counts/image, except the 22-h postinjec-
tion image [100,000 counts/image]) were obtained and stored in a 256 x
256 matrix.
The scintigraphic results were analyzed quantitatively and qualitatively.
Regions of interest (ROI) were drawn over the infected right femur and
sham-operated left femur, and over the whole body. Additional ROIs over the
lungs were drawn on the scintigrams of rabbits injected with 111In-labeled
granulocytes. Ratios of infected right femur to sham-operated left femur were
calculated. Residual activity at the osteomyelitis site compared to whole-body
activity was also calculated. Counts were corrected for differences in the
numbers of pixels before calculating ratios and percentages. All scans were
also evaluated qualitatively without knowledge of the histopathological out-
come. Scan findings were considered positive if focal accumulation of
radioactivity at the osteomyelitis site exceeded the uptake at the sham-oper-
ated site, or if inhomogeneously enhanced accumulation was present at the
osteomyelitis site.
A separate group of 2 noninfected rabbits was injected with 111In-granulo-
cytes to calculate granulocyte recovery. Serial blood samples were taken at 5,
15, 30 and 45 minutes and 1, 2, 4 and 22 hours after injection.
Assessment
The results of the scintigraphic studies were compared to the results of radio-
logical, microbiological and histopathological examination. Conventional
radiographs were obtained immediately after surgery and before additional
imaging was performed. Unaware of the results of all other procedures,
observers evaluated the radiograms with respect to 3 parameters: periostal
reaction, new bone formation, and extent of bone destruction [Norden,
1980]. Immediately after completion of the scintigraphic studies, the rabbits
were killed with an overdose of sodium phenobarbital. The left and right
femur from all animals were excised and cleaned of tissue debris. The distal
ends were removed and the femur was cut longitudinally in two halves using
a high-speed dental drill with a circular metal saw. The bone cement was
carefully removed. The external surface of the bone specimens was thorough-
ly cleaned with alchohol. One bone specimen of each femur was sent for
microbiological examination. The other bone specimens were fixed in 4%
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buffered formalin and decalcified in 10% ethylenediamine tetraacetic acid.
Longitudinal sections were made, slide-mounted, and stained with hema-
toxylin and eosin. All sections were reviewed with light microscopy with
respect to 4 parameters: necrotic bone, purulent inflammation, periostal new
bone, and granulation tissue. The presence of osteomyelitis was confirmed on
the basis of these histopathological findings.
Statistical analysis
All mean values are given as percentage injected dose per gram (%ID/g) or
ratios – one standard error of the mean (SEM). One-way ANOVA was used to
compare the uptake at the osteomyelitis site and the sham-surgery site for the
different agents. In addition, the repeated-measures ANOVA model was used
to evaluate differences among the imaging times for each agent. The level of
significance was set at p < 0.05.
I Results
One of the 9 rabbits died of a Klebsiella spp. sepsis 2 days after surgery. A sec-
ond rabbit died of unknown causes after performing 99mTc-HYNIC-PEG-lipo-
somes and 99mTc-HYNIC-IgG scintigraphy. In this rabbit, both studies were
positive for infection, confirmed by histopathological analyzis. The following
section refers to the data of the 7 rabbits that completed all studies.
Postoperative radiograms showed no fractures or cement outside the femur.
Of the 7 rabbits, 6 were found to have histopathological evidence of chronic
osteomyelitis in the right femur. In 4 of these rabbits, the infection was con-
fined to the distal femur, whereas in 2 rabbits the infection extended towards
the proximal femur. The right limb of the osteomyelitis-negative rabbit
showed only minimal leukocyte infiltration, which was found to be consistent
with a foreign body reaction. None of the sham-operated left limbs showed
any sign of infection. The microbiological studies of the bone specimens were
concordant with the histopathological findings in 5 of the 6 infected rabbits,
and confirmed the presence of S. aureus infection. In contrast, radiological
findings were abnormal in only two of these rabbits, showing periosteal ele-
vation and new bone formation at the site of the infection. Scintigraphic
analysis was performed on the images of all 7 rabbits. For comparison of the
absolute and relative uptake of the respective agents at the osteomyelitis site,
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only the data of the six infected rabbits were used. A summary of the results
is given in Table 1.
Examples of scintigraphic recordings of the 5 radiopharmaceuticals are
shown in Figure 1. Scintigraphy with 99mTc-HYNIC-PEG-liposomes and 99mTc-
HYNIC-IgG visualized the infected femur in all 6 osteomyelitis-positive rab-
bits. These scintigrams were correctly classified as positive for osteomyelitis.
In contrast, scintigraphy with both 67Ga-citrate and 111In-granulocytes gave
equivocal results each in one infected rabbit. Both rabbits had moderate
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Table 1.
R
esults of scintigraphic, radiological, m
icrobiological and histopathological procedures in
rabbits w
ith chronic osteom
yelitis.
Rabbit
99mTc-MDP
Liposomes
IgG
111In-granulocytes
67Ga citrate
Radiology
Histology
Culture
4 hr p.i.
22 hr p.i.
22 h p.i.
44 h p.i.
44 h p.i.
A
+
+
+
+
N.P.
+
+
+
B
+
+
+
N.P.
+
+
+
+
C
+
+
+
N.P.
+
-
+
+
D
+
+
+
+
N.P.
-
+
+
E
+
+
+
N.P.
±
-
+
+
F
-
+
+
±
N.P.
-
+
-
G
±
+
+
±
N.P.
-
-
-
p.i. =
 after injection ; liposom
es =
 99mTc-PEG liposom
es; IgG =
 99mTc-HYNIC-IgG; +
 =
 positive; N.P. =
 not perform
ed; - =
 negative; ±
=
 equivocal.
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infection confined to the distal femur. 99mTc-MDP findings were falsely nega-
tive in one of these rabbits. A false-positive result was noted with 99mTc-
HYNIC-PEG-liposomes and 99mTc-HYNIC-IgG in the osteomyelitis-negative
rabbit. In this case, the scintigrams of 99mTc-MDP and 111In-granulocytes
were classified as equivocal (67Ga-citrate was not performed). The cellular
infiltration that was seen on histopathological examination, albeit minimal,
probably explained the false-positive result. In 5 of the 6 infected rabbits,
scintigraphy with 99mTc-HYNIC-PEG-liposomes and 99mTc-HYNIC-IgG already
gave positive results at 4 hours after injection. At 22 hours postinjection,
however, visualization of the infection was improved as a result of increasing
focal uptake and decreasing background activity. With 67Ga-citrate and 111In-
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Figure 1. Scintigraphic images of 2 rabbits with chronic osteomyelitis after injec-
tion of 99mTc-MDP (4 h after injection), 99mTc-PEG-liposomes (22 h after injec-
tion), 99mTc-HYNIC-IgG (22 h after injection), 111In-granulocytes (44 h after
injection, rabbit A), and 67Ga-citrate (44 h after injection, rabbit B). Focal
uptake of the respective agents in the infected femur is clearly visible.
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Figure 2. Activity uptake at the osteomyelitis site as determined by quantitative
analysis of scintigraphic images of rabbits injected with 99mTc-MDP (),
99mTc-PEG-liposomes (), 99mTc-HYNIC-IgG (), 111In-granulocytes (), and
67Ga-citrate (), comparing uptake at the osteomyelitis site. Error bars repre-
sent SEM.
Figure 3. Ratios of osteomyelitis-to-sham-operated site at 4 h (99mTc-MDP), 22 h
(99mTc-PEG-liposomes, 99mTc-HYNIC-IgG) and 44 h (111In-granulocytes, 67Ga-
citrate) after injection, calculated from quantitative ROI analyses of the scinti-
graphic images. Horizontal bars represent mean values.
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granulocytes scintigraphy, the osteomyelitis could be identified first on the
22-h images. However, with both agents visualization of the infected femur
was better on the 44-h images, as a result of improved background clearance.
Results of the quantitative analysis of the images are shown in Figure 2.
Although 99mTc-MDP tended to have higher values for uptake in the infected
femur, the differences with the other agents were statistically not significant.
The residual activity at the osteomyelitis site as a fraction of the whole-body
activity, however, was significantly higher than that of the other four agents
because of the rapid whole-body clearance of 99mTc-MDP (p<0.01; data not
shown). 99mTc-HYNIC-PEG-liposomes, 99mTc-HYNIC-IgG, 67Ga-citrate and
111In-granulocytes displayed very similar absolute uptake values at all time
points ranging from 1.6 to 2.0 %ID/g in the final image (Figure 2). As shown
in Figure 3, ratios of infected-to-sham-operated site were similar for all five
radiopharmaceuticals. In accordance with the qualitative assessment of infec-
tion, the ratios for both 99mTc-HYNIC-PEG-liposomes and 99mTc-HYNIC-IgG
increased over time up to 22 hours after injection (1.31 – 0.09 and 1.36 –
0.13, respectively, at 4 hours after injection, and 1.44 – 0.08 and 1.64 –
0.14, respectively, at 22 hours after injection; p < 0.05). The difference
between the mean ratios of 67Ga-citrate and 111In-granulocytes in the 22- and
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Figure 4. In vivo measurements of granulocyte function. Blood clearance of 111In-
leukocytes, calculated from serial blood samples (). Lung clearance of 111In-
granulocytes, determined by quantitative analysis of scintigraphic images of
rabbits injected with 111In-granulocytes (). Error bars represent SEM.
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44-h images as a function of time was statistically not significant (1.46 –
0.17 versus 1.50 – 0.30, respectively, and 1.53 – 0.14 versus 1.54 – 0.30,
respectively; p>0.05). This correlated with the qualitative analysis of the
scintigrams.
Quantitative analysis of the scintigrams of 111In-granulocytes showed rapid
initial lung transit indicating that the labeling procedure had not affected
granulocyte function (Figure 4). In addition, granulocyte recovery at 45 min-
utes was >40% (Figure 4), confirming preserved granulocyte integrity
[Peters, 1988].
I Discussion
This study showed excellent performance by two new scintigraphic agents,
99mTc-IgG and 99mTc-PEG-liposomes, to visualize osteomyelitis. These new
agents performed at least as well as 67Ga-citrate and 111In-granulocytes in the
localization of chronic bone infection. Both 99mTc-PEG-liposomes and 99mTc-
HYNIC-IgG have the major advantage of a 99mTc-label, providing a high pho-
ton flux at early time points after injection in combination with a low radia-
tion dose, low costs, and continuous availability. In addition, both agents are
easy to prepare and do not require handling of potentially contaminated
blood. The lack of false-negative results for both agents refutes concern that a
99mTc-label would be less suited for the detection of low-grade osteomyelitis
[Oyen, 1990]. Indeed, most infected rabbits were identified as early as 4
hours after injection. With 9mTc-PEG-liposomes as well as with 99mTc-HYNIC-
IgG, all infectious sites were detected, whereas 67Ga-citrate and 111In-leuko-
cytes each missed one case of osteomyelitis. Awashti et al. showed that radi-
olabeled liposomes were very effective in the evaluation of acute
osteomyelitis in rabbits [Awasthi, 1998]. The target-to-nontarget ratios
obtained with labeled liposomes in present study were slightly lower than
those found in their study. This difference can be explained quite easily by the
fact that in the latter study no sham procedure was performed. In addition,
because focal accumulation of liposomes is thought to depend on increased
vascular permeability, uptake of the agent is expected to be lower in chronic
than in acute inflammation [Morrell, 1989]. The lower ratios apparently did
not compromize accurate qualitative assessment, probably because the pat-
tern of uptake of the radiolabel contributed to delineation of the infection.
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111In-labeled IgG has been shown to be very suitable for the evaluation of
patients with musculoskeletal infections, including chronic osteomyelitis
[Oyen, 1992d]. 99mTc-HYNIC-IgG has demonstrated equal efficacy to that of
111In-IgG in this patient category [Dams, 1998a]. The results of our study
confirm the ability of 99mTc-HYNIC-IgG to detect chronic, low-grade infection.
The high uptake of 99mTc-MDP at the osteomyelitis site did not result in
improved infection-to-sham-surgery ratios compared to the other agents. In
fact, the absolute uptake of the agent at the distal femur in the false-negative
case was as high as 2 %ID/g. Therefore, despite high absolute uptake in the
infected site, the ratio was only 1.07, illustrating the increased uptake of the
agent at sites of bone repair for any cause. In contrast, for 67Ga-citrate both
absolute uptake and infection-to-sham ratio were similar to the values
obtained with the other non-bone-seeking agents, indicating that accumula-
tion of 67Ga-citrate at the sham-surgery site was relatively low. Despite the
similar uptake and ratios, 67Ga-citrate and 111In-leukocytes scintigraphy
appeared to have lower sensitivity for the detection of infection than did
99mTc-PEG-liposomes and 99mTc-HYNIC-IgG. This discrepancy probably result-
ed from the suboptimal imaging characteristics of both 67Ga and 111In.
The low yield of radiography in this study confirmed that this technique is
unreliable in establishing infection in areas of violated bone [Elgazzar, 1995].
The use of labeled granulocytes in a rabbit model of chronic inflammation
has its pitfalls. Because rabbit leukocytes are easily damaged by handling, the
separation procedure could have negatively biased their performance
[Lillevang, 1994]. In this study, we were able to establish preserved granulo-
cyte function by means of in vivo tests, which are reliable markers of leuko-
cyte damage [Peters, 1988]. The predominance of mononuclear cells such as
lymphocytes and macrophages in areas of chronic infection raises the ques-
tion whether the use of a granulocyte-enriched preparation in this model was
justified. Indeed, some authors favoured the use of a mixed-cell preparation
in chronic inflammation [Datz, 1994, Schauwecker, 1988]. More recently,
however, it has been shown that 111In-labeled lymphocytes actively eliminat-
ed the radiolabel, arguing against the concept that lymphocytes contribute to
a positive image in chronic inflammation [Kuyama, 1997, Peters, 1996].
Using a granulocyte-enriched mixture, we maximized the activity made avail-
able to the infectious lesion, in accordance with the guidelines of Peters
[Peters, 1996]. Still, the equivocal result in one infected rabbit was probably
a result of the relatively mild infection in that animal.
In conclusion, in this rabbit model of chronic osteomyelitis, 99mTc-PEG-lipo-
somes and 99mTc-HYNIC-IgG performed at least as well as 111In-granulocytes
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and 67Ga-citrate. Although the latter two agents each gave one equivocal
result, labeled liposomes and labeled IgG correctly identified all infectious
lesions. The absolute uptake and target-to-non-target ratios were very similar
for the 4 agents. 99mTc-MDP gave one false-negative result because of high
uptake at the sham-operated site, illustrating the nonspecific accumulation of
this agent in areas of increased bone turnover. Because both 99mTc-PEG-lipo-
somes and 99mTc-HYNIC-IgG display favorable dosimetric and physical char-
acteristics and are easy to prepare, they can be valuable agents for the evalua-
tion of chronic osteomyelitis.
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Molecular diagnosis of
musculoskeletal infection using PCR
and reverse line blot
5Chapter
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I Introduction
Orthopaedic infections are often associated with the presence of biomaterials,
like a joint prosthesis or osteosynthesis-hardware, since these increase the
susceptibility to infection. In the presence of a foreign body, bacteria can alter
their metabolism, which can result in a reduced growth rate. Some bacteria
are also capable of producing a slime layer when adhered to the surface of a
foreign body [Gristina, 1984, Gristina, 1983]. These changes in growth char-
acteristics may not only hamper treatment, but can also complicate diagnosis
of these infections using conventional (culture) techniques. Ultrasonication
can disrupt adherent microbial biofilms and has been shown to increase
detection of bacteria in prosthetic implant related infection [Gristina, 1985,
Tunney, 1999, Tunney, 1998]. The long and tedious process of diagnosing
mycobacterial infection is just another example that illustrates some of the
limitations of conventional diagnostic modalities [Berk, 1996]. Osteoarticular
tuberculosis frequently involves spinal infections and septic arthritis, but also
tuberculous prosthetic joint infection has been reported [Berbari, 1998, Berk,
1996]. Depending on variables like the type of cultivation medium, the isola-
tion of these bacteria from clinical samples takes 10 days to several weeks
[Berk, 1996]. Contamination of cultures can occur when a long incubation
period is required, like for Propionibacterium acnes [Calderone, 1996,
Richards, 1995]. Fastidious or difficult to culture pathogens like Bartonella
henselae, Tropheryma whippelii, Mycoplasma pneumoniae, Ureaplasma ure-
alyticum, Neisseria gonorrhoeae, Mycobacterium bovis and Mycobacterium
ulcerans, Borrelia burgdorferi, Kingella kingae, and Chlamydia trachomatis
have been identified as etiological agents of osteomyelitis, and infectious or
reactive arthritis [Altwegg, 1996, Hofer, 1993, Keret, 1998, La Scola, 1997,
Lee, 1992, Liebling, 1994, Lin, 1999a, Oksi, 1994, Stahelin, 1998, Taylor-
Robinson, 1992]. In addition, prolonged courses of antibiotic treatment can
select for the small colony variant (SCV) type of growth of bacteria, with
atypical clinical microbiologic characteristics that makes identification by cul-
ture difficult [Musher, 1977, Proctor, 1998, Proctor, 1995, Roggenkamp,
1998, von Eiff, 1997]. Species identification by phenotypic tests is also time-
consuming and subjective [Fredricks, 1999]. Specific enrichments of the cul-
ture media or milieus, needed for the unknown pathogen to grow, are not
known at forehand, and may not be applied routinely. Similarly, immunologi-
cal detection of infection is only possible for the bacteria to which the
immunolabels are directed [Tunney, 1999].
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The idea that the accuracy of conventional microbiological modalities is not
optimal for diagnosis of musculoskeletal infection, is supported by the fact
that clinically evident infections sometimes remain culture-negative [Lyon,
1999]. Furthermore, empirically based treatment with broad-spectrum
antimicrobials employed in culture-negative cases frequently resolves clinical
signs of infection. Results from the Norwegian Hip Arthroplasty Registry
showing that the rate of aseptic loosening of total hip prostheses decreased
when antibiotic-containing bone cement was used for the primary implant,
strongly support this approach [Espehaug, 1997, Havelin, 1995]. Thus, in
some cases, the aseptic  (based on negative culture outcomes) loosening of a
prosthesis, might in fact have been caused by a low-grade infection or infec-
tion with fastidious bacteria [James, 1994]. An optimal diagnosis of the
infection is essential, because reimplantation of a joint prosthesis in an infect-
ed implant bed is at great risk of failure due to recurrent infection. So, there is
a need for detection techniques, which can bypass limitations of conventional
microbiological modalities in diagnosing orthopaedic infections.
A promising alternative for conventional microbiological diagnosis methods is
the use of molecular biological techniques. Deoxyribonucleic acid (DNA) was
discovered already in 1869 by Friedrich Miescher, but it was the invention of
the polymerase chain reaction (PCR) in 1983 by Kary Mullis that swung this
field of research [Mirsky, 1968, Mullis, 1986, Mullis, 1990, Mullis, 1987,
Saiki, 1985]. Genotypic identification of bacteria is possible by PCR, that rap-
idly amplifies specific regions of bacterial genomes, and subsequent molecu-
lar identification assays. The uniform requirement for PCR is only the pres-
ence of bacterial DNA, whereas cultivation conditions of diverse bacteria are
variable. This allows for reduction in diagnostic delay, especially of slow
growing or nonviable organisms, because the amplification of DNA does not
depend on phenotypic growth characteristics. Thus, treatment strategies and
antibiotic administration might be initiated earlier and more reliable aimed at
specific pathogens, including uncultured and fastidious organisms.
In addition, PCR sensitivity has been reported to be extremely high, requiring
only a small number of organisms (usually 10 bacteria or less). Due to the
almost exponential multiplication of a single copy of template DNA, a PCR
run for 30 to 40 cycles is capable of 106- to 107-fold amplification of one sin-
gle copy. This feature might reduce the delay of antibiotic treatment and
improve clinical outcome, when the treatment would otherwise have been
postponed until intraoperative cultures are taken. Furthermore, an increase of
diagnostic accuracy can facilitate diagnosis of clinical low-grade infection,
like for example encountered in some patients with chronic osteomyelitis or
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prosthesis infections. In this study, the reverse line blot hybridization (RLB)
technique was explored as a means to identify the bacterial pathogens of
musculoskeletal infection, based on the broad-range PCR amplification of the
16S ribosomal RNA (16S rRNA) gene sequence. This gene encodes the 16S
(S stands for Svedberg unit, indicating sedimentation rate) subunit of rRNA
that contains approximately 1545 nucleotides, and is commonly used as a
target for broad-range PCR amplification of DNA products from multiple
microorganisms [Conrads, 1997, Fredricks, 1996, Greisen, 1994, Jalava,
1996, Knox, 1998, La Scola, 1997, Mariani, 1995, Mariani, 1996, Relman,
1992, Sasaki, 1997, Wilson, 1990a]. The presence of such conserved
sequences in the genomes of all known human pathogens in the eubacterial
domain, but not in those of eukaryotic (including fungal and human) cells,
allows for a differentiation between DNA of human tissue and that of bacteria
[Lane, 1985, Relman, 1993]. Using RLB, it is not only possible to rapidly
identify the amplicon of the highly conserved 16S rRNA gene, but also to dis-
criminate between many eubacterial species, families, genera, and groups.
This discrimination is based upon the variation of the 16S rRNA gene across
the eubacterial domain that is present within the conserved sequences
(Figure 1). RLB involves the use of complementary oligonucleotide probes
that are tailored to target more or less variable regions of the 16S rRNA gene,
to specify them for a species or a broader group of bacteria respectively.
Previous PCR-based assays used a series of nylon membranes to which ampli-
fied DNA was attached that could be screened for hybridization with a
labeled oligonucleotide probe [Saiki, 1989]. In a reverse manner, a set of
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AGROBACT AGAGTTTGATCCTGGCTCAGAACGAACGCTGGCGGCAGG-CTTAACACATGCAAGTCGAACGCCCCGCAAGGGG------------------------AG--TGGCAGACGGGTGAGTAACGCGTGGG-AATCTACCGTGCC
MYCOBACT ....................G...............GT.-......................----.A...-.TCT--CTTCGGA--GATACT--CG-..--....GA.............A......TG....G..C...A
HELIOBAC ....................G................T.-.C....................----.AG..C..AA--GTTTCGATGGAAGCT--CTT..--....G....................AC..C......GAGA
LEPTOSPI .......................T............GC.T.....-...........A.G..------G..TA.CA------------ATACT--C--..--C...GA.............A......T.....T..TCTGA
DEINOCOC ....................GGT.............GT.-.....G.................----------.GT--CTTCGGA----------CCG..--....GC.............A...AACTG.C.....CA.AA
THERMUS  ....................GGT.............GT.-.C...G............TG..GG....GG..TTTT--ACTC-CGTG--GTC------..--C...G.....................TG.C.....CG.AA
THERMOMI ....................GGG.............GT.-.C...TG...........G...GGAN...C.CNCT----CTGGCGTGCCGAC------C.--....G........C.....A......G..C.CT..CG.GT
CHLAMYDI ...A.......T...T.....TT.............GT.GA-.G.GG...............G-----..TAATGA--CTTCGGTTGTTATTT-----..--....G..A....T.....TA.A.A.AT.....GT.C.CAA
PLANCTOM ......................T.....T........T.GA..-.GG...........TG...GAT--.T.TA.CA--ATAC--ATGGAG--------..--C...GA.A...A......TA...A..-..C.....T.CGG
ALCALIGE .....................TT.......A....G.T.-...T..................G.AGCGC--.A.AGAGCTTGCTCTCTTGGCGG-C-G..--....G.............TATA.C..-..CG.G..--CAG
ESCHERIC ...........A.........TT................-.C....................GTAACAG--.AAGAAGCTTGCT-TCTTTGCTGAC-G..--....G.............T.TC....-..A..G..--TGA
CLOSTRID ....................G.T..............T.-.C...T................A--A.TCTTCA.GAAGCTTGCT-TCCAAAAAGACTT..--....GA.............A...A..T..C..G..CATGT
MEGASPHA ....................G...............GT.-......................AGAA.AG.T.A.AA-GCTTGCT-TCTTATTGATTCG..--.....A.................AA.C..C..G..C.T.A
LEUCONOS ....................G.T.............GT.-.C...T..............GC.A.A..G.A-A.GT-GCTTGCA-CCTT-TCAAGT-G..--....GA.............A.....AC..C..G..--T.A
TREPONEM ....................................GC.-TC.T.AG...............G.AA.GG---A.GA-GCTTGCT-TCTCCCCTA---G..--....N...T.................TG.......C.TAA
BDELLOVI ....................................GT.-.C....................TGAA------A.------TCCT-TCGGGATGAGTAA..--....GC.............A...A..TG.C..G..T.TTA
BACTEROI ....................G.T.......A..TA....-...................GG.G.ATCAG-.AA.AAAGCTTGCTTTCTTTGC---TGGC.ACC...GC.............A...ATCC..C..G..C.TTA
FLAVOBAC ....................G.TN......A........-...................GG.GTATATG----------------TCTTCGGATATAG..ACC..GCC.......C.........AT.C........T.TTA
CHLOROFL ....................G...............GT.-.C...TG................---------A.CAGGCGTGC--------CTGGCTGC.--....GA....C....G...A......TG.C..G..CC.GA
 
Conserved region Variable region C onse rv ed r e gion
Figure 1. Alignment of different bacterial DNA sequences differentiates conserved regions con-
taining identical nucleotides for all species and variable regions containing different
nucleotides for each species.
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oligonucleotides can be bound in parallel lines on a membrane, and screened
for hybridization with labeled PCR products, hence the term reverse line blot
[Kaufhold, 1994]. For the design of the primers and probes, information on
16S rRNA gene sequences can be obtained from public databases, available on
the internet.
The aim of this study was to investigate the feasibility of the use of RLB as a
diagnostic tool in orthopaedic infections. For this purpose, a set of oligonu-
cleotide probes, based on bacteria typically encountered in orthopaedics, was
designed, and tested for accuracy. Intraoperative tissue specimens of
orthopaedic patients were used to evaluate diagnosis accuracy of RLB in com-
parison with subsequent culture results. Also, RLB was used complementary
to standard cultures in the experimental studies described in chapters 10 and
11 on tobramycin-containing bone cement.
I Materials and methods
Principle of reverse line blot
The principle of RLB is outlined in Figure 2. In one assay of RLB, up to 43 dif-
ferent oligonucleotide probes, attached in lines on a membrane, can be
screened for reactivity on the same number of PCR amplification products.
Broad-range 5  biotin-labeled 16S rRNA primers were used to set up the PCR.
Species-, genus-, and group-specific oligonucleotide probes were designed to
identify bacteria frequently seen in musculoskeletal infections. In addition, a
generic eubacterial probe was used to screen for the presence of other bacter-
ial species in the specimen.
Specimen collection
Accuracy and applicability of RLB was tested using bacterial lysates and sur-
gical human tissue samples from orthopaedic patients. The latter were col-
lected intraoperatively from patients undergoing orthopaedic surgery at the
University Medical Center Utrecht, like primary total hip replacement, revi-
sion of infected or aseptically loosened prostheses, septic arthritis, and surgi-
cal treatment of pseudarthrosis. To reduce sample handling, tissue samples
were immediately transferred in digestion buffer (500 mM Tris, pH 9, 20 mM
EDTA, 10 mM NaCl, 1% sodium dodecyl sulfate (SDS), 0.5 mg/ml proteinase
K) and stored at -70¡C until further processing. All molecular microbiological
hoofdstuk 05  07-05-2001  13:28  Pagina 55
testing was performed at the Research Laboratory for Infectious Diseases,
National Institute of Public Health and the Environment (RIVM), Bilthoven,
The Netherlands. Specimens for culture were obtained and processed using
standard protocols at the Eijkman-Winkler Institute for Clinical Microbiology,
University Medical Center Utrecht, The Netherlands.
DNA extraction
The samples in digestion buffer were incubated for 18 hours at 60¡C to
release total DNA. PCR fragments were purified using the QIAamp Tissue Kit
(Qiagen, Hilden, Germany), according to the supplier s instruction.
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Figure 2. Principle of reverse line blot technique (Oligos=Oligonucleotide
probes)
Apply oligos in an arry using a miniblotter Oligos are bound in line pattern on membrane
Rotate membrane 90°, 
aplly biotin-labeled PCR products
and hybridize
Incubate with peroxidase-labeled streptavidin 
and substrate and expose X-ray film
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PCR
For the 16S PCR, primers based on the highly conserved region of the eubac-
terial 16S rRNA gene were used (Table 1). DNA was amplified in 25-µl reac-
tion volumes. Each reaction mixture contained 20 pmol of primer
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Table 1. Set of oligonucleotide primers and probes used in PCR and RLB.
Oligonucleotide name Sequence (5' -> 3')* Target organism Nucleotide position
Primers
16S8FEvar1 CGGAATTCCAGAGTTTGATCMTGGCTCAG Eubacteria 8-27 
B-16S8RBvar2 5' biotin-CGGGATCCCGCTTTACGCCCARTNASTCCG Eubacteria 556-575 
Probes
A-BORTMPA 5'-amino-TACAATCTAAGATCCAGACT TmpA plasmid spike
A-16SA339 5'-amino-TCCTACGGGAGGC(AT)GCA Eubacteria 339-355
A-16SHIGHGC 5'-amino-GGTAGCCGGCCTGA Gram+, High GC 247-260
A-16SLOWGC-2 5'-amino-GTGCCTAATACATGCAAG Gram+, Low GC 45-62
A-16SPALPHA 5'-amino-GAGTGATGAAGGCCTTAG Proteo group alpha 406-423
A-16SPGAMMA 5'-amino-AAGCCTGATGCAGCCAT Proteo group gamma 383-397
A-16SSTAPH 5'-amino-AACCTACCTATAAGACTGG Staphylococci 262-280
A-16SSAUREUS 5'-amino-TCAAAAGTGAAAGACGGTC Staphylococcus aureus 334-352
A-16SCOR 5'-amino-CTTTAGTGTGTGTGGTGGA Corynebacterium spp. 183-201
A-16SNEIS 5'-amino-AACATATCGGAACGTACC Neisseriae 119-136
A-16SSALG 5'-amino-GCGGGGGATAACTATTG Streptococci 142-158
A-16SSTREPD 5'-amino-CATGTTAGATGCTTGAAAGGAG Streptococcus bovis group 197-218
A-16SSVIR 5'-amino-TGAGAGTGGAAAGTTCACAC Streptococcus viridans and bovis 311-330
A-16SSPYO 5'-amino-TAACGCATGTTAGTAATTTAAAAG Streptococcus pyogenes 144-167
A-16SPROT 5'-amino-GTTAATACCTTTATCAATTGACG Proteus spp. 381-403
A-16SPRMIR 5'-amino-GGTTAATACCCTTATCAATTGA Proteus mirabilis 380-401
A-16SECOLI 5'-amino-AAGGGAGTAAGTTAATACCT Escherichia coli 451-471
A-16SMYC 5'-amino-GCYTGGGAAACTGGGT Mycobacteria 146-161
A-16SMTUB 5'-amino-CGGGATGCATGTCTTGT Mycobacterium tube  rculosis 181-197
A-16SENTEROB 5'-amino-CTGATGGAGGGGGATAA Enterobacteriaceae (partly**) 136-152
A-16SEAG 5'-amino-CCTGTCGATTGACGTTACC Enterobacter/Pantoea agglomerans 101-119
A-16SPSA 5'-amino-TAATACCTTGCTGTTTGACG Pseudomonas aeruginosa 462-481
A-16SPACNES 5'-amino-GAAAGGCCCTGCTTTTG Propionibacterium acnes 41-5
*The underlined sequences represent the EcoRI and BamHI restriction sites.
**A-16SENTEROB targets various members of the Enterobacteriaceae, including the genera Escherichia, Enterobacter, Klebsiella, Serratia, Salmonella, and
Yersinia. 
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16S8FEvar1, 160 pmol of primer 16S556RBvar2, 12.5 µl of HotStarTaq
Master Kit (Qiagen, Hilden, Germany). A 25-µl overlay of paraffin oil added
to the tubes. HotStarTaq Master Kit is a ready-to-use mixture of HotStarTaq
DNA polymerase (0,1 U/µl), PCR buffer (containing 1.5 µM MgCl2), and
nucleotides (200 µM of each dNTP), thereby reducing the risk of carryover
(i.e. previous amplified products contaminating subsequent amplifications)
during pipetting in the setup of the PCR. Nonspecific amplification during the
setup of the PCR is prevented because the enzyme is inactive until incubation
at 95 ¡C for 15 minutes. To further minimize contamination, PCR-mixtures
were incubated for 1 hour at 37 ¡C with a combination of 3 restriction
enzymes (CfoI, NciI, Sau3A1, Boehringer Mannheim GmbH, Mannheim,
Germany 1.0 U/reaction) [Carroll, 1999, Conrads, 1997, Sharma, 1992]. The
restriction enzymes were subsequently inactivated by incubation at 95¡C for
15 minutes, following which 5 µl of the purified DNA extract or template
DNA was added and PCR amplification in an OmniGene Thermal Cycler
(Hybaid, Teddington, Middlesex, UK) commenced. To minimize nonspecific
amplification, a touchdown PCR program was used: two cycles of 20 s at
95¡C (denaturation), 1 minute at 66¡C (annealing), 1 minute at 72¡C (exten-
sion), and then two cycles with conditions identical to the previous cycles,
but with an annealing temperature of 64¡C. During subsequent two-cycle
sets, the annealing temperature was lowered by 2¡C until it reached 56¡C.
Then, an additional 40 cycles, each consisting of 20 s at 94¡C, 1 minute at
56¡C, and 1 minute at 72¡C, following the touchdown program, was per-
formed. The PCR was ended by an extra incubation for 7 minutes at 72¡C.
To monitor for the occurrence of false-positive PCR results, negative controls
(digestion buffer without patient material) were included during extraction
of the DNA samples. In addition, each time that the PCR was performed, neg-
ative control samples (reaction mixture without DNA template) were includ-
ed. Furthermore, each PCR sample was spiked with a positive control (TmpA
gene product cloned in E. coli plasmid, with built-in 16S rRNA gene primers)
to detect inhibition of PCR (not shown in this chapter). In order to minimize
contamination, the reagent setup, the extraction and sample addition, and
the PCR and RLB were performed in three separate rooms, of which the first
two rooms were kept at positive pressure and had airlocks.
Reverse line blot
The 5  terminal aminogroup of the oligonucleotide probes was used to cova-
lently link them to an activated negatively charged Biodyne C membrane
(Pall Europe Ltd., Portsmouth, United Kingdom). The membrane was activat-
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ed by incubation for 10 minutes in 16% 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide (Sigma), rinsed with water, and placed in a
miniblotter (Immunetics, Cambridge, MA). Using the miniblotter, 25 to 3200
pmol of 5  amino-linked oligonucleotide probes dissolved in 500 mM
NaHCO3 (pH 8.4) were coupled covalently to the activated membrane in a
line pattern. After 1 minute of incubation, excess solution was aspirated, and
the blot was inactivated by incubation with 100 mM NaOH for 10 minutes.
Subsequently, the membrane was washed in 2x SSPE (360 mM NaCl, 20mM
NaH2PO4, 2 mM EDTA) with 0.1% SDS at 60¡C for 5 minutes, and then
stored at 4¡C or used immediately. The membrane was placed in the miniblot-
ter with the oligonucleotide-containing lines perpendicular to the slots in the
miniblotter. Ten microliter of the biotin-labeled PCR products were diluted in
150 µl of 2x SSPE-0.1% SDS, denatured for 10 minutes at 99¡C, and cooled
rapidly on ice. After filling the slots of the miniblotter with the denatured
PCR products, hybridization was performed for 1 hour at 42¡C. Next, follow-
ing aspiration of the slots, the membrane was removed from the miniblotter
and washed twice for 10 minutes each time in 2x SSPE-0.1% SDS at 55¡C.
Subsequently, the membrane was incubated for 30 minutes at 42¡C with
streptavidine-peroxidase conjugate (Boehringer Mannheim GmbH,
Mannheim, Germany) diluted 1:4,000 in 2x SSPE-0.5% SDS, and was
washed twice for 10 minutes in 2x SSPE-0.5% SDS at 42¡C. Finally, the mem-
brane was briefly rinsed twice with 2x SSPE. Hybridization was visualized by
incubating the membrane with enhanced chemoluminescence detection liq-
uid (Amersham International plc, Den Bosch, The Netherlands) and exposing
the membrane to X-ray film (Hyperfilm; Amersham).
We designed 21 species-, genus- and group-specific oligonucleotide probes to
identify bacteria frequently seen in orthopaedic infections (Table 1) [Bouza,
1999, Brause, 1998, Deacon, 1996, Vogely, 2000a]. In addition, a generic
eubacterial probe was designed to detect bacterial species that were not iden-
tified by these specific probes. Sequences used to design these probes were
derived from GenBank (http://www.ncbi.nlm.nih.gov:80/entrez/
query.fcgi?db=Nucleotide) [Benson, 2000 #3109]. The Basic Local
Alignment Search Tool (BLAST, http://www.ncbi.nlm.nih.gov:80/BLAST/)
was used to search for similarities between a query sequence  and those con-
tained in databases of the National Center of Biotechnology Information
[Altschul, 1990]. Specificity control was also performed using the CHECK-
PROBE function available with the Ribosomal Database Project facility (RDP,
http://www.cme.msu.edu/RDP/) [Maidak, 2000]. The length of the oligonu-
cleotides was adapted to ensure equal melting temperature (Tm) of the
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probes [Saiki, 1989]. In addition, care was taken to avoid internal loops that
might influence hybridization efficacy. All probes were synthesized as 5
aminogroup bound to the oligonucleotide.
I Results
Figures 3-5 show some results of RLB in which lysates of several bacterial
species, amplified with the broad-range 16S rRNA primers, were used to
assess the accuracy of oligonucleotide probes. The generic eubacterial probe
correctly detected all bacterial species tested. In addition, the identity of most
species was correctly revealed by the group-, genus- or species-specific
oligonucleotide probes. Probe A-16SMYC, named after the genus
Mycobacteria, detected not only M. tuberculosis and M. avium (Figure 3), but
also Corynebacterium pseudotuberculosis (not shown). The A-16SHIGHGC
probe detected Gram-positives with a high %GC content, like mycobacteria,
corynebacteria and Propionibacterium acnes, but hybridization signals were
weak (Figure 3). Higher concentration of this probe resulted in false-positive
outcomes (patient 8 in Figure 6, and patient 9). The A-16SSTREPD probe cor-
rectly detected streptococci, belonging to the bovis group, but also, incorrect-
ly, S. milleri (Figure 5). However, the S. milleri group has been shown to be
heterogenous, carrying members from several serogroups [Kilian, 1998]. Also
in this figure, Klebsiella pneumoniae was misidentified as Enterobacter agglom-
erans by the A-16SEAG probe.
RLB confirmed the results of culture, being either negative or positive, in the
majority of specimens from 21 patients undergoing orthopaedic(-related) sur-
gery, presented in Table 2. In patient 16, two species were cultured from an
infected total hip prosthesis (sporadic Enterobacter cloacae and sporadic
Enterobacter agglomerans). Only the presence of the latter could be interpret-
ed from the RLB outcome. The presence of both staphylococci and streptococ-
ci were correctly identified in specimens from an infected wrist (patient 21).
A coagulase-negative staphylococcal strain was cultured in 1 of 3 specimens
in patient 17, whereas RLB results were negative.
Specimens with extracted DNA of synovial fluid of 3 patients (18, 19, and 20)
with septic arthritis, described in a previous study by Van der Heijden et al.
(respectively patient 5, 1, and 3 in their study), were generously donated (B
Wilbrink) and subjected to identification by RLB [van der Heijden, 1999b]. 
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Figure 3-5. RLB outcomes using the following bacterial lysates (added horizontally): AF=A.
felis, SA=S. aureus, SE=S. epidermidis, MT=M. tuberculosis, MA=M. avium, AS=group A
streptococcus, NG=N. gonorrhoeae, PV=P. vulgaris, NM=N. meningitides, EA=E. agglomer-
ans, EC=E. coli, PA=P. aeruginosa, KP= K. pneumoniae, SM=S. milleri, -=no lysate, SP=S
pneumoniae, CP=C. pseudotuberculosis, PM=P. mirabilis, PC=P. acnes. Oligonucleotide
probes were bound in vertical lines on the membrane (Some of these (*) were not used for
clinical specimens, Figure 4) The amount of each probe per lane increased over 4 subsequent
lanes from left to right, and the amount of each biotin-labeled bacterial PCR product
decreased 10-fold per lane from top (25 ng = 3*109 copies of PCR products) to
bottom.(Figures 3 and 4). In Figure 5, some probes were added twofold, increasing in
amount per lane from left to right.
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Figure 6-7. RLB outcomes using patient material (added horizontally). Patient numbers refer
to those in Table 2. Figure 6 includes samples taken from patient undergoing primary or revi-
sion total hip arthroplasty. Figure 7 includes patient material obtained from intraarticular biop-
sies in septic joints before or after the start of antibiotic treatment.
6
7
Figure 7 shows that in the present study, RLB detected and identified the
presence of bacterial DNA, confirming the results by the Van der Heijden et
al., obtained both by culture and by automated sequencing following univer-
sal 16S rRNA PCR of these specimens. In present study, hybridization of N.
gonorrhoeae PCR products to the A-16SNEIS probe gave relatively weak sig-
nals on day 0, and negative results thereafter.
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Serially diluted S. epidermidis spike DNA was used to test the sensitivity of
RLB for the detection of PCR products. This experiment confirmed that the
amplification of one copy of S. epidermidis chromosomal DNA resulted in a
positive signal. The sensitivity was 100 to 1000 times higher as compared to
ethidium bromide staining after gel electrophoresis (LM Schouls: personal
communication).
I Discussion
This study shows that it is possible to design oligonucleotide probes for RLB-
based detection of bacteria encountered in musculoskeletal infection.
Preclinical tests showed good accuracy in identification on group-, genus-,
and species-level for most probes described in this study. Furthermore, the
generic eubacterial probe could detect the presence of otherwise unidentified
16S rRNA gene amplification products. In addition, preliminary clinical test-
ing showed that RLB could be used to detect pathogens in tissue specimens
from patients.
Preclinical testing showed some hybridization errors of a few probes, The A-
16SMYC probe was designed to detect M. tuberculosis and other mycobacteri-
al species, and a separate study (LM Schouls, personal communication) to
identify mycobacterial species showed that at least 25 different mycobacterial
species could be detected using this probe. However, information derived
from sequence databases also indicated matches with other closely related
genera, like Corynebacterium spp., which was confirmed by this study. Based
on homology searches, S. milleri and K. pneumoniae did not completely
match the A-16SSTREPD and A-16SEAG probe sequences respectively, but
cross-hybridization was detected in this study. E. faecalis, previously known as
Streptococcus faecalis, was split from Streptococcus to form the genus
Enterococcus, only in 1984 [Holmes, 1998]. Not surprisingly, this species
hybridized to the A-16SSTREP probe (Table 2, patient 13).
Figure 6 shows an example of the detection of bacteria in clinical specimens
using RLB. Both culture-positive and culture-negative results were confirmed
by the hybridization assay. In addition, two RLB-positive results in culture-
negative samples were noted. Firstly, hybridization of the sample from patient
9 with the A-16SHIGHGC probe suggests nonspecific reactivity, although it
could not be excluded that Gram-positives in these clinical specimens were
misidentified as staphylococci by cultivation. It proved difficult to optimize
64
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hybridization conditions of this probe. Lower concentrations (<200
pmol/lane) resulted in insufficient signal after the standard 15-min exposure
of the X-ray film; stronger signals were only obtained after overnight expo-
sure. Higher concentrations increased the signal, but resulted also in nonspe-
cific hybridization with other Gram-positives. Secondly, in patient 14, the A-
16SSTREPD probe misidentified the S. oralis strain, cultivated from a tissue
specimen obtained during revision hip arthroplasty. Unfortunately, the tube
65
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Table 2. Results of culture and reverse line blot in patient material
Patient Indication Culture RLB
1 Revision THP (aseptic) - -
2 Revision THP (aseptic) - -
3 Revision THP (aseptic) - -
4 Primary THP - -
5 Primary THP - -
6 Pseudarthrosis tibia - -
7 Revision THP (infected) S. aureus S. aureus
8 Revision THP (infected) S. aureus S. aureus
9 Revision THP (infected) S. aureus S. aureus and Gram+ High GC
10 Revision THP (infected) S. aureus S. aureus
11 Revision THP (infected) S. aureus S. aureus
12 Revision THP (infected) Group C Streptococcus Streptococci
13 Revision THP (infected) E. faecalis Streptococci
14 Revision THP (infected) S. oralis Streptococcus viridans (and bovis)
15 Revision THP (infected) E. cloacae Enterobacteriaceae
16 Revision THP (infected) E. cloacae and E. agglomerans E. agglomerans
17 Revision THP (infected)* CNS -
18 Septic arthritis knee S. pyogenes Day 0: S. pyogenes
19 Septic arthritis Day -2: N. gonorrhoeae Day 0: Neisseria
Day -1: - Day 1: Neisseria
Day 0, 1, 10: Not done Day 10: Neisseria
20 Septic arthritis Day 1: S. pneumoniae Day 1: S. pneumoniae
Day 3: - Day 3: S. pneumoniae
21 Septic arthritis wrist S. aureus and Group G S. aureus and streptococci 
Streptococcus
(* 3d exchange of antibiotic-containing bone cement beads)
hoofdstuk 05  07-05-2001  13:28  Pagina 65
containing the DNA extract may have become contaminated with S. milleri
material. Indeed, positive hybridization signals like in this figure, but not of
the before mentioned probe, correctly identified the S. oralis strain previously.
The negative findings of culture in all but one specimen of patient 17 may
explain the RLB-negative result in this case.
In present study, S. pneumoniae could be detected in a specimen obtained
from a septic joint, three days after initiation of intravenous antibiotic thera-
py, with negative cultures at this time point (Figure 7, patient 20) [van der
Heijden, 1999b]. Several authors recognized the fact that remaining nonvi-
able bacteria or DNA remnants of bacteria in macrophages can create positive
PCR results [Canvin, 1997, Koehler, 1998, van der Heijden, 1999b, Wilbrink,
1998, Wilkinson, 1999]. Otherwise, when antibiotic treatment may have
decreased bacterial growth and limited detection by cultivation, positive PCR
studies could still be obtained [Canvin, 1997, van der Heijden, 1999b,
Wilbrink, 1998].
Currently, sequence databases like GenBank contain many 16S rRNA gene
sequences, but the 16S rRNA gene sequence of many bacteria, particularly
those from the environment, are still unknown. Thus, it can be expected that
accuracy of RLB increases in the near future because design of oligonu-
cleotide primers and probes can be more reliable evaluated for homology.
However, it is impossible to design 16S rRNA probes specific to each bacterial
species, because of close homology of some bacterial species and high vari-
ability between different subspecies. This feature underscores the importance
of oligonucleotide probes that target phylogenetically more conserved regions
of the eubacterial domain. These probes can confirm the presence or absence
of DNA of otherwise unidentified bacterial species, by identifying their genus
or group level. Negative hybridization results of other related species-specific
probes, may suggest the identity the otherwise unidentified species even
more. For instance, if the S. aureus species-specific probe does not detect a
pathogen, identified as a member of the genus Staphylococcus, it is likely a
coagulase-negative staphylococcal strain (Figure 3). To a certain extent, this
information may indicate the virulence of the pathogen and allow for nar-
rowing of the antibiotic treatment.
This study reflects the increasing interest in the possibilities of using tech-
niques such as PCR for research on musculoskeletal disorders, as indicated by
a number of introductory reviews on molecular based diagnosis that recently
appeared in orthopaedic(-related) literature [Chu, 1997, Dietz, 1996,
Hoeffel, 1999, Louie, 1998, Mariani, 1998, Rosier, 1999, Shore, 1994, Shore,
1995]. In orthopaedics, only a limited number of studies described the use of
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DNA-based tools for diagnosis of infection. Initially, PCR-based studies were
used primarily to detect specific bacterial pathogens in septic joints and to
differentiate septic arthritis from non-infectious (rheumatoid) arthritis [Lee,
1992, Liebling, 1994, Taylor-Robinson, 1992]. Subsequently, genus-specific
primers and broad-based 16S primers were used to screen for the presence of
bacterial DNA of various origins in bone and joint infection [Girschick, 1999,
Hoeffel, 1999, Levine, 1995, Mariani, 1995, Mariani, 1996, Rantakokko-
Jalava, 2000, Tunney, 1999, van der Heijden, 1999b, Wilbrink, 1998,
Wilkinson, 1999]. Similar formats have been used for the diagnosis of other
bacterial disorders like keratitis, meningitis, and bacteremia [Carroll, 2000,
Conrads, 1997, Dicuonzo, 1999, Goldenberger, 1997, Greisen, 1994, Jalava,
1996, Knox, 1998, Kotilainen, 1998, Kroes, 1999, Ley, 1998, Whelen, 1996].
The drawback of many current studies using PCR to detect infection is that
they either are directed at a few specific organisms, or need time-consuming
sequence procedures to reveal the identity of the bacteria. Species-specific
PCR is less sensitive to carryover and reagent contamination than when
broad-range primers are used to setup the PCR [Meier, 1993]. After separa-
tion by size and charge through agarose gel electrophoresis, the species-spe-
cific oligonucleotide bands can be readily visualized by either direct ethidium
bromide staining or by the more sensitive method of Southern blotting, in
which DNA probes can recognize transferred fractions on a membrane
[Mariani, 1995]. However, other pathogens than the ones specifically primed
and probed for cannot be detected. To amplify more bacterial sequences, a
nested PCR using primer sets that simultaneously target multiple DNA
sequences, has been used to detect putative pathogens in arthritis [Braun,
1997, Muralidhar, 1994]. For the screening of unknown pathogens in clinical
samples, a species-specific PCR is less appropriate.
Another alternative molecular microbiological method for infection diagnosis
is to sequence amplified DNA products [Rosenthal, 1995]. However, mixed
infections cannot be readily detected without additional cloning of the micro-
bial sequences before sequencing [Rantakokko-Jalava, 2000, Wilkinson,
1999]. Furthermore, some strategies to prevent carryover of 16S PCR prod-
ucts impair the sequence reactions. This has been described for the applica-
tion of heat-labile uracil-DNA-glycosylase and the incorporation during
amplification of dUTP instead of dTTP [Wilbrink, 1998].
Especially when a larger spectrum of bacterial pathogens can be encountered,
like in orthopaedic infections, a broad-range PCR on the 16S ribosomal RNA
gene is more suitable to detect DNA of any of those bacteria. Mariani et al.
compared the results of culture with those of universal bacterial PCR in
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patients with symptoms after total knee arthroplasty, indicative for biome-
chanical failure or infection of the implant [Mariani, 1996]. The presence of
PCR products from bacterial origin was detected by Southern blot analysis in
preoperative aspirates from 32 patients. Of these, preoperative culture results
were positive in only 6 samples and intraoperative culture results in another
9 patients. In contrast, all patients with a negative preoperative PCR result
also had negative intraoperative cultures. Infections caused by different bac-
terial pathogens were detected using a eubacterial probe, but these authors
did not identify the bacterial species from which the amplified DNA originat-
ed. The use of species-specific primer sets for this purpose was reported in a
subsequent study by these authors [Mariani, 1998]. Species-specific oligonu-
cleotide probes can also be used to analyze broad-range amplification prod-
ucts in Southern blot or a dot blot (in which multiple DNA samples are blot-
ted as dots on a nylon membrane) hybridization formats [Dore, 1998,
Krimmer, 1999]. This method has been used in infection diagnosis of patients
with meningitis [Dicuonzo, 1999, Greisen, 1994]. However, such formats
become laborious with an increasing number of clinical samples, or when
many oligonucleotide probes are required for hybridization [Dicuonzo,
1999].
Detection formats in which a panel of oligonucleotide probes is immobilized
on a solid support, like in RLB, offers the possibility to screen for hybridiza-
tion of a clinical sample to multiple probes in a single run. Initially, this tech-
nique was employed as a reverse dot blot assay to detect allelic variants of
human genes [Saiki, 1989]. The principal of reverse hybridization has also
been applied for the detection and identification (genotyping) of viral, fun-
gal, and bacterial species in so-called line probe assays (LiPA) [Kleter, 1999,
Martin, 2000, Miller, 2000, Stuyver, 1996, van Doorn, 1999]. In LiPA, a nitro-
cellulose membrane strip, onto which oligonucleotide probes are immobilized
as parallel lines, is used to detect hybridization of amplification products.
Unlike RLB, the above-mentioned hybridization formats cannot be used to
hybridize multiple test samples simultaneously. In contrast, RLB can simulta-
neously detect and identify multiple bacterial species in different samples
[Bunschoten, 2000, Gubbels, 1999, Jacobs, 2000, Kaufhold, 1994, Rijpkema,
1995, Schouls, 1999, Sparagano, 1999, van der Heijden, 1999a]. In addition,
unlike RLB membranes, LiPA strips are not reusable because hybridization on
the latter is visualized by a color reaction. RLB has been helpful in large-scale
epidemiological studies on mycobacteria, using probes for spacer regions in
the mycobacterial genome (spoligotyping) [Aranaz, 1996, Kamerbeek, 1997,
van Embden, 2000]. An upcoming technique that resembles RLB is the use of
68
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DNA oligonucleotide arrays on silicon microchips. These so-called DNA chips
can be used to screen for hybridization of DNA samples to thousands of
oligonucleotide probes attached on a glass slide [Fredricks, 1999, Lipshutz,
1999]. In contrast to RLB, dedicated equipment is needed to make and read
these microarrays [Cheung, 1999].
In the present study, broad range oligonucleotide primers specific for the con-
served regions of eubacterial 16S rRNA gene were used to setup the PCR.
One of the major problems of using this gene as an amplification target is
contamination of reagents with bacterial DNA, since these reagents may be
derived from bacterial sources [Corless, 2000]. In addition, contamination of
exogenous DNA is possible during the setup of the PCR. Several methodolo-
gies have been described to overcome this problem, which is exacerbated by
the highly sensitive nature of PCR [Kwok, 1989]. Many of these, such as the
use of dedicated equipment (pipettes with disposable filter tips, disposable
gloves and laboratory coats, nonreusable waste container bags) in dedicated
rooms (with biosafety hoods equipped with ultraviolet germicidal lamps) for
the extraction of DNA and the setup of the PCR, were used in the present
study. Hoeffel et al. developed genus-focused primers for PCR-based detec-
tion of periprosthetic infection, that would amplify DNA of some Gram-posi-
tive cocci, but not of Escherichia coli [Hoeffel, 1999]. These primers were
chosen because Taq polymerase enzyme may contain remnants of the latter
bacterial species, in which it is recombinantly produced. Some treatments,
like for instance ultraviolet (UV) irradiation, are highly effective in eliminat-
ing contaminating DNA, but result in an unacceptable (up to a 4- to 7-log)
reduction in PCR sensitivity, due to inactivation of reagents. Thus, to improve
accuracy of molecular diagnostic modalities, much research is focused on the
development of PCR techniques that could decrease bacterial contamination,
while maintaining high sensitivity for gene amplification.
In the near future, PCR-based diagnosis of infection will certainly comple-
ment conventional diagnostic modalities. Because RLB offers a simple and
quick strategy to identify multiple bacterial PCR products after a broad-range
PCR on the 16S rRNA gene, it may become an important tool for infection
diagnosis. This approach allows for the detection of many different bacterial
pathogens encountered in musculoskeletal infection, both in unibacterial and
mixed infection, independent of growth characteristics. RLB, using the
oligonucleotide probes described in this study, may also be applicable in diag-
nosis of other types of infections, caused by similar pathogens.
Our preliminary study indicates the feasibility of the RLB technique for use as
a diagnostic tool for (biomaterial-associated) orthopaedic infections. At this
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moment, testing is in progress to further optimize the reverse line blot tech-
nique for application in the diagnosis of orthopaedic infections. Testing a
greater number of bacterial lysates may reveal flaws in the design of some
oligonucleotide probes, or may confirm the accuracy of these in different
strains belonging to the same species, genus or taxonomic group of bacteria.
Fine-tuning of the dose of some oligonucleotide probes and identifying opti-
mal stringency conditions are the next steps in upgrading this technique.
70
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Introduction to experimental studies
on antibiotic-containing bone cement
6Chapter
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I Antibiotic-containing bone cement
In Part II of this thesis, pre-mixed tobramycin-containing bone cement was
evaluated in experimental studies. In numerous hospitals, especially in the
United States, antibiotic-containing bone cement is prepared by adding
tobramycin powder intraoperatively to bone cement and subsequent hand-
mixing [Heck, 1995) Pre-mixed antibiotic-containing bone cements are mar-
keted in Europe, but regulations of the Federal Drug Agency (FDA) do not
allow the use of these cements in the United States (U.S.). Although registra-
tion regulation for new bone cements have become less strict recently, both in
Europe and in the U.S., strict regulations for manufacturing of bone cements
should guarantee constantly reproducible manufacturing conditions and the
safe use of these products clinically [K hn, 2000) Therefore, it is somewhat
inconsistent that U.S. regulations allow less constant reproducible manufac-
turing conditions, i.e. the hand mixing of antibiotics and bone cement in the
operating room by the surgical team. This hand mixing of antibiotics with
bone cement does not allow for a consistent and controllable quality of the
cement. A standardized preparation of antibiotic-containing bone cement
benefits not only future infection-based efficacy studies, but also the evalua-
tion of its biomechanical properties. Although adding low quantities (approx-
imately one gram per unit) of tobramycin has minimal effects on the fatigue
life of cement, amounts of more than two gram of antibiotics per unit of
cement have shown to decrease the strength of cement [Davies, 1991,
Lautenschlager, 1976].
I Tobramycin
Since 1969, various combinations of antibiotics and bone cement have been
used in the prevention and treatment of arthroplasty infections [Buchholz,
1970, Elson, 1977a, Murray, 1984]. Tobramycin, developed in 1968, is one of
the aminoglycoside antimicrobial agents. Other members of this group are
gentamicin, streptomycin, kanamycin, amikacin and netilmicin. Like other
aminoglycosides, tobramycin is heat-stable, which makes it suitable for incor-
poration in polymethylmethacrylate (PMMA). Aminoglycosides are effective
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primarily against most staphylococci, certain mycobacteria and aerobic
Gram-negative bacilli such as enterobacteriaceae or Pseudomonas aeruginosa
[Edson, 1999, Wingard, 1991]. The antimicrobial spectrum of tobramycin
includes pathogens like staphylococci and aerobic Gram-negative bacilli,
which are most frequently cultured from orthopaedic implant infections
[Scott, 1999]. Aminoglycosides are bactericidal by binding to bacterial ribo-
somes and interfering with protein synthesis, and by disrupting the cell mem-
brane. Differences in structure of the compounds determine the spectrum of
activity against bacteria, the risk of toxicity in patients and occurrence of
resistance. Aminoglycosides enter the inner cell membrane of the bacteria
through an energy-dependent, aerobic process. Binding to the 30S-ribosomal
subunit inhibits protein synthesis and induces misreading of the mRNA.
These effects, together with cell membrane-related effects cause bacterial cell
death [Edson, 1999, Greenwood, 1998, Lorian, 1996]. Antibacterial activity
of aminoglycosides is concentration dependent, meaning that an increased
drug concentration will enhance the bactericidal activity [Lode, 1998]. The
respiratory processes needed for aminoglycoside uptake are absent in anaer-
obes, streptococci and enterococci, resulting in relative resistance
[Greenwood, 1998]. Due to the high polarity of aminoglycosides, these com-
pounds do not enter phagocytic cells and thus they are not active against
intracellular bacteria [Greenwood, 1998, Wingard, 1991]. Resistance mecha-
nisms involve most commonly aminoglycoside-modifying enzymes. These
enzymes are plasmid-mediated, which means that this genetically informa-
tion can spread easily to different bacterial species [Wingard, 1991]. The
structure of a particular aminoglycoside determines its inactivation by the
enzymes. Aminoglycosides can share some structural groupings vulnerable to
modifications, which explains the emergence of cross-resistance between gen-
tamicin and tobramycin. In a recent study however, more than half of gen-
tamicin-resistant isolates of Enterobacteriaceae showed susceptibility for
tobramycin [Adwan, 1998]. Susceptibility studies have shown that
tobramycin is generally more active in vitro against most strains of P. aerugi-
nosa, and gentamicin is more active against Serratia species [Edson, 1999].
Resistance rates of P. aeruginosa strains have been reported to be 7-14% for
gentamicin versus 4% for tobramycin [Edson, 1999, Lorian, 1996]. but other
authors found no difference between the two (18%) [Schmitz, 1999b].
However, data reported in literature on aminoglycoside susceptibility are of
limited value for the surgeon with respect to the choice of a specific type of
antibiotic-containing bone cement in the individual patient. Resistance to
aminoglycosides, just as to other antibiotics, varies by location and local
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usage patterns that can change over time [Schmitz, 1999a]. This is illustrated
by the fact that - despite close association of aminoglycoside resistance with
methicillin resistance [Schmitz, 1999b] - restricted use of gentamicin has
been shown to induce reemergence of gentamicin-susceptible methicillin-
resistant S. aureus [Aubry-Damon, 1997]. Therefore, is more prudent to rely
on data, if available, specific to the hospital where antibiotic-containing bone
cement is to be used for prevention of prosthesis infection. When an infected
arthroplasty is being revised and culture results are known, the selection of
the antibiotic-containing bone cement should be tailored to the causative
pathogens.
I Carriers of antimicrobials for local drug
delivery
In Chapter 7, antimicrobial-loaded biomaterials are discussed that can be
implanted locally for the prophylaxis or treatment of musculoskeletal infec-
tion. Each of these carriers, of which tobramycin-containing bone cement is
just one example, has its specific indications for use in the management of
these infections, because properties of these materials, such as form and
biodegradability, vary. The multitude of antibiotics and other antimicrobial
substances that are incorporated in these carriers, together with the material
properties, determine the drug-release profiles that can be found either in
vitro or in vivo.
I Release of tobramycin from tobramycin-
containing bone cement
The efficacy of antibiotic-containing bone cement in preventing or treating
arthroplasty infection depends on the antibiotic release characteristics. In
Chapter 8, the release of tobramycin from pre-mixed tobramycin-containing
bone cement in the rabbit s femur was investigated. In order to be effective in
preventing or treating arthroplasty infection, antibiotic-containing bone
cement should release the antibiotic in concentrations above the susceptibili-
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ty level of the microorganism involved. Secondly, this concentration should
be reached at the site of the implant, especially at the bone-cement interface
and in the surrounding bone. In addition, the antibiotic concentration in
serum should not exceed toxic levels, to limit risk of side effects. Therefore,
both serum and bone concentrations of tobramycin were investigated in the
rabbit model described in this chapter.
I Susceptibility of bacteria to tobramycin
Still, it is difficult to translate results from susceptibility tests and release
studies to clinical efficacy of antibiotic-containing bone cement. Several fac-
tors may influence the effect of antibiotics released from bone cement on the
bacteria. This complicates the prediction whether the use of local antibiotic-
containing bone cement will prevent or inhibit bacterial growth in the setting
of implant infection. Firstly, concentrations of antibiotics that are higher than
the minimum inhibitory concentration (MIC), will theoretically eliminate
bacteria, defined as susceptible to these antibiotics [Johansson, 1991].
However, when initial release of antibiotic is high, even bacteria that are
defined as resistant, based on their MIC, may be killed [Scott, 1999].
Secondly, in device-related infection, standard susceptibility tests do not cor-
relate with treatment success [Blaser, 1995]. The microenvironment in
arthroplasty infection might favor bacteria, as it includes the presence of for-
eign bodies and eventually devitalized bony due to previous surgical proce-
dures or to the infectious process itself. In such a setting, bacteria can alter
their phenotype, rendering them less susceptible to local defense mechanisms
and immune responses of the body and to antibiotics. This phenomenon has
been described for different biomaterials especially in relation with the capa-
bility of some bacteria to produce a polysaccharide biofilm on the surface of
the implant. These phenotypic alterations in vivo may not be detected by
standard susceptibility tests, since these tests measure in vitro phenotypic sus-
ceptibility of bacterial isolates [Johansson, 1991]. Gristina showed that
despite normal MIC levels of tobramycin in broth suspension, exposure to
higher levels of tobramycin of Staphylococcus epidermidis, enclosed in a
biofilm on a stainless steel implant, did not result in a total reduction of
viable bacteria [Gristina, 1987]. Similar results were obtained by Nickel et al.
after exposure of P. aeruginosa, growing as a biofilm on urinary catheters, to
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tobramycin [Nickel, 1985]. Other in vitro studies showed that gentamicin or
tobramycin, impregnated in PMMA bone cement, could not completely pre-
vent biofilm formation after incubation with S. epidermidis [Chang, 1991,
Chang, 1992, Oga, 1992]. However, the addition of aminoglycosides to the
PMMA reduced adherence and viability of these microorganisms [Chang,
1991, Chang, 1992, Oga, 1992]. In fact, in contrast to plain bone cement, the
addition of gentamicin prevented infection after implantation of PMMA,
preincubated with S. epidermidis [Chang, 1994, von Eiff, 1998]. Darouiche et
al. showed that S. epidermidis, grown on stainless steel nuts in presence of
vancomycin, could not be eradicated completely, even though high levels of
vancomycin were reached in the biofilm [Darouiche, 1994]. Binding of antibi-
otics to glycocalyx material and consequent inhibition of diffusion is not a
major mechanism of antibiotic resistance in biofilms, as has been shown for
tobramycin and vancomycin [Darouiche, 1994, Nichols, 1988]. More likely,
an altered physiology and growth rate of the bacteria diminish the antimicro-
bial effect in the biofilm environment [Darouiche, 1994, Nichols, 1988].
Another aspect of the problem of extrapolating laboratory results to the clini-
cal situation, which has been described as the minefield of difficulties , is
related to aminoglycoside-containing polymers: [Greenwood, 1981]. Von Eiff
has shown that in the presence of gentamicin-containing beads, S. aureus can
transform into so-called small colony variants (SCVs). These SCVs show a
decreased growth rate, are therefore more resistant to antibiotics, especially
to aminoglycosides, and may be easily missed in the clinical laboratory
[Proctor, 1998, Proctor, 1995, von Eiff, 1997, von Eiff, 1998]. Subsequently,
testing of susceptibility of only the parent strain may give misleading results
[Proctor, 1998, von Eiff, 1997].
I Tobramycin-containing bone cement and
prophylaxis of infection
Thus, the efficacy of antibiotic-containing bone cement to prevent or treat
arthroplasty infection cannot be extrapolated just from susceptibility studies.
Therefore, we performed various animal studies to evaluate the efficacy of
the new tobramycin-containing bone cement. Firstly, in Chapter 9, the effi-
cacy of this bone cement was evaluated for the prevention of local S. aureus
and S. epidermidis infection. These bacterial species were used because they
76
hoofdstuk 06  07-05-2001  13:06  Pagina 76
are most frequently isolated in arthroplasty infection. Incidence rates after
total joint arthroplasty of S. epidermidis (26-38% of infections) are somewhat
higher than those for S. aureus (16-24% of infections) and have increased
over the last decade [Fitzgerald, 1994, Garvin, 1993, Ostendorf, 2001,
Sanzen, 1988, Tsukayama, 1996].
In literature, the optimal mode of administration of antibiotics - prior to or
during surgery - is still subject of discussion. Dutch guidelines state that there
is no indication for the use of antibiotic-containing bone cement in primary
arthroplasty, if operated under prophylaxis of systemic antibiotics and an
ultra-clean air system [Dutch Institute for healthcare improvement, 1994].
Data from the Swedish hip arthroplasty registry show however an increased
use of antibiotic-containing bone cement in primary hip arthroplasty from
approximately 10% of all primary hip arthroplasties performed in 1978 to
80% in 1996 [Swedish-National-Hip-Arthroplasty-Registry, 1998]. The differ-
ent modes of administration of antibiotics have been compared for efficacy by
only a few experimental and clinical studies. Petty et al. showed in a study in
dogs that systemic antibiotic treatment as well as local treatment with antibi-
otic-containing bone cement reduced infections of the implant bed, but only
the latter was found to be significantly different from controls [Petty, 1988].
Josefsson et al. compared prophylaxis with systemic antibiotics versus gen-
tamicin bone cement in total hip arthroplasty in a prospective randomized
clinical trial [Josefsson, 1990, Josefsson, 1993]. At 5 years follow-up, signifi-
cantly more infections occurred in the group receiving systemic antibiotics.
However, at 10-years follow-up of 1688 hips, infection rates in the systemic
antibiotics group and in the antibiotic-containing bone cement group were no
longer significantly different. In a similar study, McQueen et al. found no dif-
ference between these two modes of infection prophylaxis in 401 patients, at
two years follow-up [McQueen, 1990].
It is obvious from the few available studies that there is still a lack of scientif-
ic proof regarding the efficacy of systemic (intravenous) and local (bone
cement) administration of antibiotics to prevent implant bed infection. In
Chapter 10, we evaluated the efficacy of either intravenous cefazolin or
tobramycin-containing bone cement in preventing experimental implant
infection. Cefazolin was used for systemic administration, since it is used
widely by orthopaedic surgeons for treatment and prevention of staphylococ-
cal infections.
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I Tobramycin-containing bone cement and
treatment of infection
In revision surgery, antibiotic-containing bone cement is often used, since
revised implants become more frequently infected than primaries [Fitzgerald,
1977, Nasser, 1992, Wilson, 1990b]. The higher infection rate is not only the
result of another operation in compromized tissue, but the previously men-
tioned difficulties in diagnosing implant infection may play their role as well.
When an implant is inserted in an implant bed that has not been totally
cleared from bacteria, the second implant is likely to become infected too. In
case a prosthesis is infected, rigorous treatment modalities are necessary to
eliminate the infection, but the best choice for treatment of an infected total
joint prosthesis still remains to be clarified. Consensus exists among most
orthopaedic surgeons to remove the infected prosthesis if possible, because
the infection is difficult to treat in presence of foreign material covered with
bacteria [Brandt, 1997]. Such a revision operation can be performed either as
a one-stage procedure or as a two-stage procedure. In the one-stage revision,
the infected implant is removed and, after debridement and lavage of the
implant bed, replaced by a new prosthesis during the same session. In a two-
stage revision, the insertion of the new implant is postponed until several
weeks after removal of the infected implant. During this period, the infection
is treated with systemic antibiotics and/ or local antibiotic-containing beads.
The new prosthesis is inserted not until the infection parameters have
regained normal levels. The use of antibiotic-containing bone cement for fixa-
tion of the revision prosthesis is preferred, given the higher incidence of infec-
tion after revision in comparison with primary joint prostheses. Where most
surgeons choose the two-stage procedure for exchange of an infected prosthe-
sis, also large series have been reported using the one-stage procedure, espe-
cially in Europe [Buchholz, 1981, Raut, 1995]. So far, reviews of literature on
arthroplasty infection reported success rates of 82-83% for one-stage revi-
sions, and 91-93% for two-stage revisions [Garvin, 1995, Pagnano, 1997].
Clinically, direct comparison between a one-stage or two-stage revision of a
total joint prosthesis is difficult because of the lack of prospective, random-
ized studies evaluating the timing of this procedure [Garvin, 1995]. Clearly,
the initial costs of a one-stage procedure as opposed to the two-stage proce-
dure are less. Fewer operations means also less inconvenience for the patient.
These advantages must be weighed against the risk of a re-infection of the
prosthesis since frequently a second operation is needed anyhow. Together
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with the increase of the number of revision procedures a patient will undergo,
there is an increased risk of complications due to bone loss and of potentially
fatal outcome. The risk of a re-infection after the first revision procedure,
rather than the costs associated with the initial procedure itself, is probably
the major factor in comparing the cost-effectiveness between the one- or two-
stage procedure. Comparative trials between both options have been advocat-
ed for to clarify this matter [Gillespie, 1997]. The need for long-term follow-
up in the evaluation of infection rates has also been emphasized [Raut,
1995]. Some consensus exists on the indications for a one-stage revision.
Infections caused by less virulent bacteria, fully susceptible to the antibiotics
used for treatment, in otherwise healthy patients who lack additional risk fac-
tors for infection (rheumatoid arthritis, diabetes, decubitus, need for bone
grafting) can probably be treated safely and effectively by a one-stage proce-
dure. Using these criteria, two small series (respectively, 15 patients with a
mean follow-up of 53 months and 20 patients with a mean follow-up of 10
years) reported no recurrence of infections [Mulcahy, 1996, Ure, 1998].
Altered circumstances (e.g. the emergence of resistant bacterial strains as the
causative organisms in infected arthroplasties) can pose the surgeon to
choose for a two-stage procedure, even when he favors the one-stage revision
[Elson, 1994]. Still, the criteria for one- or two-stage revisions are subject to
debate. For instance, Raut argued that a discharging sinus is not always a
contraindication for a one-stage revision of an infected hip prosthesis [Raut,
1994]. The outcome of one-stage revisions of infected total knee prostheses
has been reported to be inferior to those of hip prostheses, probably due to
lower vascularity and minimal soft-tissue coverage of the knee [von Foerster,
1991].
To prevent a recurrent infection after implant revision, antibiotic-containing
bone cement should be able to treat an already established osteomyelitis.
This can be investigated in a one-stage revision model, since it lacks the tem-
porarily treatment with antibiotic-containing beads or a spacer that could
reduce the infection. Therefore, in Chapter 11, a one-stage revision model
was used to test the efficacy in treating an infection with either tobramycin-
containing bone cement or systemic cefazolin.
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I Aims of Part II of this thesis:
¥ To review the literature on antimicrobial-loaded carriers that are clinically
available or are being developed for use in the management of muscu-
loskeletal infection (Chapter 7)
¥ To investigate the in vivo release of tobramycin in blood and bone as a
function of time, after insertion of premixed tobramycin-containing
cement. (Chapter 8)
¥ To investigate the efficacy of premixed tobramycin-containing bone
cement in the prevention of S. aureus and S. epidermidis infections.
(Chapter 9)
¥ To investigate the efficacy of both premixed tobramycin-containing bone
cement and systemic cefazolin in the prevention of S. aureus infection.
(Chapter 10)
¥ To investigate the efficacy of tobramycin-containing bone cement and sys-
temic cefazolin for treatment of S. aureus infection in a one-stage revision
model. (Chapter 11)
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Review on antimicrobial-loaded
carriers in musculoskeletal infection
7Chapter
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I Introduction to antimicrobial-loaded carriers
Part of this thesis describes experimental studies that were performed using a
new premixed tobramycin-containing polymethylmethacrylate (PMMA) bone
cement. This antibiotic-containing bone cement is just one example of the
variety of carriers with different kinds of antimicrobials that has been studied
in vitro or in vivo for prophylactic and therapeutic purposes in musculoskele-
tal infection, as illustrated in Table 1. Although some carriers can be used for
different types of osteomyelitis, their indication for use depends primarily on
the form and characteristics of the material. A major indication for the use of
antibiotic-containing bone cement in its injectable form lies in the manage-
ment of arthroplasty infection. However, also the use of antibiotic-containing
PMMA beads are widely used to treat osteomyelitis locally. To put the use of
antibiotic-containing bone cement in a broader perspective, an overview of
the available literature on antimicrobial-carriers used in orthopaedics is dis-
cussed below. Many experimental and a smaller, but increasing, number of
clinical studies on these materials have been published. Some of those antibi-
otic-carriers are or will become available for clinical use by the orthopaedic
surgeon, and it will be interesting to see whether this will influence the cur-
rent role of antibiotic-containing PMMA bone cement in the management of
orthopaedic infections.
I Bone graft
One of the first carriers to which antibiotics were added was bone graft. In
1946, Prigge reported some success after the use of autologous cancellous
bone grafts to chronic osteomyelitic defects after local instillation with peni-
cillin [Prigge, 1946]. In 1947, De Grood mixed these bone chips with peni-
cillin before filling osteomyelitic defects [de Grood, 1947]. In the following
decades, only a few studies on antibiotic-loaded bone graft, either allogeneic
or autologous, have been reported [Durig, 1986, Lindsey, 1993, McLaren,
1988, McLaren, 1986, Petri, 1984a, Petri, 1984b]. Only minor differences in
release of tobramycin or vancomycin were seen in human versus bovine grafts
[Winkler, 1999]. The lower antibiotic binding capacity of cortical versus can-
cellous bone relates to differences in surface area [Winkler, 1999]. In general,
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antibiotics are released from bone graft for only a short time period (hours-
days) [Miclau, 1993]. In a recent study, only rifampicin demonstrated in vitro
a release up to 21 days [Wits¿, 1999]. When human bone graft is implanted
in animals to study the in vivo release of antibiotics, the release might be
increased due to the local inflammatory response induced by the xenograft
[Wits¿, 2000]. High doses of tobramycin (up to 30 mg/g) did not inhibit the
osteogeneic potential of bone grafts and may therefore promote bone healing
of a contaminated fracture [Lindsey, 1993, Petri, 1984a, Petri, 1984b].
Following a period of treatment with antibiotic-containing PMMA beads,
Chan et al. reached bony union in all, and infection arrest in 95% of small
infected tibial defects, by filling them with autogeneic cancellous bone graft
impregnated with various antibiotics [Chan, 1998]. However, the adverse
effects of therapeutic serum concentrations of antibiotics like fluoro-
quinolones on cartilage in fracture callus, has recently been demonstrated in
an experimental model fracture healing, and should be considered in the
management of (contaminated) fractures [Huddleston, 2000]. An experi-
mental study of Thomas et al. suggested that the presence of demineralized
bone powder itself, despite local supplemental cephalothin administration,
contributed to the persistence of chronic osteomyelitis in rabbits [Thomas,
1989]. However, data on statistical significance were not provided.
I Plaster of Paris
For more than a century now, calcium sulfate, or plaster of Paris (POP) has
been used as a filler of dead space in chronic osteomyelitis and bone cysts
[Mackey, 1982, Peltier, 1961, Stachow, 1894]. In 1953, early after the begin-
ning of the so-called antibiotic era, penicillin and sulfonamide added to POP
showed to contribute to the healing of osteomyelitic defects in the tibia
[Kovacevic, 1953]. In 1982, Mackey et al. demonstrated an initial high burst
release of gentamicin (60-80% of the loaded antibiotic), followed by a slow
in vitro release from POP pellets until final disintegration of the pellets at 7-9
weeks [Mackey, 1982]. To prevent high toxic serum levels, these authors sug-
gested that it might be necessary to place these pellets, as part of their prepa-
ration, in an elutant fluid for up to 24 hours. The biodegradation (or better:
resorption) of POP and the subsequent antibiotic elution period was shorter
(up to 2-3 weeks) in most other in vitro studies [Bowyer, 1994, Dacquet,
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1992, Miclau, 1993, Rauschmann, 1998, Wichelhaus, 1998]. Bowyer et al.
suggested that antibiotic-impregnated POP beads may be indicated for short
term use, such as for infection prophylaxis after acute trauma, eventually
with open fracture. The optimal spectrum of antibacterial activity and the
pattern of release needed for this situation might be different from the treat-
ment of chronic osteomyelitis. Benoit et al. used a polylactide:coglycolide-
coating to control the release of vancomycin from POP beads [Benoit, 1997].
Effective levels up to 4 weeks after implantation were measured in the rab-
bit s femur. In a rabbit model, the fast release of gentamicin from POP was
not sufficient for the treatment of an established S. aureus infection [Dahners,
1987]. In two prospective clinical trials, Evrard et al. treated chronic
osteomyelitis in 83 patients by sequestrectomy completed with insertion of
POP pellets, impregnated with predominantly gentamicin or cefazolin
[Evrard, 1990]. These authors reported a success rate of 61.5% and suggest-
ed that a wide extension of the lesion, which is frequent in chronic
haematogenous osteomyelitis, might be a contraindication for this technique.
I PMMA cement and spacer
The mixing of antibiotics to PMMA bone cement was introduced by Buchholz
and Engelbrecht in 1970 [Buchholz, 1970]. The release of methylmethacry-
late monomer from polymerized bone cement lead them to investigate the
release of antibiotics from PMMA. According to them, this characteristic
might be beneficial when poorly vascularized tissues are encountered in
implant surgery. Results of later studies supported this idea, showing that
gentamicin eluted from PMMA can permeate necrotic bone, and that after
systemic administration, bone concentration of tobramycin, another amino-
glycoside, was dependent on vascular supply [Elson, 1977a, Winkelmann,
1978]. Four heat-resistant antibiotics were used in the experiments of
Buchholz and Engelbrecht, in order to prevent inactivation due to the
exothermal phase of polymerization [Buchholz, 1970]. Of these, tetracyclin
was the least effective in in vitro experiments, probably due to its relative
instability in solution. Similar results were presented by Hessert and
Ruckdeschel [Hessert, 1970]. Although penicillin showed good antistaphylo-
coccal efficacy over 6 months in the study of Buchholz, this antibiotic was not
tested further because of its narrow antibacterial spectrum. Since 1969, these
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authors used clinically gentamicin, erycin, or, initially, penicillin to mix with
bone cement, and reported a reduction in deep infection rate of hip prosthe-
ses from 1.2 to 0.09% in the aforementioned study. Since gentamicin could
not be detected in urine, these authors argued that such low systemic levels
of antibiotic could not induce resistance. In a subsequent study, using 0.5 g
Palacos R bone cement and in most cases no additional systemic antibiotic,
Buchholz in vivo. reported infection rates varying from 0.9 to 2.4% for pri-
mary total hip replacements, performed from 1972 to 1975 [Buchholz,
1984]. When antibiotic-containing PMMA was used for the treatment of
infected hip prostheses, the failure rate (also including loosening of implants)
was higher. For the revised prostheses, the 11-years  survival rate after one or
more one-stage exchange procedures was 50%. The only pathogen that
resulted in significantly inferior outcome in this study was Pseudomonas.
According to some authors, antibiotic elution from Palacos R bone cement
was superior to that from other brands of cement, like Simplex P and CMW
bone cement [Elson, 1977b, Hoff, 1981, Kuechle, 1991, Penner, 1999,
Wahlig, 1980]. Others reported higher release of gentamicin from Simplex P
or CMW bone cement in vitro [Bayston, 1982, Brien, 1993, Holm, 1976,
Marks, 1976]. Holm and Vejlsgaard noted that sample variation, due to
uneven mixing of the antibiotics with cement, lead to considerable variation
in results up to 300%. In a prospective study of 49 patients undergoing a two-
stage revision that involved a temporary prosthesis of antibiotic-loaded
acrylic cement (PROSTALAC), Masri et al. did not find a statistically signifi-
cant difference between Palacos-R and Simplex-P in the in vivo elution of
vancomycin or tobramycin in joint fluid, obtained at the time of the second
stage [Masri, 1998b]. Because a minimal adequate elution rate has never
been demonstrated, the clinical significance of such variable differences in
outcomes reported in literature, has yet to be determined [Penner, 1999].
Scepticism about the role of antibiotic-containing bone cement for infection
prophylaxis came from Hill et al [Hill, 1977]. Prophylactic topical and sys-
temic administration of antibiotic would be more effective in achieving bacte-
ricidal concentrations, because bone cement is not implanted at the start of
the surgery.
The bacterial inhibitory efficacy of various antibiotics released from Simplex
P bone cement in vitro was studied by Levin [Levin, 1975]. Gram-positives
were much longer inhibited by clindamycin and cephalothin than by gentam-
icin. No significant inhibition of P. aeruginosa was found for any of the antibi-
otics tested, mixed as 3 g of powder within 40 g of PMMA powder. In a simi-
lar study, Welch demonstrated inhibition of this pathogen by gentamicin,
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added in a ratio of 0.5 g or more antibiotic per 10 g PMMA [Welch, 1978].
CMW cement was also shown to be capable of releasing several antibiotics
with potent antibacterial activity in vitro, including cephalosporins, peni-
cillins and aminoglycosides [Ger, 1975]. Only chloramphenicol showed no
inhibitory capacity in this study. In a study of Fisher et al. this finding was
true for Simplex P, but not for CMW or Palacos [Fischer, 1977]. Of 4
cephalosporins tested, bone cement (CMW) containing cephalexin showed
the longest antibacterial activity in vitro [Hughes, 1979].
Among the 12 antibiotics tested by Wahlig et al. for release from Palacos R
bone cement, fusidic acid, colistin, bacitracin and dicloxacillin were released
poorly in vitro [Wahlig, 1980]. In dogs and patients, concentrations of gen-
tamicin were higher in connective tissue samples than in bone samples, and
were detectable for 6 to 69 months in some patients.
Low quantities of release from Simplex P or Palacos R bone cement were
found by Picknell et al. (in vitro and in mice or rats]. for both penicillins and
other antibiotics like gentamicin [Picknell, 1977]. The activity of - according
to these authors - heat-labile penicillins was not lost due to the polymeriza-
tion of acrylic cements. Other authors confirmed this finding [Fischer, 1977,
Hoff, 1981]
Clindamycin, nor gentamicin, was detectable in serum or soft-tissue samples
after insertion of antibiotic-containing Simplex P bone cement in the rabbits
thigh [Chapman, 1976].
In an experimental model of Rodeheaver et al., the efficacy in preventing
osteomyelitis was investigated for Simplex P bone cement, containing 0.73 g
of erythromycin and 0.24 g of colistin per unit of bone cement [Rodeheaver,
1983]. In their extensive study, the authors measured the highest bone con-
centration (respectively, 14 and 11 µg/g of bone) of these antibiotics 12 hours
after implantation in the rabbit femur. The amount of bone cement inserted
was not reported, but erythromycin showed a decline to undetectable levels
within 16 days, more than twice as fast as that of colistin. Their data suggest
that positive cultures were found in 13 to 73% of the femora treated with
antibiotic-containing bone cement after inoculation with S. aureus or
Escherichia coli. However, the authors defined infection as more than 105
colony-forming units per gram (CFU/g) of bone cultured by day 14, which
definition could be supported to some extent by their histological analysis up
to 28 days of a separate group of rabbits. Taking the level of 105 CFU/g of
bone as definition of infection into account, the authors demonstrated that
this bone cement was fully effective against S. aureus, and prevented infection
in 87% of the femora inoculated with the highest dose of E. coli.
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Antibacterial efficacy of gentamicin-containing Palacos R has been tested in a
knee hemiarthroplasty model [Schurman, 1978]. Release of gentamicin was
not measured in bone, but therapeutic levels were demonstrated up to 3 days
in synovial fluid. Interestingly, the protective effect of gentamicin-containing
Palacos R cement could not be demonstrated in rabbits challenged with E.
coli one week after implantation. This was due to the fact that controls did
not develop an E. coli infection, in contrast with those challenged immediate-
ly after surgery. In a preliminary study, the growth inhibitory time (i.e. leach-
ing time of growth inhibitory concentration from cement in medium that is
changed every day) of tobramycin was longer than that of gentamicin, using
E. coli as the test organism [Yaniv, 1999]. These authors suggested that the
two additional aminogroups of tobramycin contributed to this finding.
Several antibiotics that were not tested before to impregnate bone cement
with, were studied by Beeching et al. for antibacterial activity in vitro after
release [Beeching, 1986]. These included ceftriaxone, coumermycin,
rifampicin, cotrimoxazole and vancomycin. Rifampicin disturbed the setting
of PMMA, making it unsuitable for clinical use. Coumermycin was superior to
vancomycin in inhibiting S. aureus, but both were ineffective against the
Gram-negative organism E. coli.
Recently, K hn reported that most of the 18 different antibiotic-containing
bone cements, available on the market at that time, contain gentamicin (as a
sulphate) [K hn, 2000]. One of these, Copal, also contains clindamycin,
whereas Antibiotic Simplex is nowadays available with erythromycin and col-
istin (AKZ), or with tobramycin. Since 1977, tobramycin-impregnated bone
cement has been used for the anchorage of joint prostheses [Desoto, 1984,
Duncan, 1995, Greene, 1998, Hofmann, 1995a, Kendall, 1995, Lawson,
1990, Lodenkamper, 1982, Long, 1977, Marr, 1983, Pritchett, 1992,
Wininger, 1996].
In addition, several in vitro studies investigated this mixture as well [De
Palma, 1982, Fischer, 1977, Klekamp, 1999, Yaniv, 1999]. Like Beeching et
al., other authors (mostly American) have recently also investigated the
incorporation of vancomycin in bone cement, and compared it with
tobramycin, which is frequently used in non-European countries for this pur-
pose [Wininger, 1996]. This interest reflects the emergence of methicillin
resistant S. aureus (MRSA) in these countries [Kuechle, 1991].
Duncan and Masri reported that they measured therapeutic tobramycin and
vancomycin levels in drainage fluid in patients treated for an infected pros-
thesis with PMMA that contained one of these antibiotics [Duncan, 1995].
Serum levels remained below 3 µg/ml in these patients, despite the addition
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of as much of 3.6 g of tobramycin per 40g of bone cement. Tobramycin was
shown to elute more efficiently than vancomycin in several studies [Duncan,
1995, Greene, 1998, Klekamp, 1999, Masri, 1998a, Seyral, 1994]. Lawson et
al. reported no difference in elution characteristic from PMMA of these two
antibiotics [Lawson, 1990]. The release of vancomycin from low viscosity
PMMA was studied by Chohfi et al. in a sheep model [Chohfi, 1998]. Bone
levels above the break point of susceptibility to vancomycin (4mg/l) were
obtained for 6 months, although the bone levels varied considerably. For clin-
ical use, these authors added gentamicin to the vancomycin-loaded cement,
since the antibacterial spectrum of vancomycin is narrow. Yaniv et al. found
longer leaching times from PMMA for vancomycin and a polymyxin B
derivate than for gentamicin, novobiocin, and erythromycin [Yaniv, 1999].
The combination of tobramycin and vancomycin in PMMA increased the elu-
tion of one or both in the study of Penner et al. and Masri et al., whereas it
had no influence on the elution of either of the two in the study of Seyral et
al., and even decreased the elution of tobramycin in the study of Klekamp et
al [Klekamp, 1999, Masri, 1998a, Penner, 1996, Seyral, 1994]. Variation in
mixing of the bone cement, and dose or particle size of the antibiotics might
explain some of these reported differences. The survival of bacteria on
tobramycin- or vancomycin-containing PMMA, as noted by Kendall et al. in
an in vitro model, was not seen in their subsequent prospective in vivo
retrieval study in patients treated for an infected joint prosthesis [Kendall,
1995, Kendall, 1996]. The latter study revealed no bacterial growth and no
bioadherence to bone cement that was loaded with tobramycin or van-
comycin.
Risk of allergy to antibiotics in bone cement is often cited, but until now no
hypersensitivity reaction has been reported, although topical use of neomycin
has been reported to be associated with allergic reactions [Chapman, 1976,
Chohfi, 1998, Desoto, 1984, Holm, 1976, Levin, 1975, Schurman, 1978,
Wininger, 1996].
Temporary spacers, made of antibiotic-loaded PMMA, or in which some kind
of endoskeleton is coated with this bone cement, like PROSTALAC, have been
developed to prevent some of the drawbacks of a two-stage exchange proce-
dure [Abendschein, 1992, Booth, 1989, Borden, 1987, Duncan, 1995,
Haddad, 2000, Ivarsson, 1994, Masri, 1995, Masri, 1998c, Wilde, 1988,
Younger, 1998, Younger, 1997]. Such spacers may prevent shortening of the
soft-tissues and limit the loss of mobility of the joint, and provides for local
antibiotic delivery during the interval between the two stages of the proce-
dure. Articulating spacers, made from PMMA or loosely fixated with PMMA,
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have been developed to allow for joint mobility during treatment [Fehring,
2000, Hofmann, 1995a, Masri, 1998b]. This modification may not improve
functional outcome as compared to static spacers, but decreases the risk of
bone loss [Fehring, 2000]. The elution of antibiotics from PMMA spacers is
lower as compared to PMMA beads, due to the smaller surface area of spacers
[Greene, 1998]. Because the load-bearing demands are lower for spacers
than for bone cement used to anchor prostheses, higher amounts of antibi-
otics are usually loaded in these spacers. Hofmann et al. used 4.8 g of
tobramycin with each 40-g batch of Simplex cement applied on articulating
knee spacers to fill bone defects without adherence to bone [Hofmann,
1995a]. Masri et al. showed that the use of at least 3.6 g of tobramycin per
package of bone cement to coat the temporary spacer, allows reliable antibi-
otic elution for at least 4 months following implantation [Masri, 1998b].
Vancomycin release was not as reliable as tobramycin in this study. Using
PROSTALAC before the reimplantation of a definitive prosthesis, the infection
cure rate was reported to be higher than 90% after minimum 2-year follow-
up [Masri, 1998a, Younger, 1997].
The in vivo release of antibiotics from PMMA that is presumed to be sufficient
for inhibition of local bacterial growth of most bacteria encountered in pros-
thesis infection, has been reported to last from a few weeks to months
[Lodenkamper, 1982]. Baker and Greenham suggested that release of gen-
tamicin from PMMA occurs from the surface of cement and through a net-
work of bubble-like voids and cracks in its matrix [Baker, 1988]. In their
study, no diffusion of gentamicin through a 0.8 mm thick PMMA disks was
observed in a 9-months experiment. These findings confirmed results from a
similar diffusion study by Bayston et al [Bayston, 1982]. Recently, Van de Belt
et al. concluded from their in vitro study that the release kinetics of gentam-
icin from bone cement are controlled by a combination of surface roughness
and porosity [van de Belt, 2000]. Masri et al. demonstrated that the elution
of antibiotic from bone cement up to one week was merely related to surface
patterns rather than changes in volume [Masri, 1995]. However, the clinical
significance of this phenomenon can be questioned, since it might be more
effective to improve low elution rates beyond this time frame. Kuechle et al.
suggested the addition of dextran to PMMA beads, because the resulting
increase of porosity facilitated elution of antibiotics [Kuechle, 1991]. The
inclusion of such additives in PMMA was proposed earlier by Ruckdeschel et
al., and studied by other authors [Robinson, 1989, Ruckdeschel, 1973].
Because the majority of antibiotic may remain inside the PMMA when the dif-
fusion rate is low or zero, it is not surprising that disruption of the bone
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cement mantle during revision or in experiments, can result in detectable
concentration of antibiotic for months or years after insertion. Several
authors confirmed such findings [Baker, 1988, Bayston, 1982, Lodenkamper,
1982, Wahlig, 1980, Wannske, 1976]. Powles et al. detected antibiotic con-
centrations even up to 10 years after insertion of antibiotic-containing bone
cement [Powles, 1998].
In 1979, PMMA containing silver composites were tested by Spadaro et al. for
antibacterial activity [Spadaro, 1979]. Of the 4 different silver composites,
silver sulfate (Ag2SO4]. was the most effective. This cement was compared
with gentamicin-containing PMMA in an experimental model of S. aureus
osteomyelitis [Dueland, 1982]. Both cements, introduced in the rabbit tibia
as prepolymerized rods, did not prevent completely the development of infec-
tion, but gentamicin-containing PMMA had a significant higher reduction of
bacterial counts as compared to plain or silver-containing PMMA.
Voos et al. demonstrated in a goat model that tobramycin-impregnated
PMMA, in the form of pin sleeves, could also protect external fixator pins
from infection [Voos, 1999].
I PMMA beads
Since 1971, two years after the first clinical use of gentamicin-containing
PMMA by Buchholz et al. for implant fixation, gentamicin-containing PMMA
beads have been used for the treatment of osteomyelitis defects [Buchholz,
1981, Buchholz, 1970, Eitenmuller, 1985, Klemm, 1974, Klemm, 1979,
Wahlig, 1978]. Hovelius et al. reported the successful use of these beads in
two-stage exchange procedures [Hovelius, 1979]. Initially applied as loose
beads, these beads were later attached on a stainless steel wire and placed as
chains in the debrided wound cavity. This facilitated subsequent removal of
the beads, usually after a period of 10-15 days. Wahlig et al. reported effec-
tive elution of gentamicin up to two weeks in the cortex of canine femora, in
which gentamicin-containing PMMA beads were added [Wahlig, 1978]. Later,
also other PMMA beads impregnated with other antibiotics were studied.
Laky et al. showed that gentamicin and tobramycin, released from
intramedullary placed PMMA beads in rabbit tibiae, were longer detectable
than cephalothin [Laky, 1983]. Unfavorable elution characteristics from
PMMA beads of cefazolin, ciprofloxacin and ticarcillin in canine tibiae, in
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contrast to the good elution of tobramycin, vancomycin and clindamycin
were reported [Adams, 1992]. In an in vitro study of Mader et al., clin-
damycin and tobramycin concentrations derived from PMMA beads remained
much longer (through 30 weeks) above their respective breakpoint sensitivi-
ties than vancomycin (12 days) [Mader, 1997]. These and other authors com-
pared the release of antibiotics from PMMA beads with that from other
biodegradable carriers [Becker, 1994, Bowyer, 1994, Garvin, 1994, Mader,
1997]. As discussed below, a release profile from PMMA beads can be dis-
tilled from most studies that includes a lower initial burst, and a subsequent
longer release of antibiotics than that of biodegradable carriers. Greene
reported that the in vitro elution of tobramycin from PMMA beads remained
above the MIC for more than 3-6 months, whereas others showed adequate
tobramycin release levels eluted in vitro from PMMA beads for as long as 14
to 28 days [Goodell, 1986, Greene, 1998, Kirkpatrick, 1985, Miclau, 1993,
Nelson, 1992, Wilson, 1988]. Nelson et al. studied the in vitro release charac-
teristics of commercially and noncommercially prepared antibiotic PMMA
beads. The addition of 2.0 g of gentamicin to hand-mixed PMMA beads did
not produce any higher long term antibiotic levels than did 1.2 g of
tobramycin mixed with cement of any brand [Nelson, 1992]. Others found
superior elution characteristics of tobramycin- or vancomycin-loaded PMMA
beads or spacers for one brand of cement (Palacos R) as compared to another
(Simplex P) [Greene, 1998]. In an in vitro study, the release of tobramycin
from a single bead over three months was calculated to be only a fraction of
the theoretically available tobramycin [Goodell, 1986]. The differences in
elution of tobramycin and other antibiotics from PMMA beads that are found
in both in vitro and in vivo studies can be explained by the variations in size,
shape, porosity and number of the beads, the amount of impregnated antibi-
otics and differences in sampling methods and -solutions [Adams, 1992,
Bayston, 1982, Seligson, 1993, Seligson, 1985, von Frauhofer, 1985, Wilson,
1988]. For instance, elution of antibiotics from bone cement has been meas-
ured using techniques of different bioassays, scintillation counting, radioim-
munoassay or a more recent technique of immunofluorescence polarization
assay [Kuechle, 1991, Penner, 1999, Schurman, 1978]. To ameliorate the
inhibition of bone metabolism, caused by acidification due to osteomyelitis
and high local tobramycin concentration (>500 µg/ml), Murakami et al. sug-
gested the incorporation of an alkalinizing agent (Ca(OH)2) into PMMA
beads impregnated with antibiotics such as tobramycin [Murakami, 1996,
Murakami, 1997].
Treatment of a contaminated fracture with tobramycin-containing PMMA
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beads in rabbits had a success rate of 75% in contrast to 25% in the group
treated with tobramycin intramuscularly [Seligson, 1992]. In a similar exper-
iment, tobramycin-containing PMMA beads were shown to be effective in pre-
venting bacterial adherence to these beads [Lyons, 1992]. In a limited in vivo
study of Yaniv et al., implantation of PMMA beads impregnated with a
polymyxin B derivate was superior to gentamicin-impregnated beads in pro-
tecting rabbits against P. aeruginosa osteomyelitis [Yaniv, 1999]. Adequate
concentrations of tobramycin were demonstrated in patients with compound
fractures, who had been treated prophylactically with tobramycin-impregnat-
ed PMMA beads [Eckman, 1988]. Due randomization problems, Blaha et al.
failed to demonstrate superiority of systemic antibiotics or gentamicin-con-
taining PMMA beads (Septopal) [Blaha, 1993]. According to Chen et al.,
tobramycin-containing beads enhanced the effect of systemic antibiotics in
bacterial clearance of wounds contaminated with S. aureus [Chen, 1993].
Although the authors claimed that the doses of the systemic antibiotics
(tobramycin and cefazolin) produced therapeutic serum concentrations, they
failed to cite the studies that could support this claim. Thus, the effect of
tobramycin-containing beads might have been less pronounced when higher
systemic doses were given. Successful management of chronic osteomyelitis
in patients with tobramycin- or vancomycin-impregnated PMMA beads has
been reported [Scott, 1988].
Antibiotic-impregnated PMMA beads have not only been studied for use in
orthopaedic infections, but also for infections of the abdomen, head or chest
[Alpert, 1989, Mavroudis, 1988, McKellar, 1999, Rosen, 1991]. Gentamicin-
containing beads were implanted in maxillofacial wounds in dogs by Alpert et
al., and by Rosen et al. in sacroperineal wounds after rectum excision in
patients with rectal or anal carcinoma. McKellar et al. used vancomycin- and
tobramycin-impregnated PMMA beads to control an infection of an implanted
artificial heart assist device. In an experimental model, Mavroudis et al. used
tobramycin-impregnated PMMA beads to treat thoracic empyema in guinea
pigs
I Calcium phosphate ceramics
Hydroxyapatite ceramics (HA) and other calcium phosphates are osteocon-
ductive materials and can be used as bone fillers. In addition, these materials
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have been studied for use as a delivery system for antibiotics and other drugs.
Eitenm ller et al. reported some experimental and clinical success in treating
osteomyelitic defects in dogs and patients with flucloxacillin-, respectively
gentamicin-containing HA granules [Eitenmuller, 1985]. Cornell et al.
obtained similar results using gentamicin-containing HA beads in
osteomyelitic defects in tibiae of rabbits (infection control rate 73%)
[Cornell, 1993]. Cefoperazone and flomoxef were shown to be less effective
released from sintered porous HA than gentamicin in vitro, and in subsequent
experiments the latter antibiotic was detectable until approximately 2 months
after insertion of this HA in rabbit tibia [Shinto, 1992]. In a subsequent study,
these authors found gentamicin-HA composites to be efficacious in treating
implant-related infections in rats [Korkusuz, 1993]. In a preliminary report,
Itokazu et al. showed that porous HA blocks impregnated with different
antibiotics contributed to infection control in 14 of 15 patients [Itokazu,
1998]. Although HA implants allow healing of bone defects by ingrowth of
bone, reports on the biodegradability of the crystalline matrix range from full
to none [Cornell, 1993, Eitenmuller, 1983, LeGeros, 1993]. Thus, theoretical-
ly, their persistence as a foreign body may complicate infection healing, when
these implants are used as an alternative for bone graft to replace PMMA
beads for the treatment of chronic osteomyelitic defects [Hamanashi, 1996,
Korkusuz, 1993].
Self-setting HA cements loaded with antibiotics can be formed in situ and
molded in osteomyelitic defects [Hamanashi, 1996, Otsuka, 1990, Solberg,
1999]. Higher antibiotic concentrations in such cements resulted in a longer
in vitro release periods, but may have an inhibitory effect on bone conduction
[Hamanashi, 1996, Otsuka, 1990]. Solberg et al. showed that both self-set-
ting HA and PMMA, used as a gentamicin-containing void-filler for an chron-
ic osteomyelitic defect in the rat tibia, could actually treat the infection.
Biphasic calcium phosphate ceramic, processed by compaction instead of sin-
tering, allows for a more regular and sustained release of antibiotics, provid-
ed that the integrity of the compact can be controlled [Gautier, 2000, Trecant,
1997].
Since hydroxyapatite is brittle, self-setting apatitic glass ceramics with high
compressive strength have been developed that can be loaded with antibiotics
[Kawanabe, 1998, Otsuka, 1997]. The bioactivity (i.e. the capacity to form a
chemical bond with bone) of these and other composites containing glass
ceramics can enhance bone ingrowth in (osteomyelitic) bone defects [Ragel,
2000].
By changing the composition and/or porosity of the material, or the solubility
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of the antibiotic agent, release rates can be varied. In addition, the technique
applied for incorporating antibiotic into ceramics influence the loading capac-
ity and release rate [Gautier, 2000]. The release rate of antibiotics from
biodegradable materials like some calcium phosphate materials depends also
partially on the biodegradation or bioresorption rate of these materials. This
biodegradation rate is not only influenced by the chemical composition, form
and cristallinity of the material, but also by variables like implantation site
(osseous or non-osseous, cancellous or cortical bone), metabolic activity,
presence of infection and type of cells involved [LeGeros, 1993].
Modification of the solubility of the antibiotic agents can optimize the release
rate. The lower release rate of vancomycin from tricalcium phosphate ceram-
ic beads as compared to gentamicin was explained by the higher molecular
weight and lower solubility of vancomycin. The incorporation of cefotiam
with a lipid before loading HA beads was shown to decrease its release rate
from these beads [Yamamura, 1992]. An additional biodegradable coating
has been proposed to delay the release of antibiotics from tricalcium phos-
phate beads [Eitenmuller, 1983]. A similar principle was applied by Radin et
al. to prevent a burst  release from an antibiotic-loaded calcium phosphate
ceramic coating [Radin, 1997]. A second lipid coating on titanium discs pro-
longed the release of vancomycin up to 3 days in their in vitro study. Sasaki
and Ishii included poly-L-lactic acid particles loaded with gentamicin in calci-
um phosphate cement implants to extend the release over a 2-months period
of this antibiotic from the cement [Sasaki, 1999]. Composites of similar mate-
rials were shown earlier to release prophylactic levels of kanamycin in rabbit
tibiae over a period of 3-4 weeks, and other authors sought to improve the
release characteristics with additional coating formulations [Ikada, 1985,
Soriano, 2000].
Because the rapid release of antibiotics from biodegradable materials may
result from the adherence of antibiotics to the surface, rather than truly con-
tainment of the latter, an alternative for antibiotic-containing PMMA bone
cement was developed by Gerhart et al [Gerhart, 1988]. Although the
mechanical strength of this hydrolyzable polymer cement, with calcium -
phosphate and -carbonate substitutes, is not that high as PMMA, it is more
biodegradable than the latter, thereby eliminating the need for a subsequent
removal of the beads. In a later study, Gerhart et al. could not show a differ-
ence in treatment efficacy in rats between these two types of bone cement,
added with both gentamicin and vancomycin [Gerhart, 1993].
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I Collagen
Gentamicin-containing collagen sponges from bovine origin are commercially
available since 1987. Release of the antibiotic occurs through diffusion and
enzymatic degradation of the collagen [Mehta, 1996]. Becker showed that
tobramycin-loaded PMMA beads delivered therapeutic concentrations longer
than tobramycin loaded collagen sponge, because the first can withstand
compressive loading generated by the body [Becker, 1994]. Because drug
release from a collagen implant declines rapidly within one week, this materi-
al may not be optimal for the treatment of chronic osteomyelitis [Becker,
1994, Humphrey, 1998, Wachol-Drewek, 1996]. However, some authors
reported clinical success, using this material as an adjunct treatment in bone
and soft-tissue infections [Ipsen, 1991, Kwasny, 1994]. In addition, gentam-
icin-containing collagen sponge, which also has a hemostatic effect, has been
used as a prophylactic agent mixed with bone graft or in cementless arthro-
plasty [Ascherl, 1986, Kwasny, 1994].
I Biodegradable synthetic polymers
Another biodegradable carrier of antibiotic is polymerized lactic acid, in the
form of polymerized dilactide or lactide/glycolide copolymer of various
molecular weights [Kanellakopoulou, 2000]. The degradation rate of lactic
acid polymers, and thereby the release rate of antibiotic from these implants,
depends on their molecular weight [Ikada, 1985]. Lactic acid oligomer
degrades faster and releases antibiotic more rapidly than high-molecular-
weight polylactide [Kanellakopoulou, 1999, Wei, 1991]. Wei et al. showed
effective local release levels of kanamycin in the vicinity of lactic acid
oligomer implants in the rabbit s femur up to 4 weeks after implantation
[Wei, 1991]. Release and penetration rate of this antibiotic was shown to be
10-fold higher in bone marrow than in cancellous or cortical bone. Bulk ero-
sion of lactic acid polymers, in contrast to erosion of other polymers by lay-
ers, can result in an in vitro release profile of quinolones or aminoglycosides
that has its maximum beyond the first week of implantation, as seen by some
authors [Andreopoulos, 1996, Dounis, 1996, Wei, 1991]. Again, in vivo stud-
ies can show a more rapid release from these implants than in vitro data sug-
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gest [Kanellakopoulou, 1999]. Zhang et al. tried to control drug release by
changing the length of small antibiotic-containing PLA cylinders with an
additional PLA coating, out of which the antibiotic could only diffuse through
the open ends [Zhang, 1994]. These authors concluded that cefazolin and
penicillin were unsuitable for sustained release longer than 25 days due to
their instability in water.
Copolymers of polylactide with for instance polyglycolide, in use since 1975
as synthetic absorbable suture materials alternatively to the existing PLA and
polyglycolic acid sutures, have also been studied to improve the administra-
tion of antibiotics for treatment of orthopaedic infections [Calhoun, 1997,
Galandiuk, 1997, Garvin, 1994, Gilding, 1979]. In a model of a thigh muscle
wound, ampicillin encapsulated in polylactide:coglycolide (PL:CG) was found
to treat all rats inoculated with Streptococcus pyogenes, and most wounds
inoculated with S. aureus [Setterstrom, 1985]. In addition, the efficacy of
these microcapsules to prevent S. aureus infections was shown for tibial
osteomyelitis in rabbits [Jacob, 1991]. When the treatment was delayed for
one week in this model, the ampicillin-PL:CG microcapsules cleared all infec-
tions only when used in conjunction with surgical debridement.
Unencapsulated ampicillin powder was less effective than its microencapsu-
lated counterpart when applied locally [Jacob, 1991, Setterstrom, 1985].
Similar results were found in a rabbit model of prophylaxis (delayed for 2
hours) of S. aureus infection in tibial fractures with either cefazolin micros-
pheres or free cefazolin powder [Jacob, 1997]. In contrast, prophylaxis with
locally applied free cefazolin powder reached some moderate efficacy when
this treatment started within 30 minutes after contamination with S. aureus
[Jacob, 1993]. In the in vitro study of Mader et al., discussed above, the
release of antibiotics from PMMA beads was compared with that from
biodegradable materials [Mader, 1997]. Antibiotic-loaded PLA, PL:CG, and a
combination of these two, did not release adequate concentrations for longer
than 10 weeks and dissolved between 5 and 25 weeks. Both tobramycin and
clindamycin, but not vancomycin, were released longer from PMMA. Garvin
et al. compared the efficacy of PL:CG- and PMMA implants containing gen-
tamicin in the treatment of S. aureus osteomyelitis in dogs [Garvin, 1994]. No
significant difference was found in the successful treatment of this infection
between the implants, both with a relatively (as compared to previous stud-
ies) high gentamicin:polymer ratio of 1:1. Calhoun and Mader used van-
comycin-containing PLA- and PL:CG beads to treat S. aureus osteomyelitis
that was induced in the rabbits two weeks earlier [Calhoun, 1997]. Although
the outcome in the rabbits treated with these beads after debridement
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improved as compared to controls and systemically treated rabbits, the
osteomyelitis could not be eradicated completely. In another rabbit model,
the local application of a PL:CG containing ofloxacin resulted in an steriliza-
tion rate  of 83-91%, 4 weeks after the inoculation with P. aeruginosa in the
distal femur [Nie, 1998]. The limited histological data presented in this study
suggest that the infection continued in a higher number of rabbits than
expected from the outcome of culture. Liu et al. studied the effect of process-
ing parameters, like sintering temperature and compression pressure, on the
in vitro release rate (up to 4-5 weeks) of vancomycin from PL:CG beads [Liu,
1999]. Like PLA, changes in molecular weight or composition ratio, size of
beads and an additional coating also influenced the release of antibiotic from
PL:CG beads [Lin, 1999c, Liu, 1999, Nie, 1995].
Du et al. composed soft, bioerodible implantable discs of a poly(ortho esters)
polymer to release tobramycin over a 3-week period for the treatment of
osteomyelitis [Du, 1997]. Results from their in vitro study suggested that the
release rate of tobramycin could be controlled by altering the concentration
of acidic additives to the implant.
Laurencin et al. reported that a bioerodible polyanhydride copolymer of bis-
carboxyphenoxypropane and sebacic acid loaded with gentamicin reduced
the bacterial counts in a rat model of osteomyelitis, but 3 out of 5 infections
were still present after 3 weeks of treatment [Laurencin, 1993]. Another
polyanhydride (Septacin) that has been developed for the local treatment of
osteomyelitis, contains erucic acid as the copolymer of sebacic acid
[Stephens, 2000].
Recently, the biodegradable aminopolysaccharide chitosan was introduced as
an antibiotic carrier that could be used in treatment of chronic osteomyelitis
[Aimin, 1999]. In this study, the gelatinized substance, in the form of small
cylinders, released gentamicin in concentrations above MIC level for S. aureus
over 25 days in vitro and up to 2-8 weeks in vivo in rabbits. As could be noted
from a small peak in the gentamicin release at 6 weeks, these implants finally
cracked and burst due to swelling. In vitro, the inhibitory effect on the growth
of S. aureus lasted for 7 weeks, whereas this effect ended within 3 weeks for
P. aeruginosa [Aimin, 1999].
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I Other materials and approaches
Other examples of anti-infective techniques for local application in surgery
are silver ionthophoresis and the use of local drug pumps. In the first, the
wound penetration of silver ions from a silver wire anode was limited to a
depth of 1 cm [Becker, 1978]. The latter technique consists of drug delivery
via a catheter that connects the infected site with a subcutaneously implanted
or portable pump [Meani, 1994, Meani, 1998, Perry, 1992, Perry, 1985, Perry,
1986]. The risk of infection of the catheter and implantable pump has been
reported by these authors, and might be less for the portable variant. Such
techniques are not widely used for the local treatment of orthopaedic infec-
tions. In contrast, some antibiotic-loaded carriers are being used extensively
for this purpose, and much of the ongoing research focuses on the improve-
ment of the characteristics, like biodegradability, of these implants.
Instead of studying intrinsic  biodegradation characteristics of the material,
antibiotic-delivery systems might also be optimized by creating a release
response that specifically depends on the local infection. Susuki et al. devel-
oped a hydrogel wound dressing that would not release antibiotic per se, but
only in the presence of specific bacteria [Lin, 1999b, Suzuki, 1998]. These
authors showed some inhibition of P. aeruginosa growth in vitro, by binding
gentamicin to the dressing material through a peptide that is cleavable by a
proteinase specific to this bacterial species.
Since not all implantations of orthopaedic prostheses and fracture-fixation
hardware are associated with the use of PMMA bone cement or biodegrad-
able pellets, alternatives for local antibiotic delivery systems have been stud-
ied for infection prophylaxis. These include the binding of antimicrobials, or
proteins that inhibit bacterial adherence to the surface of an implant.
Attempts have been made to decrease bacterial adherence on orthopaedic
devices by a cross-linked albumin coating. Despite in vitro studies that
showed more than 85% inhibition of bovine or human serum albumin on
bacterial adherence to titanium surfaces, only a reduction of 35% in
osteomyelitis rate was reported by An et al., using such an implant in a rabbit
model [An, 1997, An, 1996, McDowell, 1995].
Other studies aim at binding antimicrobials, either antiseptics or antibiotics,
to the surface of orthopaedic devices to prevent infections. Such drugs can be
attached (directly or as a coating) to the implant surface, or the existing coat-
ing (like an HA-coating of an uncemented prosthesis) can be loaded with
antimicrobials. These techniques have also found their application in other
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fields of surgery for the prevention of infections, related to prosthetic-devices
like urinary catheters, cerebrospinal fluid shunts, vascular grafts, and pace-
makers [Kockro, 2000, Leblebicioglu, 1999, Raad, 1995, van Wachem, 1998].
In 1994, Dunn et al. introduced a technique to attach ciprofloxacin electrosta-
tically to the surface of a porous coated titanium-6% aluminium-4% vanadi-
um alloy (Ti-6Al-4V) implant [Dunn, 1994]. He showed that more antibiotic
(up to 3 mg/cm2, released in vitro over a period of 5 days) could be attached
to the implants using this technique, as compared to a previously reported
method that involved the electrostatically attachment of gentamicin to the
anodized surface of Ti-6Al-4V [Dunn, 1993]. In their latest study, the authors
did not perform fatigue tests, but earlier results showed that a microporous
oxide coating decreased the fatigue strength of Ti-6Al-4V samples with 19%
[Dunn, 1993, Dunn, 1994]. Price et al. impregnated gentamicin in a PLGA-
film on a stainless steel fracture plate [Price, 1996]. The in vitro release rate
of gentamicin as a function of antibiotic concentration of the film had its opti-
mum at a 20% loading concentration of the coating. The coating with a high-
er load did not maintain effective levels in elution through 20 days, despite
an initially high release rate (burst effect). Their in vitro bacterial inhibition
study, using the implant containing 40 mg of gentamicin (20% loading con-
centration), showed an almost complete reduction of bacterial growth over
24 days.
In an experimental study of Darouiche et al., the use of intramedullary nails,
coated with an antiseptic combination of chlorhexidine and chloroxylenol, for
fixation of tibial fractures was associated with a significant reduction in the
rate of device-related osteomyelitis (relative risk, 6.81) [Darouiche, 1998].
This reduction might have been higher when the rabbits would not have
received cefazolin as an additional perioperative infection prophylaxis.
Campbell et al. incorporated chlorhexidine into the hydroxyapatite coating of
external fixator pins [Campbell, 2000]. A lipid overlayer was needed to
retard the initial release rate to over 24 hours. Improvement of release char-
acteristics seems warranted, because the indication for use of this type of
coating is the prevention of infection of external fixator pins, which, as the
authors indicated, may remain in place for several months. In other studies of
pin tract infections, silver-coated pins were used for this indication. In vitro,
some reduction in bacterial adherence was seen using these pins [Wassall,
1997]. Only a small reduction in infection rate was found in a goat model,
whereas Masse et al. found no significant reduction in a prospective random-
ized clinical study [Collinge, 1994, Masse, 2000]. Because the implantation
of silver-coated screws in 24 patients with lower limb fractures also resulted
99
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in a significant increase in serum iron levels, the authors of the latter study
considered it ethically unacceptable to continue their investigation.
I Summary remarks on antimicrobial-loaded
implants
In this chapter, the limited review of literature on antimicrobial-loaded carri-
ers that have been proposed for use in musculoskeletal infection shows that
treatment options are evolving. The concept of a local anti-infective agent
that is directed specifically at the local site of the infectious process has stood
firmly for more than half a century now in the management of orthopaedic
infections. Nevertheless, in the latest decades many new variants of antimi-
crobial-loaded carriers have been studied, aiming at a still more efficacious
antimicrobial treatment. Antibiotic-containing bone cement, like the one that
is the subject of experimental studies described in the next chapters of this
thesis, is most often used in the management of prosthesis infection. In bead
form, this cement is used frequently to treat chronic osteomyelitic processes
or in exchange procedures for an infected implant. Other carriers are primari-
ly indicated for infection prophylaxis in fracture fixation, or should eventually
be fully replaced by ingrowth of surrounding bone or soft tissues in large
osteomyelitic defects. Thus, the site and extent of an infectious process
directs the choice for a specific type of antimicrobial-loaded implant.
However, because many new materials have become available, which allow
tailoring of release and biodegradation characteristics of such implants, the
armamantarium of local anti-infective treatment has grown.
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I Introduction
Since 1969, various combinations of antibiotics and bone cement have been
used in the prevention and treatment of arthroplasty infections [Buchholz,
1970, Elson, 1977b, Murray, 1984]. Tobramycin, like other aminoglycosides,
is heat-stable, which makes it suitable for incorporation in polymethyl-
methacrylate (PMMA). In addition, tobramycin is potentially active against
the most frequently found causative infective organisms in arthroplasty sur-
gery (Staphylococcus species and aerobic Gram-negative bacilli).
In order to be effective in preventing or treating arthroplasty infections antibi-
otic-containing bone cement must fulfil two requirements. Firstly, the antibi-
otic should elute in a concentration that exceeds the susceptibility level for
the infecting bacteria. This is the minimal inhibitory concentration (MIC),
defined as the lowest concentration of antibiotic that prevents visible growth
after an 18-24 hours incubation in vitro. Secondly, this concentration should
be reached at the site of contamination or infection. Thus in arthroplasty sur-
gery, the antibiotic concentration should be sufficiently high (i.e. well above
the MIC) at the site of the implant, especially at the bone-cement interface
and in the surrounding bone. In addition, the antibiotic concentration in
serum should not exceed toxic levels.
Release studies of tobramycin-containing bone cement are limited. Seyral et
al., Miclau et al. and Lawson et al. demonstrated in vitro elution of
tobramycin from PMMA bone cement [Lawson, 1990, Miclau, 1993, Seyral,
1994]. The presence of tobramycin in wound drainage, serum and urine of
patients who underwent total hip arthroplasty with tobramycin-containing
cement has been shown [Brien, 1993, Pritchett, 1992]. In addition,
tobramycin release from cement beads and spacers has been studied in vivo
[Adams, 1992, Masri, 1995, Seligson, 1992].
In the present study, we determined the release of tobramycin from
tobramycin-containing bone cement in an animal model. Tobramycin release
in blood and bone as a function of time was measured in rabbits, after inser-
tion of tobramycin-containing cement into the femur. The longest follow-up
period was 28 days.
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I Materials and methods
Animals
Thirty-nine healthy adult female New Zealand White rabbits (Ico:NZW,
Broekman Instituut BV, Someren, The Netherlands), ranging in weight from
2.8 to 3.5 kg, were obtained one week before surgery to acclimatize to the
housing in the Central Animal Laboratory Institute, Utrecht University. The
animals were caged individually, fed with 80-100 g antibiotics-free rabbit diet
(Hope Farms Standard laboratory Diet LKK-20, Hope Farms BV, Woerden, The
Netherlands) and water ad libitum.
Cement
Surgical Simplex P bone cement, containing 1.0 g tobramycin as a sulphate in
60.0 g methyl metacrylate (batch: # N6043), was supplied by Stryker-
Howmedica-Osteonics, Rutherford, NJ.
This radiopaque bone cement is a mixture of a liquid component (monomer)
and a powder component (polymer), both sterilized. The composition of the
powder component is: polymethyl methacrylate (6.0 g), methyl methacry-
late-styrene copolymer (30.0 g) barium sulphate (4.0 g) tobramycin (as a sul-
phate, 1.0 g). The liquid component (20 ml) is composed of methyl
methacrylate (97.4% vol/vol), N,N-dimethyl-p-toluidine (2.6% vol/vol) and
hydroquinone (75 – 15 ppm). The bone cement (4¡C) was vacuum-mixed (-
0.9 bar) for 1 minute on the surgical table (Simplex cement vacuum-mixer;
Stryker-Howmedica-Osteonics, Rutherford, NJ).
Experimental design
Tobramycin-containing bone cement was introduced into the medullary canal
of the right femur of the rabbits. At 1, 3, 7, 14, 21 and 28 days, groups of six
rabbits were killed and the tobramycin levels in bone adjacent to the cement
were assayed. Bone from the left femur without cement served as control.
Tobramycin serum levels were also measured.
The experimental design was approved by the institutional review board
(Animal Care and Use Committee, Faculty of Medicine, Utrecht University).
Anesthesia
Surgery was performed under general inhalation anesthesia. The anesthesia
was prepared by an intramuscular (i.m.) injection of 0.2 mg methadone
(methadoneHCl 10 mg/ml), 0.2 mg acepromazinemaleate (Vetranquil;
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Sanofi Sant BV, Maassluis, The Netherlands) and 0.5 mg atropine (Atropine-
sulphate, Kobivet, Etten-Leur, The Netherlands). A pressure line was intro-
duced into the auricular artery for measuring blood pressure. Subsequently,
anesthesia was induced by an intravenous injection of 8-12 mg etomidate
(Hypnomidate; Janssen Pharmaceutica BV, Tilburg, The Netherlands). An
endotracheal tube (#3) was introduced through which the anesthesia was
maintained with a 1:1 mixture of nitrous oxide, oxygen and halothane 1%
(Albic BV, Maassluis, The Netherlands). If the blood pressure fell after inser-
tion of the cement, dopamineNaCl (0.25 mg/ml; ICN Pharmaceuticals
Holland BV, Zoetermeer, The Netherlands) was injected intravenously.
Operative technique
Surgery was performed under strict aseptic conditions. The skin of the outer
right thigh was clipped and the rabbit was placed with its left side on the
table. The operative area was disinfected with a 2% tincture of iodine and
isolated by sterile drapes. Subsequently, a skin incision (approximately 3 cm)
was made over the trochanter tertius of the right femur, parallel to the femur
shaft. The trochanter tertius was exposed by splitting the fascia, retracting
the femoral biceps and coccygeofemoral muscles posterio-medially, and
scraping the periost. Using an air-pressured AO minidrill the cortex was pene-
trated by a small drill (diameter 1.2 mm). Subsequently this hole was
widened and the femoral canal was reamed with drills and fraises up to 4.0
mm in width until a silicon tube (monitor line, outer diameter 3.0 mm) could
be inserted. After vacuum mixing of the PMMA-tobramycin bone cement, a
small 6-ml syringe, with a 2-cm long silicon tube (outer diameter 3.0 mm,
inner diameter 1.5 mm) attached to it, was filled with cement. The syringe
was weighed on an electronic balance (PT150; Sartorius-Instrumenten BV,
Nieuwegein, The Netherlands). 
Before insertion of cement, the medullary canal was washed with sterile
physiologic saline and suctioned. The syringe was placed in an adapted
device on an applicator gun and approximately 1.2 ml cement was injected
gently into the femoral canal, while the syringe was slowly being retracted.
Subsequently, the syringe was weighed again in order to know the exact
amount of cement injected. After polymerization of the cement and wound
drainage with sterile saline solution, the fascia, subcutis and cutis were
closed with Vicryl 3-0 (Ethicon GmbH & Co KG, Norderstedt, Germany). Pain
relief was provided by 0.3 ml nalbufine (Nubain; Lamepro BV,
Raamsdonkveer, The Netherlands) i.m. immediately postoperative, and sub-
sequently 0.3 ml buprenorfine (Temgesic; Rechitt and Colman Products,
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Kingston-upon-Hull, United Kingdom) i.m. (if necessary, buprenorfine injec-
tion was repeated postoperatively).
Follow-up
Postoperatively, routine AP and lateral x-rays of the right femur visualized the
position of the cement. The rabbits recovered in a temperature-controlled
recovery cage. The rabbits were monitored by a daily clinical examination,
with special attention to wound healing, the presence of a fracture, eating,
activity level and body temperature. At 1, 3, 7, 14, 21 and 28 days, groups of
six rabbits were killed with an overdose of pentobarbital N2 (Euthesate;
Apharmo BV, Arnhem, The Netherlands) intravenously.
Tobramycin assay technique
Tobramycin concentrations in bone and serum were measured by fluores-
cence polarization immunoassay (TDX, Abbot Laboratories, Chicago, IL) The
minimal detectable tobramycin concentration was 1.0 µg/g in bone and 0.10
µg/ml in serum.
Bone
The left (control) and right femur from all animals were excised and cleaned
of tissue debris. First a bone fragment was taken from the left femur from a
region corresponding to the right femur. Secondly, using a high-speed dental
drill with a circular metal saw, the external surface of the right femur was
notched circumferentially at each end of the shaft and longitudinally on two
sides, posterior and anterior. An osteotome was used to free the lateral half of
the bone from the medial half, with the cement core in situ (Figure 1). Care
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Figure 1. Femur of rabbit with lateral half of cortex excised. Cement (dotted line)
was injected proximally (arrow).
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was taken not to damage the cement. Only full-thickness cortex adjacent to
the cement was used. The bone fragments of the lateral half of each femur
were ground in a metal mortar. Samples of 1.00 g of bone were homogenized
in 10.0 ml Phosphate Buffered Saline (PBS, pH 7.4) using a Polytron PT 3100
tissue grinder (Kinetica Benelux BV, Best, The Netherlands), 3 minutes at
2500 rpm and 5 minutes at 6000 rpm. The homogenate was stored at 4¡C
overnight. Following centrifugation (3000 rpm, 7 minutes, 4¡C) the super-
natant was removed for tobramycin TDX assay.
Serum
Blood samples were taken from the auricular vein of all rabbits on the day of
killing. The 28-days rabbits also had tobramycin serum levels measured pre-
operatively, subsequently at 12 hours, and at 1, 3, 7, 14 and 21 days postop-
eratively. These samples were centrifuged at 3000 rpm for 9 minutes at 4¡C,
after which the serum was collected for tobramycin TDX assay.
E-test
The minimal inhibitory concentration (MIC) of tobramycin against S. aureus
Wood 46 was determined using the E-test (E test; AB Biodisk, Solna,
Sweden) [Brown, 1991].
Statistical analysis
Dixon s Q-test was used to determine outliers in extreme values of
tobramycin concentration.
I Results
The mean weight (– standard error of the mean, SE) of cement inserted was
1.24–0.03 g.
Two rabbits died during surgery. Histology showed fat and bone marrow
embolisms in lungs and heart. All other animals recovered well. Post-opera-
tive x-rays showed no fractures or cement outside the femur. A fracture was
seen at necropsy in one rabbit at day 21 (excluded from study).
Figure 2 shows the tobramycin concentration (mean–SE) for a period of up
to 4 weeks in serum and bone of both the operated right femur and the left
femur (control). Extreme values in each follow up group of rabbits were not
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outliers (Dixon s Q test, p<0.05). Peak tobramycin concentrations in the right
and left femur were reached on day 3 (29.9–7.0 vs. 1.7–0.3 µg/g bone
respectively, mean–SE).
The tobramycin concentration in the right femur decreased to 5.10–2.2 µg/g
(mean–SE) over 28 days. The tobramycin concentrations in serum remained
constant throughout the study, just above the detection limit of 0.1 µg/ml
(highest concentration at 12 hours 0.25–0.0 µg/ml, mean–SE).
The minimal inhibitory concentration of tobramycin for S. aureus Wood 46
was determined as 0.125 µg/ml.
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Figure 2. Tobramycin release (mean–SE) in bone of right femur (insertion of
cement) and left femur (control), and in serum.
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I Discussion
In the present study, tobramycin concentrations in the rabbit femoral cortex
adjacent to the inserted bone cement exceeded the MIC for S. aureus Wood 46
for up to 28 days: On day 3 (peak level), a mean tobramycin concentration of
239 times MIC was measured, and on day 28 still 40.8 times MIC. These
results, showing local antibiotic concentrations above the MIC levels of fre-
quently encountered bacteria in arthroplasty infection, suggest some efficacy
in the prevention and/or treatment of such an infection. Furthermore, the
measured tobramycin concentrations in bone appear to be low enough to pre-
vent bone toxicity: In recent studies, local bone concentrations of tobramycin
below 200-500 µg/ml are recommended [Miclau, 1995, Murakami, 1996].
The threshold for tobramycin-induced nephrotoxicity, another side effect asso-
ciated with aminoglycosides, is 6.0 µg/ml [Seligson, 1992]. Only serum levels
of tobramycin well below this threshold could be detected.
The exact mechanism of antibiotic release from PMMA-bone cement is not
yet clear. Amongst others, elution characteristics of antibiotic-containing
bone cement depend on amount of antibiotic, and the surface area-to-volume
ratio of the cement and the presence of voids and cracks in the cement
[Baker, 1988, Gerhart, 1988, Marks, 1976, Masri, 1995, Miclau, 1995,
Schurman, 1978, Seyral, 1994, Welch, 1978, Wroblewski, 1977]. Therefore,
the release pattern of a certain formulation of antibiotic-containing bone
cement is difficult to predict exactly from earlier studies, especially from
those using different types of antibiotics and/or bone cement. An efficacy
study on such a new formulation to be used in arthroplasty surgery should be
preceded by a release study in vivo.
Because the size of the rabbit femur is relatively small as compared to human
bone, the risk of creating a rise in intramedullary pressure by entrapment of
air during insertion of cement is present. This rise in intramedullary pressure
is a major pathogenic factor for the development of fat embolism syndrome
[Hofmann, 1995b]. Not surprisingly, histology showed embolisms to be the
cause of death of two rabbits who died just after insertion of the cement.
In conclusion, after insertion of tobramycin-containing bone cement in the
femur of a rabbit, the tobramycin release in bone up to 28 days results in high
concentrations next to the cement. Serum concentrations of tobramycin are
well below systemic toxicity threshold. Subsequent studies were performed in
order to evaluate the prevention of actual implant infection using this pre-
mixed tobramycin-containing bone cement.
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I Introduction
Staphylococcus aureus and Staphylococcus epidermidis are the most frequently
found organisms involved in arthroplasty-related infection. Incidence rates
after total joint arthroplasty of S. epidermidis (26-38% of infections) are
somewhat higher than those for S. aureus (16-24% of infections) and have
increased in the last decade [Fitzgerald, 1994, Garvin, 1993, Ostendorf,
2001, Sanzen, 1988, Tsukayama, 1996] Apparently, staphylococci have sur-
face properties that enable them to adhere and grow on implant-surfaces.
Some of these surface factors that mediate adhesion to biomaterials have
been more or less well characterized for S. epidermidis [Fleer, 1990] This sur-
face-adherent growth mode might even hamper killing of the bacteria by
antibiotics [Naylor, 1990]. Darouiche et al. showed that S. epidermidis, grown
on stainless steel nuts in presence of vancomycin, could not be eradicated
completely even though high levels of vancomycin were reached in the
biofilm [Darouiche, 1994].
The use of antibiotic containing bone cement in arthroplasty surgery provides
for high concentrations of antibiotics at the implant side, whereas the low
systemic levels of antibiotics reduce possible systemic toxicity such as in case
of aminoglycosides. Among the latter class of antibiotics, tobramycin is one of
the prime candidates for the preparation of antibiotic bone cement, because
of its antibacterial spectrum. This spectrum includes staphylococci as well as
aerobic Gram-negative bacteria like Pseudomonas aeruginosa, which is an
example of another isolate involved in arthroplasty-related infections
[Buchholz, 1981, Fitzgerald, 1994]. As compared to gentamicin, tobramycin
has a greater activity against Pseudomonas aeruginosa [Edson, 1991, Lode,
1998, Whelton, 1984]. In numerous hospitals, especially in the United States,
antibiotic containing bone cement is prepared by adding tobramycin powder
perioperatively to bone cement and subsequent hand-mixing [Heck, 1995].
This hand mixing of antibiotics with bone cement does not allow for a consis-
tent and controllable quality of the cement. A standardized preparation of
antibiotic-containing bone cement benefits not only future infection-based
efficacy studies, but also the evaluation of its biomechanical properties.
Although adding low quantities (approximately 1 g per unit) of tobramycin
has minimal effects on the fatigue life of cement, amounts of more than 2 g of
antibiotics per unit of cement has been shown to decrease the strength of
cement [Davies, 1991, Lautenschlager, 1976].
The efficacy of premixed tobramycin-containing bone cement in preventing
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implant infections has not been investigated before. In a previous study on
the release of tobramycin from commercially prepared tobramycin-containing
bone cement, the minimal inhibitory concentrations of this antibiotic against
staphylococci were exceeded for up to 28 days [Nijhof, 1997]. The purpose of
the present study was to investigate the efficacy of the same bone cement in
the prevention of local S. aureus and S. epidermidis infections.
I Materials and Methods
Experimental design
Premixed tobramycin-containing bone cement or plain bone cement (con-
trols) was introduced into the medullary canal of the rabbits right femur.
Prior to cement injection, this medullary canal had been inoculated with S.
aureus or S. epidermidis in five increasing doses. To monitor infection, the
amount of bacteria in the cortex of the femur was quantified after 7 and 28
days, when the animals were killed. In both bacteria groups 40 rabbits (20
tobramycin-cement, 20 controls) were killed after 7 days, and 20 rabbits (10
tobramycin-cement, 10 controls) after 28 days.
The guidelines according to the Dutch act on animal experiments (1985)
have been observed.
Animals
120 Healthy adult female New Zealand White rabbits (Ico:NZW, mean weight
3.1 kg, range 2.6 to 3.6 kg) were obtained one week prior to surgery to accli-
matize them to the housing in the Central Animal Laboratory Institute,
Utrecht University. The animals were fed with 80-100 g antibiotics-free rabbit
diet and water ad libitum.
Cement
Surgical Simplex P bone cement, premixed with 1.0 g of tobramycin as a sul-
phate in 60 g methyl methacrylate (batch: N6043), was supplied by Stryker-
Howmedica-Osteonics, Rutherford, NJ). This radiopaque bone cement is a
mixture of a liquid component (monomer) and a powder component (poly-
mer), both sterilized. The composition of the powder component is: poly-
methyl methacrylate (6.0 g), methyl methacrylate-styrene copolymer (30.0
g), barium sulphate (4.0 g) and tobramycin (as a sulphate, 1.0 g). The liquid
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component (20 ml) is composed of methyl methacrylate (97.4% vol/vol),
N,N-dimethyl-p-toluidine (2.6% vol/vol) and hydroquinone (75±15 parts per
million). The shelf life of premixed tobramycin-containing bone cement is 2
years. In this study all cement was used within 18 months after manufacture
and stored at room temperature until use.
Surgical Simplex P bone cement without antibiotics was used as control
[Stryker-Howmedica-Osteonics, Rutherford, NJ]
Bacterial strain
Two bacteria were used to contaminate the femur: S. aureus, strain Wood-46
(American Type Culture Collection Number 10832) and S. epidermidis, strain
O-47, [Heilmann, 1996]. The inoculum sizes of S. aureus were 103, 104, 105,
106 and 107 colony-forming units (CFU); those of S. epidermidis were 108,
108.5, 109, 109.5 and 1010 CFU. To prepare the different inocula, the concen-
tration of bacteria in Mueller-Hinton broth had been determined by serial
dilution and plating on blood agar. The injection volume of each inoculum
was 0.1 ml. Using the E-test, we determined the minimal inhibitory concen-
tration (MIC) of tobramycin to be 0.125 and 0.064 µg/ml, for S. aureus
Wood-46 and S. epidermidis O-47, respectively [Brown, 1991].
Anesthesia
Surgery was performed under strict aseptic conditions and under general
inhalation anesthesia. Preoperatively, the rabbits were weighed. The anesthe-
sia was prepared by an intramuscular injection of 4 mg methadone, 4 mg ace-
promazinemaleate and 0.5 mg atropine. Blood samples on leukocyte counts
and erythrocyte sedimentation rate were taken of all rabbits preoperatively. A
pressure line was introduced into the auricular artery for measuring blood
pressure. Subsequently, the anesthesia was induced by an intravenous injec-
tion of 8-12 mg etomidate. An endotracheal tube (#3) was introduced
through which the anesthesia was maintained by a 1:1 mixture of nitrous
oxide, oxygen and halothane 1%.
Postoperatively, pain relief was provided by 3 mg nalbufine intramuscularly
immediately postoperative and subsequently 0.1 mg buprenorfine intramus-
cularly (if necessary, buprenorfine injection was repeated postoperatively).
Operative technique
The skin of the right leg was clipped and the rabbit was placed with its left
side on the table. The operative area was disinfected with povidone-iodine
and isolated by sterile drapes. Subsequently, a skin incision (approximately 3
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cm) was made over the trochanter tertius of the right femur, parallel to the
femoral shaft. The trochanter tertius was exposed by splitting the fascia,
retracting the femoral biceps and coccygeofemoral muscles postero-medially
and scraping the periost. Using an air-pressured AO minidrill, the cortex was
penetrated by a small drill (diameter 1.2 mm). Subsequently this hole was
widened and the femoral canal was reamed with 50-mm drills and fraises up
to 4 mm in width until a silicon tube (monitor line, outer diameter 3 mm)
could be inserted. Cooled PMMA bone cement (4°C) was vacuum-mixed
(Simplex cement vacuum-mixer; Stryker-Howmedica-Osteonics, Rutherford,
NJ) at 0.9 bar for 60 s (tobramycin-containing bone cement) or 100 s (plain
bone cement) on the surgical table. Subsequently, a 6-ml syringe with a 2.0
cm long silicon tube (outer diameter 3.0 mm, inner diameter 1.5 mm) was
filled with cement, weighed, and placed in an adapted device on an applica-
tor gun. During these steps, the medullary canal was washed with sterile
physiologic saline, suctioned and inoculated with bacteria. Immediately after
inoculation, approximately 1.2 ml of the doughy cement was injected gently
into the femoral canal, while the syringe was slowly being retracted. The
expansion of the cement sealed of the entrance of the medullary canal at this
moment, thereby preventing any spill of the bacterial suspension out of the
medullary canal. The cement was allowed to polymerize in situ. The syringe
was weighed again to determine the amount of cement injected (mean
weight of cement in all rabbits was 1.24 ± 0.16 gram). After wound drainage
with sterile saline solution, the fascia, subcutis and cutis were closed with
Vicryl 3-0.
Follow-up
Postoperatively, localization of the cement was evaluated by routine antero-
posterior and lateral radiographs of the right femur (Figure 1), and the rab-
bits were allowed to recover in a temperature-controlled recovery cage.
The rabbits were monitored by a daily clinical examination, with special
attention to wound healing, the presence of a fracture, eating, activity level
and body temperature.
Erythrocyte sedimentation rate in the first hour and leukocyte counts were
measured preoperatively and weekly postoperatively.
At day 7 or 28, rabbits were killed with an overdose of pentobarbital sodium
intravenously.
Post mortem sample acquisition
Excision of the femora was performed under strict aseptic conditions. The left
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femur (no bacteria, no cement) was excised to study contamination during
the culture procedure. The skin of the hindlimbs was clipped and, with the
rabbit placed in prone position on the table, disinfected with a 2% tincture of
iodine and isolated by sterile drapes. The left (control) and right femur were
excised from all animals and tissue debris was cleaned off. First, a bone frag-
ment was taken from the left femur from a region corresponding to that of
the right femur. Then, using a high-speed circular saw, the external surface of
the right femur was notched circumferentially at each end of the cement plug
and longitudinally on two sides, posterior and anterior. An osteotome was
used to free the lateral half of the bone from the medial half. Without damag-
ing the cement plug, the cement was carefully separated from the bone in
order to prevent release of tobramycin, which could influence the sampling of
bacteria [Powles, 1998]. Only full-thickness cortex adjacent to the cement
was used for both bacteriologic culture and histology; bone that was not
directly adjacent to the cement was discarded.
Bacteriological culture
All the bone fragments of the lateral half of each femur (in each case approxi-
mately 1 g) were ground in a sterile metal mortar. The samples were homog-
enized in 10 ml of phosphate buffered saline (pH 7.4) using a tissue grinder
(Polytron PT 3100 tissue grinder, Kinetica Benelux BV, Best, The
Netherlands), 3 minutes at 2500 rpm and subsequently for 5 minutes at 6000
rpm.
A volume of 10 µl of the homogenate (containing 1.0 mg of bone) was then
plated on blood agar plates in serial 10-fold dilutions. After an overnight
124 Figure 1. Lateral radiograph of the right femur of a rabbit, which shows the
injected cement in situ. The arrow indicates the site of injection of the cement.
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incubation at 37°C, the samples were counted for viable bacteria. For each
femur the number of viable bacteria per gram of bone was calculated (mini-
mum 1000 CFU/g of bone). Infection was defined as a positive culture.
Histology
The medial half of the bone adjacent to the bone cement was used for histo-
logical evaluation and fixed in 4% buffered formalin. After decalcification
and dehydration the cortex was embedded in paraffin and sectioned on a
microtome (Reichert-Jung 2030, Biocut, Leica, Rijswijk, The Netherlands).
The sections were mounted on slides and stained with hematoxylin and
eosin.
Statistical analysis
The results of the bacteriological cultures were analyzed using the SPSS
(Statistical Package for the Social Sciences) version 6.1 for the Macintosh.
Differences were considered significant at p ≤ 0.05. Animals with a compara-
ble history were grouped. To each group one of the five inoculum doses and
one of the two follow-up periods were assigned. One half of each group
received tobramycin, the other half not, which formed the controls. For each
animal a response of the 0/1 type was recorded (negative or positive culture)
and the number of cultured bacteria. In the first case, a Mantel-Haenszel type
of analysis is called for with a test for trend over the strata (inoculum doses),
which was carried out using logistic regression. Differences in response over
the strata may be caused by differences between groups. It is, however,
unlikely that this would exactly be like a trend, which is more plausibly a
dose effect. In the second case a two-way analysis of variance was used to
investigate the effect of follow-up and inoculum dose. In particular, a positive
relationship of the inoculum dose with the number of cultured bacteria was
analyzed by means of polynomial contrasts.
I Results
General
In the S. aureus group, one rabbit with tobramycin-containing bone cement
(7-days follow-up group, inoculum 105 CFU) and one control (107 CFU, 28-
days follow-up group) died just after the cementing procedure. The controls
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showed a loss of body weight and elevated erythrocyte sedimentation rate at
7 days. At 28 days these parameters had returned to normal, but the macro-
scopical aspect of the right femur of these rabbits was suggestive for a local
osteomyelitic process (thickened and soft cortex, pus). The S. epidermidis
controls, as well as all rabbits receiving tobramycin-cement recovered well
from surgery and did not develop clinical signs of infection (erythrocyte sedi-
mentation rate, leukocyte count, body temperature and body weight
remained normal).
Bacteriological cultures
No positive cultures were found in any of the rabbits receiving tobramycin-
cement (Figure 2a and 2b). Twenty-seven out of 29 of the S. aureus controls
and 16 out of 30 of the S. epidermidis controls had positive bacterial cultures.
One control rabbit in the 7-days follow-up group that had received 107 CFU
of S. aureus was killed after 5 days, because it was severely ill. The results of
the culture of its right femur (10log 5.89) was included as a 7-days result.
Table 1 shows an overview of the incidence of infection in the various groups.
For both staphylococcal species, the prophylactic effect of tobramycin-con-
taining bone cement was significant (p < 0.001). Since all tobramycin treat-
ed animals (for both follow-up periods and both bacteria species) did not
show positive cultures, differences in trend of the inoculum dose between
controls and tobramycin treated animals have not been statistically tested.
The number of cultured bacteria in the S. aureus controls increased signifi-
cantly from 7 to 28 days follow-up (p = 0.044, F1,19 = 4.64). Testing for a
linear relationship [trend of a positive relationship of inoculum with the
extent of infection, see Figure 2(a)]. showed a significant difference of inocu-
lum size (p = 0.034, one-sided). For the S. epidermidis controls, a significant-
ly lower number of bacteria was cultured after 28 days as compared to 7 days
(p = 0.07, F1,20 = 9.06). The effect of the inoculum concentration (linear
relationship) was not significant (p = 0.082).
All cultures from left femora (not operated on) were negative.
Histology
In the S. aureus group, the majority of rabbits in the control group showed a
moderate periosteal reaction of the femoral cortex next to the cement after 7
days (Figure 3a). At 28 days follow-up, the S. aureus controls showed besides
a more severe periosteal reaction also other signs for infection like destruc-
tion of the cortex, enlarged Haversian canals and a leukocytes infiltrate
(Figure 3b). These changes were also present in the S. epidermidis controls,
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Figure 2. (a) Results of cultures (mean ± SEM) of rabbits contaminated with S.
aureus.
(b) Results of cultures (mean ± SEM) of rabbits contaminated with S. epider-
midis.
a
b
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but were less pronounced. We found no histological signs of infection in any
of the rabbits that received tobramycin-containing bone cement (Figure 4).
128
Figure 3. Photomicrographs (hematoxylin and eosin, 50x) of tissue sections of
control rabbits contaminated with S. aureus showing (a) minimal periosteal
reaction after 7 days and (b) severe periosteal thickening, destruction of cor-
tex, leukocyte infiltrate and granulation tissue after 28 days.
a
b
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Table 1a. Incidence of infections in the S. aureus groups
7 days 28 days
Inoculum (10log CFU) tobramycin control tobramycin control
3 0/4 2/4 0/2 2/2
4 0/4 4/4 0/2 2/2
5 0/3 4/4 0/2 2/2
6 0/4 4/4 0/2 2/2
7 0/4 4/4 0/2 1/1
Total 0/19 18/20 (90%) 0/10 9/9 (100%)
Figure 4. Photomicrograph (hematoxylin and eosin, 50x) of a tissue section from
a rabbit with tobramycin-containing bone cement contaminated with S. aureus
showing no signs of infection after 28 days.
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I Discussion
In the present study we showed that premixed tobramycin containing-bone
cement did prevent infection after inoculation of S. aureus and S. epidermidis.
These findings support our previous study, which showed that the release of
tobramycin from this cement, 28 days after insertion, is still more than 40
times the minimal inhibitory concentrations for these staphylococci [Nijhof,
1997]. However, tests of susceptibility based on minimal inhibitory concen-
tration may not be accurate for biomaterial-adherent bacteria and, therefore,
in vivo studies are required [Naylor, 1990]. Previously, other infection studies
in the rabbit, rat, or dog have shown the efficacy of bone cements containing
gentamicin or erythromycin/colistin [Elson, 1977b, Petty, 1988, Rodeheaver,
1983, Schurman, 1978]. The efficacy of these antibiotic-bone cement combi-
nations is less clear in the clinical setting: Lynch et al. found the efficacy of
the gentamicin loaded cement to be statistically proven only in revision oper-
ations, not in primary arthroplasties [Lynch, 1987]. Josefsson et al. compared
the prophylactic efficacy of systemic antibiotics vs. gentamicin bone cement.
The difference in favor of the antibiotic bone cement group had lost its statis-
tical difference at 10 years follow-up [Josefsson, 1990, Josefsson, 1993].
Results from the Norwegian arthroplasty show that the additional use of
antibiotic bone cement can reduce the infection rate compared to systemic
antibiotic only [Espehaug, 1997].
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Table 1b. Incidence of infections in the S. epidermidis groups
7 days 28 days
Inoculum (10log CFU) tobramycin control tobramycin control
8 0/4 1/4 0/2 0/2
8.5 0/4 4/4 0/2 0/2
9 0/4 3/4 0/2 1/2
9.5 0/4 2/4 0/2 0/2
10 0/4 4/4 0/2 1/2
Total 0/20 14/20 (70%) 0/10 2/10 (20%)
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The advantage of antibiotic-containing bone cement is the high local release
of antibiotic, which can overcome the decreased susceptibility of bacteria
growing on an infected prosthesis. High local release of aminoglycosides like
tobramycin increases the rate of bacterial killing, because of their concentra-
tion-dependent antibacterial activity [Lacy, 1998]. Eckman et al. found effec-
tive wound and serum levels of tobramycin in patients with compound frac-
tures after prophylactic treatment with tobramycin-impregnated PMMA beads
[Eckman, 1988]. No acute wound infections were seen in these 70 patients.
Lyons et al. showed that tobramycin-PMMA beads prevented adherence of S.
aureus in a rabbit model of a contaminated fracture [Lyons, 1992]. The
release from hand-mixed tobramycin bone cement has been investigated in
primary total hip arthroplasties, but these studies did not mention whether
infections were actually prevented [Brien, 1993, Pritchett, 1992]. In another
study, infection recurred in one out of ten patients, treated with revision total
hip arthroplasty using bone cement hand-mixed with tobramycin (0.5 g
tobramycin per unit cement) [Soto-Hall, 1983]. Perioperatively, no systemic
antibiotic had been given in this patient, who had intraoperative positive cul-
tures for Pseudomonas aeruginosa. Hofmann et al. treated 26 infected total
knee arthroplasties using hand-mixed tobramycin bone cement (both for the
spacer and fixation of the revision prosthesis) together with systemic antibi-
otics [Hofmann, 1995a]. After a mean follow-up of 30 months, no infection
recurred.
The S. aureus controls showed an inoculum-size dependent infection, which
increased up to 28 days follow-up. In contrast, the virulence of S. epidermidis
appeared to be lower, given the higher inoculum dose needed to establish an
infection and the lower incidence of infection. S. aureus produces a number
of extracellular and cell-associated virulence factors, like enterotoxins, colla-
gen- and fibronectin-specific receptors and exopolysaccharides, and probably,
therefore, causes more evident signs of infection than S. epidermidis
[Cunningham, 1996]. S. epidermidis is known to adhere preferably to poly-
mers like PMMA [Barth, 1989, Gristina, 1996]. This capability of coagulase-
negative staphylococci to colonize and produce a biofilm on a biomaterial is
probably an important virulence factor in causing foreign body infections,
which infections are more indolent by nature.
The initial loss of two rabbits after cementing probably was caused by pul-
monary embolism, due to the increased intramedullary pressure during injec-
tion of the cement [Nijhof, 1997]. Thorough lavage of the femoral canal and
testing of the width of the reamed femur prevented this complication as
much as possible.
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It should be noted that, because the method used to culture and count bacte-
ria has a detection limit of around 1000 CFU per gram of bone, very low
numbers of bacteria could not be detected. All negative cultures were consid-
ered as 0 bacteria present in the sample, whereas theoretically a negative
culture can be any culture below 1000 CFU. This might explain the relative
large standard errors at some inoculum doses in the control group. Such a
minimal detection limit is a relative drawback of all studies that evaluate
implant-related infections using a comparable plating and counting technique
[Cordero, 1996, Cremieux, 1996, Curtis, 1995, Eerenberg, 1994, Fitzgerald,
1983, Isiklar, 1996, Korkusuz, 1993, Melcher, 1994, Rodeheaver, 1983].
However, many studies do not mention the minimal detectable level of bacte-
ria. Early experiments have shown that in the presence of a foreign body, a
number of 100 CFU of a staphylococcal strain is enough to produce an infec-
tion in man [Elek, 1957]. Waldvogel et al. stated that, because even clean
wounds were found to be contaminated, the control of infection is more a
quantitative than a qualitative problem [Waldvogel, 1991]. Therefore, the
value of antibiotic bone cement is to eliminate the bacteria to such low num-
bers that host defense mechanisms can clear the remaining infection. It is
noteworthy that in present study, the histological appearance of the rabbits
with tobramycin-containing bone cement confirmed the negative bacteriolog-
ical cultures. Especially, the recovery of variant and resistant strains such as
small colony variants may be even more difficult due to their altered growth
mode [von Eiff, 1997]. It has been reported that both S. aureus and coagu-
lase-negative staphylococci can develop resistance against gentamicin after
use of gentamicin-containing cement or beads [Hope, 1989, von Eiff, 1997].
Adequate diagnosis of infection is a prerequisite to evaluate new biomaterials
and operative techniques optimally, and, of course, to treat patients with an
infected implant successfully.
In conclusion, this animal model shows that premixed tobramycin-containing
bone cement can prevent implant bed infection in rabbits after contamination
with S. aureus Wood-46 and S. epidermidis O-47.
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I Introduction
Adequate infection prophylaxis is mandatory in arthroplasty surgery.
Methods to reduce the sources of bacterial contamination in the operating
theatre (like ultraclean air, waterproof gowns, gloves, and adhesive plastic
drapes) are useful but not perfect [Davis, 1999]. Contamination can still
occur and antibiotics may be indicated to prevent infections. In the literature,
the optimal mode of administration of prophylactic antibiotics is still subject
of discussion. Dutch guidelines state that there is no indication for the use of
antibiotic-containing bone cement in primary arthroplasty, if operated under
prophylaxis of systemic antibiotics and an ultra-clean air system [Dutch
Institute for healthcare improvement (CBO), 1994 #448]. Data from the
Swedish hip arthroplasty registry show an increased use of antibiotic-contain-
ing bone cement in primary hip arthroplasty from approximately 10% of all
primary hip arthroplasties performed in 1978 to 80% in 1996 [Swedish-
National-Hip-Arthroplasty-Registry, 1998]. The different modes of adminis-
tration of antibiotics have been compared for efficacy by only a few experi-
mental and clinical studies. Petty et al. showed in a study in dogs that
systemic antibiotic treatment as well as local treatment with antibiotic-con-
taining bone cement reduced infections of the implant bed, but only the latter
was found to be significantly different from controls [Petty, 1988]. Josefsson
et al. compared prophylaxis with systemic antibiotics versus gentamicin bone
cement in total hip arthroplasty in a prospective randomized clinical trial
[Josefsson, 1990, Josefsson, 1993]. At 5-years follow-up, significantly more
infections occurred in the group receiving systemic antibiotics. However, at
10-years follow-up of 1688 hips, infection rates in the systemic antibiotics
group and in the antibiotic-containing bone cement group were no longer sig-
nificantly different. In a similar study, McQueen et al. found no difference in
these two modes of infection prophylaxis in 401 patients at two years’ follow-
up [McQueen, 1990].
It is obvious from the few available studies that there is still a lack of scientif-
ic proof regarding the efficacy of systemic (intravenous) versus local (bone
cement) administration of antibiotics to prevent implant bed infection. In the
present study, we investigated the efficacy of prophylaxis either with intra-
venously administered cefazolin or by use of tobramycin-containing bone
cement in an experimentally infected implant bed. We chose these two types
of antibiotic with different routes of administration (systemic and local)
because of their clinical relevance. Cefazolin is a first-generation
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cephalosporin and is used widely by orthopedic surgeons for treatment of
staphylococcal infections. It has a longer half-life and provides for higher
serum concentrations than the other first-generation cephalosporins.
Tobramycin-containing bone cement has previously been shown to be effica-
cious in prevention of infections both in vitro and in vivo in rabbits [Nijhof,
1999, Scott, 1999]. For this type of cement, no data are available on its effi-
cacy as a prophylactic treatment in comparison with systemic antibiotics.
Therefore, the aim of the present study was to investigate the efficacy of
tobramycin-containing bone cement and systemic cefazolin in preventing
infection in a rabbit model.
I Materials and Methods
Design
In a total of 18 rabbits, the femoral cavity was inoculated with 106 colony-
forming units (CFUs) of Staphylococcus aureus. Six rabbits (group A - systemic
antibiotic) received an intravenous injection of cefazolin before inoculation.
Subsequently, plain Simplex-P bone cement (Stryker-Howmedica-Osteonics,
Rutherford, NJ) was injected into the femoral cavity. Six rabbits (group B -
tobramycin cement) received only Simplex-P tobramycin-containing bone
cement (Stryker-Howmedica-Osteonics, Rutherford, NJ) after local inocula-
tion of the femoral canal. Six rabbits (group C - control) did not receive any
antibiotic treatment, and plain Simplex-P bone cement was injected in the
femur after local inoculation. Seven days after surgery, the animals were
killed and the femoral cortex adjacent to the cement was cultured. The effica-
cy of the three treatments was assessed based on the number of CFUs of the
bacteria and on the detection of S. aureus DNA by a polymerase chain reac-
tion (PCR) hybridization assay. The guidelines according to the Dutch act on
animal experiments (1985) were observed.
Bacterial strain
S. aureus, strain Wood-46 (ATCC 10832) was used to inoculate the rabbit’s
femur. After culture in Mueller-Hinton broth, a stock of aliquots was frozen.
The concentration of bacteria was determined by serial dilution and plating
on blood agar. Preoperatively, samples containing 107 CFU/ml were prepared.
A volume of 0.1 ml (106 CFU) was injected into the rabbit femoral cavity.
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Previous studies have shown this dosage to result in a 100% infection rate of
cement bodies [Nijhof, 2000a].
Surgery
Healthy adult female New Zealand white rabbits (Ico: NZW) weighing 3000-
3500 gram were obtained one week before surgery to acclimatize them to the
housing in the Central Animal Laboratory. They were fed daily with 80-100
gram antibiotics-free rabbit diet and water ad libitum.
Preoperatively the rabbits were weighed. The systemic antibiotic (cefazolin, 30
mg/kg) was injected 30 minutes before surgery, into the left auricular vein of
the rabbits in group A. The anesthesia was prepared by an intramuscular injec-
tion of 4 mg methadone, 4 mg acepromazinemaleate and 0.5 mg atropine. A
preoperative blood sample was taken from the left auricular vein, 5 minutes
before surgery. A pressure line was introduced into the auricular artery for
measuring blood pressure. Subsequently the anesthesia was induced by an
intravenous injection of etomidate (8-12 mg). An endotracheal tube was intro-
duced through which the anesthesia is maintained by a 1:1 mixture of nitrous
oxide, oxygen and halothane 1%. The skin of the outer right thigh was clipped
and the rabbit was placed with its left side on the table.
The operative area was disinfected with povidone-iodine and isolated by ster-
ile drapes. Subsequently, a skin incision (approximately 3 cm) was made par-
allel to the femur shaft, over the trochanter tertius of the right femur. The
trochanter tertius was exposed by splitting the fascia, retracting the femoral
biceps and coccygeofemoral muscles posterior-medial and scraping the
periost. The cortex was penetrated with a small drill (diameter 1.2 mm),
using an air-pressured AO minidrill. Subsequently, the femoral canal is
reamed up to 4.0 mm in width. The content of the medullary canal was suc-
tioned. Cooled (4°C) sterile bone cement was vacuum-mixed on the surgical
table. The rabbits received either plain Simplex-P bone cement (groups A and
C) or tobramycin-containing Simplex-P bone cement (group B). After injec-
tion of 0.1 ml of the bacteria suspension into the femoral canal, approximate-
ly 1.2 ml of cement was inserted. The exact amount of inserted cement was
determined by weighing the syringe containing the cement. The fascia, sub-
cutis, and cutis were closed with Vicryl 3-0 after polymerization of the
cement and wound drainage with saline. Pain relief was provided by intra-
muscular injection of 3.0 mg nalbufine immediately postoperatively and sub-
sequently 0.1 mg buprenorfine. Buprenorfine injection was repeated when
necessary.
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Follow-up
Postoperatively, routine AP and lateral X-rays were made of the right femur.
The rabbits recovered in a temperature controlled recovery cage. The rabbits
were monitored by a daily clinical examination, with special attention for
wound healing, the presence of a fracture, eating, activity level, and body
temperature. The erythrocyte sedimentation rate (ESR) and white blood cell
counts (WBC) were measured before surgery and 1 and 7 days after. After 7
days, the rabbits were killed with an intravenously administered overdose of
pentobarbital N2.
Autopsy and sample acquisition
After the animals were killed, the skin of the left and right thighs was clipped,
disinfected with povidone-iodine, and isolated with sterile drapes. The right
and left (control) femora from all animals were excised and cleaned from tis-
sue debris. Using a high-speed dental drill with a circular diamond saw, the
external surface of the right femur was notched circumferentially at each end
of the shaft and longitudinally on two sides. A mallet and an osteotome were
used to break off each metaphysis and then to free the lateral half of cortex
adjacent to the cement. Care was taken not to damage the cement. The bone
samples from the left femur were taken from the site corresponding to the
right femur operation site.
Bacteriological examination
The lateral half of cortex adjacent to the cement plug (in the right femoral
canal) and bone from the corresponding site of the left femur were submitted
for quantification of bacteria. For this purpose, the bone samples of approxi-
mately 1 g were cut into small pieces and homogenized in 10 ml phosphate-
buffered saline (pH 7.4) using a Polytron tissue grinder. Subsequently, the
number of bacteria (CFU) per gram of bone was determined by dilution and
plating on blood-agar plates.
Histology
The medial half of the bone was used for histological evaluation and fixed in
4% buffered formalin. After decalcification and dehydration the cortex was
embedded in paraffin and sectioned on a microtome (Reichert-Jung 2030;
Biocut, Leica, Rijswijk, The Netherlands). The sections were mounted on
slides and stained with hematoxylin and eosin.
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PCR hybridization assay
A part of the lateral half of the right femoral cortex (mean weight 0.24 g)
adjacent to the cement plug was collected for molecular biological analysis
for the presence of bacterial DNA. Samples were incubated for 18 hours at
60°C in digestion buffer [500 mM Tris (pH 9), 20 mM ethylenediamine
tetraacetic acid (EDTA), 10 mM NaCl, 1% sodium dodecyl sulfate(SDS), 0.5
mg/ml proteinase K]. to release total DNA. DNA was isolated using a PCR
purification kit (Qiagen, Hilden, Germany). DNA was amplified by the tech-
nique described by Wilbrink et al [Wilbrink, 1998]. Broad-range biotin-
labeled primers, targeting conserved regions of the 16S-rRNA gene, were
used to set up an eubacteria-specific PCR. An internal spike was added to
screen for possible inhibition of PCR and to reduce the amplification of con-
taminating DNA. The presence of S. aureus DNA was determined by reverse
line blot hybridization (RLB). We used the RLB technique as described by
Kaufhold et al [Kaufhold, 1994]. For this purpose, we used a genus-specific
staphylococcal oligonucleotide probe (5’-AACCTACCTATAAGACTGG-3’) and a
species-specific S. aureus oligonucleotide probe (5’-TCAAAAGTGAAAGACG-
GTC-3’) which were covalently linked to a membrane (Biodyne C; Pall
Biosupport, Portsmouth, UK). PCR products were hybridized to the oligonu-
cleotide probes on the membrane for 1 hour at 42°C, using a miniblotter sys-
tem (MN45, Immunetics, Cambridge, MA). Subsequently, nonspecific DNA
was washed of the membrane at 55°C and the membrane was incubated at
42°C with Streptavidin-peroxidase (Boehringer Mannheim Biochemica,
Mannheim, Germany). Finally, the presence of S. aureus DNA was visualized
on a film (Hyperfilm ECL) using an enhanced chemoluminescent detection
system (ECL; Amersham international, Little Chalfont, England).
I Results
All rabbits recovered well from surgery. The inserted cement [mean ± stan-
dard deviation (SD)]. weighed 1.46 ± 0.09 gram in group A (tobramycin
cement), 1.28 ± 0.18 gram in group B (systemic antibiotic), and 1.29 ± 0.17
gram in group C (control).
The loss of body weight (mean ± SD) of the rabbits at 7 days was 106 ± 101
gram (3.7% as a percentage of their initial body weight) in group A, 65 ± 52
gram (2.1%) in group B and 246 ± 109 gram (8.5%) in group C.
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Figure 1. Erythrocyte sedimentation rates (mean) in the antibiotic treated groups
and the untreated control group, at three different time points (preoperatively
and 1 and 7 days’ follow-up). Error bars represent standard deviation.
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Figure 2. White blood cell counts (mean) in the antibiotic-treated groups and the
untreated control group, at three different time points (preoperatively and 1
and 7 days’ follow-up). Error bars represent standard deviation.
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The ESR was elevated at 7 days’ follow-up, especially in the control group
(Figure 1). The elevation of ESR was less in both antibiotic groups. Leukocyte
counts were not different between the three groups (Figure 2).
Cultures from the rabbits which received antibiotic prophylaxis (either cefa-
zolin systemically or tobramycin-containing bone cement) were all negative.
In contrast, all six rabbits in the control group (plain bone cement, no antibi-
otics) had positive cultures (Table 1). In all rabbits, cultures from the left
femur (not operated on) were negative.
Histology of sections of the right femur showed no marked differences
140
Figure 3. Photomicrographs (hema-
toxylin and eosin, original magnifi-
cation x30) of tissue sections of the
femoral cortex of rabbit. Histological
changes are nearly absent in rabbits
in which tobramycin-containing
bone cement (a) or systemic cefa-
zolin (b) was used to prevent
staphylococcal infection. Controls
(c) showed minimal periosteal reac-
tion and enlargement of Haversian
canals.
a
c
b
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Table 1. Results of culture of right femoral cortex
Group of rabbits Incidence of infection Culture
(10log CFU/g, mean ± SD)
Tobramycin cement 0/6 0
Cefazolin systemically 0/6 0
Controls 6/6 5.39 ±0.79
Figure 4. Details of the film with the results of the reverse line blot hybridization
assay. PCR products of the right tibiae of the rabbits in the three different
treatment groups are oriented in vertical lanes (T = tobramycin group, C =
control group, S = systemic cefazolin group). The oligonucleotides are orient-
ed in horizontal lanes (1 = staphylococci probe, 2 = S. aureus probe, 3 =
internal spike probe). An internal spike was added to all samples to exclude
possible inhibition: The lower lane shows no inhibition in samples that were
negative for staphylococci or S. aureus.
between the three groups with regard to signs of infection. In sections of the
control group only minimal elevation of the periost and enlargement of
Haversian canals was seen, with no destruction of the cortex or increase in
leukocytes (Figure 3a-c).
Using the PCR-hybridization assay, the presence of S. aureus DNA was identi-
fied in the right femur of all the rabbits in the control group (Figure 4). In
contrast, the femur samples from groups that received antibiotic prophylaxis,
either cefazolin systemically or tobramycin-containing bone cement, S. aureus
DNA was not detectable.
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I Discussion
In the present study, we demonstrated that both tobramycin-containing bone
cement and systemically administered antibiotic can prevent infection of the
rabbit’s femur after inoculation with S. aureus. Nielsen et al. obtained similar
results comparing the use of gentamicin-impregnated bone cement with sys-
temic administration of dicloxacillin in a rabbit model [Nielsen, 1996]. In a
canine model, Petty et al. compared the prophylactic efficacy of adding gen-
tamicin to bone cement with other antibiotic treatment modalities, including
the use of intravenous cefazolin [Petty, 1988]. The prophylactic effect of the
use of gentamicin-impregnated bone cement was absolute; that of the use of
intravenous cefazolin was not. In contrast to their results, we did not see any
infection in rabbits, which received cefazolin systemically to prevent local
infection. Because details of their infection model regarding the inoculum
size, volume of inserted cement and type of bacterial strain used were not
provided, it is difficult to explain the different results obtained in their model.
The prophylactic effect of systemic antibiotics may depend on the animal
species used, because in another rabbit model, a single preoperative dose of
cefazolin prevented S. aureus infection during spinal instrumentation
[Guiboux, 1998]. Another factor that influences the outcome of an infection
model is the timing and mode of administration of the inoculum. Blomgren
and Elson et al. studied the effect of gentamicin-impregnated bone cement on
haematogenous infection in experimental models [Blomgren, 1981, Elson,
1977b]. When the inoculum was administered intravenously, 6 weeks after
the initial operation, both authors found no significant difference in the inci-
dence of infection whether or not gentamicin was used in the bone cement.
The antibacterial effect of gentamicin could was shown only when the
haematogenous inoculation occurred immediately after wound closure
[Elson, 1977b]. Even when a knee arthroplasty in rabbits is inoculated via an
intra-articular injection seven days after implantation, an infection is difficult
to initiate [Schurman, 1978]. As a consequence of this, Schurman et al. could
not show a persistent prophylactic effect up to 1 week of bone cement con-
taining gentamicin.
The infection rate after joint replacement surgery can be influenced by many
prophylactic methods. Guidelines for prevention of infection differ between
hospitals, mainly due to the fact that it is hard to prove the effect of an indi-
vidual factor contributing to the reduction of infection rate after surgery.
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Clinically, randomized prospective studies evaluating such factors need to
include many patients, and as a consequence, it is difficult to control the con-
tribution of one factor when studying the other [Fitzgerald, 1992, Hill, 1981,
Lidwell, 1982, Salvati, 1982a]. In addition, the generalizability of the results
of randomized trials is often low owing to restrictive patient selection in
these trials or to the fact that results obtained in centers of excellence are
often not representative of results in the community [Herberts, 1997].
In the literature, the debate as to whether to use antibiotic-containing bone
cement or systemic antibiotics for prophylaxis of arthroplasty infection is not
yet concluded [Josefsson, 1993, McQueen, 1990, Petty, 1988]. The difficul-
ties in correctly diagnosing deep infection have prompted authors to reclassi-
fy their results at longer follow-up periods [Josefsson, 1993]. The long-term
follow-up studies of Josefsson et al. illustrated nicely that for some patients it
took years for the infection to manifest itself, whereas others’ signs and symp-
toms of infection had to be reinterpreted [Josefsson, 1990, Josefsson, 1993,
Josefsson, 1981]. It might well be that the combination of the two strategies,
both antibiotic-containing bone cement and systemic antibiotics, is the opti-
mal choice. Espehaug et al. evaluated infection incidence after 10,905 pri-
mary cemented hip replacements in Norway, with a follow-up of 8 years
[Espehaug, 1997]. The effect of prophylaxis of antibiotics administered sys-
temically, in bone cement, or both was studied. The best results were
obtained with the combination therapy. Nowadays, economic arguments
could also influence the choice between different strategies in medicine.
Persson et al. calculated that although the use of antibiotic-containing bone
cement as a prophylactic option next to systemic antibiotics can reduce the
risk of costly revisions, this might not always be the most cost-effective strate-
gy [Persson, 1999].
In the present study, the minimal detectable level for S. aureus was 1000
CFUs per gram of bone. For reasons of reproducibility, we did not choose to
concentrate the bacteria in smaller sample volumes after milling of the bone.
However, in addition to our dilution and plating method, we also used a PCR-
hybridization assay. PCR-based methods for detection of bacterial DNA can
improve sensitivity of diagnosis of orthopedic implant infections [Mariani,
1996]. Using a PCR-hybridization assay, we confirmed both the presence of S.
aureus DNA in the untreated controls, as well as its absence in the two antibi-
otic-treated groups. These findings convincingly demonstrate the efficacy of
both types of antibiotic prophylaxis.
It can be disputed that, although our study provided enough power to reveal
differences between the cefazolin or tobramycin and the control group
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respectively, the power of actual comparison between the cefazolin and
tobramycin groups was low, and therefore we could not arrive at a conclusion
regarding differences between the two antibiotic groups. This power is low,
because both treatments were efficacious as none of the animals in each
group had positive cultures. Thus, such a comparison of two apparently effi-
cacious treatments would require a large number of animals  (>100). The
question of clinical relevance of data would then arise. In addition, the subse-
quent PCR-hybridization assay supported our findings that both systemic
antibiotic and local tobramycin bone cement are effective for infection pre-
vention.
We used S. aureus (strain Wood 46), susceptible to both tobramycin and cefa-
zolin, as the infectious agent. Recently, Scott et al. showed in an in vitro study
that some bacterial strains, resistant to the usual systemic concentrations, dis-
played some degree of susceptibility to tobramycin-containing bone cement
[Scott, 1999]. This phenomenon has been addressed by other authors who
compared systemic administration of cefazolin with topical cefazolin adminis-
tration using microspheres [Fallon, 1999]. Similarly, The high local release of
antibiotic from antibiotic-containing bone cement might be an advantage
compared to systemic antibiotics in preventing infections with resistant
strains of bacteria.
This animal model was used to study the development of an infection in the
rabbit after initial contamination with a pathogen. This aspect differs from
the situation of treating an already existing infection. Thus, this model does
not allow for the evaluation of the efficacy of different treatment options for
an infected prosthesis, like treatment with a one- or two-stage revision, or by
retaining the prosthesis and systemic antibiotics [Buchholz, 1981, Elson,
1998, Isiklar, 1996, Ivarsson, 1994, Lieberman, 1994, Masri, 1998c,
McDonald, 1989, Raut, 1995, Ure, 1998]. Study of the efficacy of
tobramycin-containing bone cement as a treatment modality is the goal of a
future animal study.
In conclusion, we have demonstrated the efficacy of tobramycin-containing
bone cement and systemically administered cefazolin in preventing infection
in the rabbit, by both culture and detection of bacterial DNA. Possibly, both
antibiotic regimes applied together will provide optimal prophylaxis of ortho-
pedic prosthesis infection.
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Tobramycin-containing bone cement
and systemic cefazolin in a one-stage
revision
Treatment of infection in a rabbit model
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I Introduction
Infections of total joint prostheses are frequently associated with the presence
of necrotic bone, devascularization and bacteria with specific growth charac-
teristics. Especially the latter, that is the ability of pathogens to adapt to the
presence of a foreign body and sustain capability to withstand antibiotics and
host defenses, complicates treatment. Therefore, rigorous treatment modali-
ties are necessary to eliminate the infection, but the best choice for treatment
of an infected total joint prosthesis still remains to be clarified. Consensus
exists among most orthopaedic surgeons to remove the infected prosthesis if
possible, because the infection is difficult to treat in presence of foreign mate-
rial covered with bacteria [Brandt, 1997]. Usually antibiotic-loaded bone
cement is used for fixation of a new prosthesis to provide a high local tissue
concentration of antibiotics. Such a revision operation can be performed
either as a one-stage procedure or as a two-stage procedure. In the one-stage
revision the infected implant is removed and, after debridement and lavage of
the implant bed, during the same session replaced by a new prosthesis. In a
two-stage revision, the insertion of the new implant is postponed until after
removal of the infected implant in a time period whereby the infection is
treated with systemic antibiotics and/or local antibiotic-loaded beads. The
new prosthesis is inserted not until the infection parameters have regained
normal levels. The use of antibiotic-loaded bone cement for fixation of the
revision prosthesis is preferred given the higher incidence of infection after
revision in comparison with primary joint prostheses. Where most surgeons
choose the two-stage procedure for exchange of an infected prosthesis, also
large series have been reported using only the one-stage procedure, especially
in Europe [Buchholz, 1981, Raut, 1995]. So far, reviews of literature on
infected arthroplasties reported success rates of 82-83% of one-stage revi-
sions, and 91-93% of two-stage revisions [Garvin, 1995, Pagnano, 1997].
In a previous study, it has been shown that Simplex P tobramycin-containing
bone cement can prevent Staphylococcus aureus and Staphylococcus epidermidis
infections in the rabbit’s femur [Nijhof, 2000a]. In that model we evaluated the
development of an infection after inoculation of the medullary canal with bac-
teria, immediately followed by insertion of the antibiotic-containing bone
cement. However, in order to treat a pre-existent implant infection, one that
has developed after introduction of bacteria at an earlier time point, the antibi-
otic-containing bone cement should also be effective against pathogens that
may have become phenotypically adapted to their new habitat. In a one-stage
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revision procedure, when no previous surgical attempts have been undertaken
to treat such an infection, this may be even more demanding. The purpose of
the present study was to compare the efficacy of tobramycin-containing bone
cement with that of systemic cefazolin for treatment of infection in a one-stage
revision model. In addition to conventional culture techniques a PCR hybridiza-
tion assay was used in the detection of bacteria as bacterial DNA.
I Materials and methods
Design
To establish an infection, a pre-formed non antibiotic-containing cement plug
was introduced in the right tibial medullary canal of 30 rabbits, after local
inoculation with S. aureus. Four weeks after insertion of the implant, the rab-
bits were divided into three groups (10 rabbits each), and a one-stage revi-
sion of the implant was performed in all rabbits. After removal of the infected
implant and lavage of the implant bed (without formal debridement), bone
cement was injected into the medullary canal. Group 1 received tobramycin-
containing bone cement, Group 2 received plain bone cement (no antibiotics)
as control, and Group 3 received plain bone cement and additional systemic
antibiotics. Fourteen days after the revision procedures the tibiae were
excised and the cortex adjacent to the cement was cultured. The efficacy of
the different treatments was compared based upon the number colony-form-
ing units of bacteria following culture.
Bacterial strain
Staphylococcus aureus, strain Wood-46 (ATCC 10832) was used. After culture
in Mueller-Hinton broth, a stock of aliquots was frozen. The concentration of
bacteria (colony-forming units per milliliter, CFU/ml) was determined by
serial dilution and plating on blood agar. In a volume of 0.1 ml, a dose of
either 105 CFU or 106 CFU was injected in the medullary canal of the rabbit’s
tibia. The first 4 rabbits in each group received an inoculum dose of 106 CFU.
This dose was the same as was used in a previous study on the prevention of
implant bed infection in the tibia of rabbits [Nijhof, 2000b]. In an attempt to
reduce loss of rabbits due to sepsis the dose was changed to 105 CFU in the
subsequent rabbits. The latter inoculum dose has proved to establish an infec-
tion in another animal model of tibial implant infection [Vogely, 2000b].
147
CHAPTER 11  I  ONE-STAGE REVISION USING SYSTEMIC OR LOCAL ANTIBIOTICS
hoofdstuk 11  07-05-2001  13:42  Pagina 147
Animals
Healthy adult female New Zealand white rabbits (Ico:NZW, Broekman
Instituut BV, Someren, The Netherlands) weighing 3000-3500 gram were
obtained one week prior to surgery to acclimatize to the housing in the
Central Animal Laboratory. The animals were caged in individual cages, fed
with 80-100 gram antibiotics free Hope Farms rabbit diet LKK-20 and water
ad libitum. Postoperatively, the animals were kept in the barrier housing facil-
ity of the Central Animal Laboratory until they were killed.
Surgery
The anesthesia protocol was the same for both operations (induction of infec-
tion and revision of implant). Surgery was performed under strict aseptic
conditions and under general inhalation anesthesia. Preoperatively the rab-
bits were weighed. The anesthesia was prepared by an intramuscular injec-
tion of 4 mg methadone, 4 mg acepromazinemaleate and 0.5 mg atropine. A
pressure line was introduced into the auricular artery for measuring blood
pressure. Subsequently the anesthesia was induced by an intravenous injec-
tion of etomidate (8-12 mg). An endotracheal tube (#3) was introduced
through which the anesthesia is maintained by a 1:1 mixture of nitrous oxide,
oxygen and halothane 1%. The skin of the right leg was clipped and the rab-
bit was placed with its left side on the table. The operative area was disinfec-
ted with povidone-iodine and isolated by sterile drapes. Postoperatively, pain
relief was provided by 3 mg nalbufine i.m. immediately postoperative and
subsequently 0.3 mg buprenorfine i.m. If necessary, buprenorfine injection
was repeated postoperatively.
Infection of primary implant
At the first operation (establishment of infection), the right knee joint was
opened via a parapatellar incision. Anterior to the insertion of the anterior
cruciate ligament on the tibia, the medullary canal was opened. Using an air-
pressured AO minidrill the cortex was penetrated by a small drill (diameter
1.2 mm) and the medullary canal was reamed with drills and fraises up to a
length of at least 25 mm and 3.9 mm in width. The content of the medullary
canal was suctioned and flushed with saline. Prior to insertion of the implant,
the bacterial suspension was introduced in the tibial canal. Subsequently, the
implant (pre-formed cement on a central metal wire, 25 mm in length, 3.9
mm in diameter, Figure 1) was press-fit inserted in the medullary canal. The
joint capsule and skin were closed in layers with Vicryl 3-0.
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Revision of implant
The implant was exchanged 28 days after the first operation. Through the
parapatellar scar the knee joint was opened. The present implant was
removed from the right tibial canal, inoculated on blood agar plates and incu-
bated for 24 hours at 37°C. In addition, medullary tissue samples were
obtained for culture. Subsequently, the canal was debrided and washed with
sterile antibiotic free physiologic saline. In Group 1, tobramycin-containing
bone cement (Simplex P bone cement, premixed with 1.0 g of tobramycin as
a sulphate in 40 g powder, Stryker-Howmedica-Osteonics, Rutherford, NJ)
was inserted in the right tibial medullary canal. In the same manner, plain
Simplex-P bone cement was used in Groups 2 and 3. The animals in Group 3
received also systemic antibiotics (cefazolin, 30 mg/kg, injected subcuta-
neously every 8 hours for 14 days total, from day 28 through day 42). The
rabbits in Group 2 did not receive any form of antibiotic treatment. The bone
cement (precooled at 4°C) was vacuum-mixed for 60 seconds (tobramycin-
containing bone cement) or 100 seconds (plain bone cement) on the surgical
table. Approximately 1.2 ml cement was injected gently into the medullary
canal, while the syringe was slowly being retracted. The exact amount of
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Figure 1. Example of implant used to create an infection.
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injected cement was determined by weighing the syringe containing the
cement. After polymerization of the cement and wound drainage with saline,
the joint capsule and skin were closed in layers with Vicryl 3-0.
Follow-up
The follow-up period after revision surgery was 14 days (42 days after the
first operation). Routine AP and lateral X-rays of the right femur were
obtained after the first operation and before and after revision surgery on day
28. Body weight and body temperature were recorded on a regular basis.
Blood samples from the auricular vein on erythrocyte sedimentation rate
(ESR) and white blood cell counts (WBC) were taken prior to the first opera-
tion and at day 1, 7, 14, 21, 28 (prior to revision), 35 and 42 postoperatively.
The animals were killed with an overdose pentobarbital sodium intravenously.
Autopsy and sample acquisition
After the animals were killed, the skin of the both legs was clipped, disinfec-
ted with povidone-iodine and isolated by sterile drapes. The right and left
(not operated on) tibia were excised and cleaned from soft tissue debris.
First, bone samples were taken from the left tibia from a region correspon-
ding to the right tibia samples. Secondly, the external surface of the right
tibia was notched circumferentially at each end of the shaft and longitudinal-
ly on two sides, posterior and anterior. An osteotome was used to break off
each metaphysis and then to free the medial half of the bone from the lateral
half. Care was taken not to damage the cement.
Bacteriological culture
Both the medial bone half of the right tibia adjacent to the cement plug and
bone from the corresponding region of the left tibia were submitted for quan-
tification of bacteria. The bone samples were homogenized in a sterile phos-
phate buffered saline solution (pH 7.4) using a Polytron tissue grinder
(Kinetica, Best, The Netherlands) and the number of bacteria per gram of
bone was determined by dilution and plating techniques.
PCR hybridization assay
A part of the medial half of the right tibial cortex adjacent to the cement plug
was collected for molecular biological analysis for the presence of bacterial
DNA. These samples were incubated for 18 hours at 60°C in 1.5 ml digestion
buffer (500 mM Tris (pH 9), 20 mM EDTA, 10 mM NaCl, 1% SDS, 0.5 mg/ml
proteinase K) to release total DNA. A volume of 200 µl of the extracted DNA
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was used for DNA isolation the QIAamp Tissue Kit (Qiagen, Hilden,
Germany). The last step in the isolation of the DNA included the elution of
DNA in an end-volume of 400 µl. Subsequently, 2.5 µl of the dissolved DNA
was amplified by the technique described by Wilbrink et al. [Wilbrink, 1998].
Broad range biotin-labeled primers, targeting conserved regions of the gene
for the 16S subunit of ribosomal RNA (16S rRNA), were used to set up an
eubacteria-specific polymerase chain reaction (PCR). An internal spike was
added to screen for possible inhibition of PCR and to reduce the amplification
of contaminating DNA. The presence of S. aureus DNA was determined by
reverse line blot hybridization. We used the reverse line blot hybridization
technique as described by Kaufhold et al. [Kaufhold, 1994]. For this purpose,
we used a genus-specific staphylococcal oligonucleotide probe (5’-AACCTAC-
CTATAAGACTGG-3’) and a species-specific S. aureus oligonucleotide probe
(5’-TCAAAAGTGAAAGACGGTC-3’) which were covalently linked to a mem-
brane (Biodyne C, Pall Biosupport, Portsmouth, UK). Ten microliter of PCR
products were hybridized to the oligonucleotide probes on the membrane for
1 hr at 42 °C, using a miniblotter system (MN45, Immunetics, Cambridge,
MA). Subsequently, nonspecific DNA was washed of the membrane at 55 °C
and the membrane was incubated at 42 °C with Streptavidin-peroxidase
(Boehringer Mannheim Biochemica, Mannheim, Germany). Finally, the pres-
ence of S. aureus DNA could be visualized on a film (Hyperfilm ECL) by using
an enhanced chemoluminescent detection system (ECL, Amersham interna-
tional, Little Chalfont, England).
Statistics
The probability of a positive culture was compared between the three groups
of rabbits using the Fisher’s exact test. Furthermore, to account for inoculum
dose, also a more sophisticated analysis by using a stratified two by two chi-
squared test was performed. One-sided tests were performed for comparison
of each antibiotic group (tobramycin-bone cement and systemic cefazolin)
with the control group. Two-sided tests were performed for comparison of the
two antibiotic groups. A P-value of less than 0.05 was considered significant.
Exact P-values have been computed using the statistical program StatXact 4.
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I Results
General
Three rabbits were lost before the time of revision. Two of these rabbits died
in the first week after the initial operation, the third showed signs of severe
sepsis and was killed in the third postoperative week. In all three rabbits the
culture revealed an overwhelming S. aureus infection at the side of the
implant. All other rabbits had a good recovery from both operations. The
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Figure 2. Lateral radiographs of the right tibia of the same rabbit at day-28,
before (left) and after (right) revision surgery. Periostal reactive bone forma-
tion as a sign of local response to infection is seen in the proximal half of the
tibia. At the time of revision surgery, the implant was removed and bone
cement was injected into the tibial canal after debridement.
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inserted cement (mean ± standard deviation) weighed 0.97±0.17 g in Group
1 (tobramycin cement), 1.03±0.13 in Group 2 (systemic antibiotic), and
1.02±0.16 g in Group 3 (control).
The development of an infection in all rabbits was confirmed at the time of
revision by the presence of pus macroscopically and/or positive cultures of
debrided tissue or the revised implant. The X-rays of all rabbits taken on day
28 all showed clear signs of reactive bone tissue predominantly at the proxi-
mal half of the right tibia, indicating a response to the presence of a local ful-
minant infection at the site of the implant (Figure 2).
No signs of side effects of systemic cefazolin, like diarrhea caused by
pseudomembraneous colitis, were seen in rabbits treated with cefazolin.
No clear differences between the three treatment groups were seen in body
temperature and loss of body weight, ESR and WBC. Table 1 shows the
results of ESR and WBC.
Bacteriological culture
The outcome of cultures is presented in Table 2. Results of culture of the cor-
tex of the right tibia adjacent to the cement (weight 1.03 ± 0.03 g, mean ±
SD) showed a decrease for both antibiotic groups (tobramycin-cement and
systemic cefazolin) in comparison with the control group. Since in both
antibiotic groups most rabbits (7 out of 9 and 8 out of 8, respectively)
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Table 1: Erythrocyte sedimentation rate and white blood cell count
Group of rabbits ESR (mm/hr, mean±SD)
Day 0 Day 7 Day 28 Day 42
Tobramycin 1.3±0.5 42.9±34.7 0.9±0.3 1.3±0.5
Cefazolin 1.1±0.4 35.3±27.2 1.0±0.0 1.1±0.4
Control 1.5±0.5 41.9±26.5 1.6±0.5 1.7±0.7
WBC (x 109/l, mean±SD)
Day 0 Day 7 Day 28 Day 42
Tobramycin 5.5±1.6 13.2±3.5 4.7±0.7 6.7±1.7
Cefazolin 4.2±1.1 10.4±1.2 6.5±2.0 5.8±1.8
Control 4.3±0.7 10.8±1.9 5.8±2.4 6.8±2.3
ESR = erythrocyte sedimentation rate; WBC = white blood cell count
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showed negative culture results, no statistical analysis was performed on the
mean culture results to point out the difference. The rate of infection in both
antibiotic groups was significantly lower than in the control group, p<0.01.
The rate of infection in the tobramycin-cement group was slightly higher
(2/9) but not significantly different from the systemic cefazolin group (0/8),
p = 0.47. When the inoculum dose (105 or 106 CFU) was taken into account,
the statistical analysis also showed significant differences between both
antibiotic groups and the control group, p < 0.01, but no significant differ-
ence between the two antibiotic treatment groups, p = 0.5.
Reverse line blot hybridization assay
No PCR sample at 42 days follow-up was obtained in 6 out of the 27 rabbits
of which culture results were available at that time. Figure 3 shows a detail of
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Figure 3. Details of the film with the results of the reverse line blot hybridization
assay. PCR products of the right tibiae of the rabbits in the three different
treatment groups are oriented in vertical lanes (T = tobramycin group, C =
control group, S = systemic cefazolin group). The oligonucleotides are orient-
ed in horizontal lanes (1 = staphylococci probe, 2 = S. aureus probe, 3 =
internal spike probe). An internal spike was added to all samples to exclude
possible inhibition: The lower lane shows no inhibition in samples that were
negative for staphylococci or S. aureus
Table 2. Outcome of cultures
Group of rabbits Infection rate Culture
(mean ± SD, 10log CFU/g)
Tobramycin 2/9 1.1 ± 2.2
Control 10/10 5.7 ± 1.4
Cefazolin 0/8 0
CFU/g = colony forming units per gram of bone
S C S C T C T S C T S C T S C T S C T
"
"
" 3
1
2
hoofdstuk 11  07-05-2001  13:42  Pagina 154
the film on which the results of the reverse line blot hybridization assay on
samples (weight 0.34 ± 0.12 g, mean ± SD) of the right tibia of the other 21
rabbits are visualized. Table 3 relates the results of the reverse line blot
hybridization assay on these samples to the subsequent culture results.
I Discussion
In the present investigation, we demonstrated that both tobramycin-contain-
ing bone cement and systemic cefazolin reduce size and rate of infection in
the treatment of an infected prosthesis by a one-stage revision procedure in
rabbits, based on the results of bacteriological culture. This model was
designed to mimic a one-stage revision procedure for an infected joint arthro-
plasty, so that a high efficacy of an antibiotic treatment would be required to
clear the infection. We did not incorporate a two-stage revision model in this
study, since our main objective was to test a specific antibiotic-containing
cement. The temporary treatment between removal of the implant and inser-
tion of the cement at a subsequent operation, may be a confounding factor
for this purpose. Furthermore, this model differs from previous efficacy stud-
ies done by us and many other authors, in that the treatment did not start
immediately after inoculation, but after a prolonged time period. This delay
of treatment was introduced to create an established infection with the subse-
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Table 3. Outcome of reverse line blot hybridization 
Culture - Culture +
Tobramycin 2 Tobramycin 0
RLB - Control 0 Control 3
Cefazolin 1 Cefazolin 0
Tobramycin 4 Tobramycin 1
RLB + Control 0 Control 5
Cefazolin 5 Cefazolin 0
The results (in number of rabbits) of the reverse line blot hybridization compared by culture. RLB = reverse line blot hybridization assay; - = negative result; 
+ = positive result.
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quent inflammatory responses and alterations in microcirculation and bone
morphology. Therefore, in comparison with the ‘direct-infection’ models, this
model is more similar to the clinical situation in which antibiotic treatment is
started only after the infection has settled itself.
Only a few studies have addressed an animal model to evaluate the option of
treating an established prosthesis-related infection with antibiotic-containing
bone cement. Fitzgerald showed that gentamicin-containing bone cement
could effectively prevent, but not treat Staphylococcus aureus infections
around injected PMMA in tibiae of dogs [Fitzgerald, 1983]. In three out of
five infections, the one-stage revision failed as a treatment. Gerhart et al.
showed that gentamicin- and/or vancomycin- loaded bone cement had some,
but no absolute efficacy in the treatment of Staphylococcus aureus infections
in 34 rat tibiae, based upon the number of colony-forming units [Gerhart,
1993]. The number of failed treatments however, was not mentioned. The
use of pre-formed cement to create an infection in this model could have
made the removal of the cement easier as compared to the model of
Fitzgerald, who inserted the initial cement in as dough.
In the present study, systemic cefazolin was effective in treating the infection
in rabbits after revision of the implant. Salez-Mghir et al. studied the treat-
ment with either systemic vancomycin or teicoplanin of a tibia implant infec-
tion in rabbits [Saleh Mghir, 1998]. Neither of these antibiotics could fully
clear the infection in the majority of rabbits. In contrast with our study, these
rabbits were inoculated with methicillin-resistant S. aureus and treated only
for one week. Notably, also in contrast with our study, the implants in these
rabbits were not revised before starting treatment, stressing the need for
revising the prosthesis once infected. In present study, systemic antibiotic
treatment was not significantly superior to local antibiotic treatment,
although higher numbers of animals may have revealed such a difference. In
another animal model, tobramycin-containing bone cement could prevent all
infections [Nijhof, 2000b]. In the present study, the same cement could not
fully treat 2 out of 9 infected rabbits. This can be explained by the more
extensive spread of infection at the time of revision, i.e. not restricted only to
the local area around the bone cement. Destruction of the cortex might be
severe, and remaining necrotic tissue some distance from the antibiotic-con-
taining bone cement may cause treatment failure [Fitzgerald, 1983]. In such
a case, it is doubtful whether an antibiotic course of more than two weeks
would have been more successful, although a previous study has shown that
antibiotic elution from tobramycin-containing bone cement could be detected
up to 4 weeks in vivo [Nijhof, 1997]. Clinically, in patients with such an
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extensive implant infection, few surgeons will opt for only local antibiotics.
For this matter, a combination of both antibiotic-containing bone cement and
systemic antibiotic might be optimal: Systemic antibiotics for the wound
problems and bacteria outside the operative area, and antibiotic-containing
bone cement for local, high release of antibiotic. Indeed, this combination of
antibiotic administration was predominantly used in many series reporting on
one-stage revision, although an important early study of Buchholz et al.
reported success rates of 77 to 90 per cent in one-stage revisions mainly with-
out administration of systemic antibiotics [Buchholz, 1981, Loty, 1992, Miley,
1982, Mulcahy, 1996, Salvati, 1982a, Ure, 1998, von Foerster, 1991,
Wroblewski, 1986].
In addition to culture, we have determined the presence of staphylococcal
DNA in the samples of the tibial cortex of the rabbits by means of a reverse
line blot hybridization assay. PCR-based assays like RLB might become valu-
able complements of conventional microbiological techniques, or even
improve diagnostic accuracy [Hoeffel, 1999, Mariani, 1996, Mariani, 1998,
Tunney, 1999]. In 9 out of 12 rabbits with negative culture results, reverse
line blot hybridization showed the presence of S. aureus DNA in the right
tibia, 14 days after treatment with antibiotics (either systemically or with
antibiotic-containing bone cement). Do these reverse line blot hybridization
results demonstrate the sensitivity of DNA-based detection methods, or
should these findings be interpreted as false-positive results based upon the
outcome of culture? The sensitivity of a PCR-based detection method, using
broad range bacterial primers, is at the same time its ‘Achilles heel’: PCR does
not only amplify DNA of viable bacteria, present at the site of the implant,
but also contaminating DNA or small quantities of DNA that can still be pres-
ent shortly after antimicrobial killing of the bacteria. Strict policies in han-
dling the samples should be and have been obtained in this study to exclude
false-positive results due to contamination, either from contaminated
reagents or from previously amplified bacterial DNA products. We think that
the presence of S. aureus DNA as confirmed by the reverse line blot hybridiza-
tion in rabbits with negative culture can be explained to a large extent by
non-viable bacteria after antibiotic treatment. Clearance of all bacterial DNA
after antibiotic treatment may be species specific, but van der Heijden et al.
have shown that it can take up to 26 days after initiation of therapy that PCR
of non-staphylococcal DNA becomes negative in septic joints [van der
Heijden, 1999b]. In a previous animal model we studied the infection pro-
phylaxis with systemic cefazolin or tobramycin-containing bone cement after
inoculation of the rabbit tibia with S. aureus [Nijhof, 2000b]. S. aureus DNA
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could not be detected 7 days after the procedure. These findings may impli-
cate that the clearance of DNA after antibiotic treatment is dependent on bac-
terial load, since in the present model, the therapy was started only after a
full-blown infection had developed. Further studies should be employed to
address the persistence of bacterial DNA after antibiotic treatment, because
DNA-based diagnosis will become increasingly important in the near future
[Rantakokko-Jalava, 2000]. Important clinical decisions based on this type of
diagnosis regarding the continuation of antibiotic therapy, whether systemi-
cally or locally via antibiotic-containing bone cement or beads, will benefit
from more insight on this matter. Furthermore, the viability of microorgan-
isms can be studied using molecular techniques targeting RNA. Reverse tran-
scriptase PCR and nucleic acid sequence amplification (NASBA) have been
used for this purpose [Sheridan, 1998, van der Vliet, 1994]. Both ribosomal
RNA (rRNA) and messenger RNA (mRNA) can be targeted, but rRNA has
been shown to persist longer than mRNA in mycobacteria after chemotherapy
[Hellyer, 1999]. In situ hybridization for staphylococcal 16S rRNA can give
additional information whether the detection of bacterial DNA represents the
presence of the causative organism at the site of an implant or that it is
caused by contamination [Krimmer, 1999].
RLB confirmed the presence of S. aureus DNA in only 6 of the 9 rabbits in
which S. aureus was cultured 14 days after revision. Since we added an inter-
nal spike in the PCR samples, we could exclude inhibition of amplification in
the 3 control rabbits with a negative reverse line blot hybridization result and
a positive culture. These rabbits had a relatively low bacteria load as com-
pared to the 6 rabbits with a positive reverse line blot hybridization result and
positive cultures (respectively 3.8±0.8 and 6.3±0.6, mean 10log CFU/g). The
PCR samples of the three rabbits with negative reverse line blot hybridization
results may have originated from a part of the tibial cortex where infection
was minimal, causing sampling error. Furthermore, the differences between
the weights of the bone samples taken for culture or PCR, and the magnitude
of dilution of the original volumes during the two techniques should be con-
sidered. The amount of a bone used for a PCR sample was approximately 500
times less than that for culture.
It is concluded from the current study that both tobramycin-containing bone
cement and systemic cefazolin used in a one-stage revision for an infected
implant can reduce size and rate of infection. However, in cases of virulent
infections, a combination of systemic and local antibiotics may be necessary
in a one-stage revision procedure. Further studies on the feasibility of PCR-
reverse line blot hybridization are advised.
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Summary and conclusions
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Osteomyelitis and other musculoskeletal infections have a major impact on
the clinical outcome after trauma and surgical procedures. These infections
can be the onset of a prolonged period of illness, hospitalization and disabili-
ty of the patient. The treatment of such infections can be demanding for the
(orthopaedic) surgeon when diagnostic and therapeutic options are limited.
The financial costs involved with this complication certainly form an unwant-
ed and high burden on health care and hospital budgets. The search for new
techniques and products to optimize the prevention and treatment of muscu-
loskeletal infections continues. A multifactorial approach that takes into
account the variety of aspects involved in this clinical entity is required to
achieve the goal of eliminating its development and consequences. This
approach involves the identification of any risk factor that makes the patient
prone to infection and adequate prophylactic measurements. Efficient tech-
niques for detection and imaging of musculoskeletal infections facilitate early
diagnosis and treatment. The (orthopaedic) surgeon will have to choose from
a broad spectrum of products and techniques. Since options are multifold, the
surgeon and other specialists involved should have knowledge about the per-
formance of such techniques or products, so they can choose what is most
appropriate for the specific patient and site and type of infection. Existing
and new tools have to be evaluated in clinical trials, animal experiments and
in vitro studies. This thesis describes studies on the applications of recently
developed techniques for the imaging and detection of musculoskeletal infec-
tions in Part I, and a new premixed tobramycin-containing bone cement for
the prevention and treatment of prosthesis-related infection in Part II.
Chapter 2 introduces the reader to the first part of this thesis on new tools
for diagnosis of musculoskeletal infection. Firstly, several conventional and
nuclear imaging techniques that are available in clinics or recently have been
developed are being discussed in this chapter with regard to their use in mus-
culoskeletal infection. Conventional imaging techniques like radiography,
computed tomography and magnetic resonance imaging can depict anatomic
alterations or water displacement caused by infection. The accuracy of visual-
ization of osteomyelitis depends on time of imaging and possible alterations
in anatomy after trauma, implant surgery or previous infection. Also, image
interpretation of bone scintigraphy can be hampered in previously affected
bone, because prolonged non-infectious uptake of the radiopharmaceutical
technetium-99m-methylene diphosphonate designates the increased bone
turnover in for instance fracture healing. Nuclear imaging modalities like
67Ga-citrate scintigraphy and others that use radiolabeled leukocytes, anti-
bodies, or liposomes show an uptake that is more functional rather than
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anatomically. These techniques seem therefore more suitable for the visuali-
zation of the extent of musculoskeletal infection than the previously men-
tioned. Each scintigraphic imaging technique has its own specific advantages
and disadvantages. These pros and cons depend among others on the mecha-
nism of uptake of the tracer and the localization and nature of the infectious
process. In the last few decades several radiopharmaceuticals have been
developed in order to improve scintigraphic imaging of (musculoskeletal)
infections. These scintigraphic agents should be investigated both pre-clini-
cally and clinically for their performance in the imaging of different muscu-
loskeletal infections at different sites in the body. These studies might provide
better insight in the limitation of each technique, which enables the
(orthopaedic) surgeon and nuclear medicine physician to choose on a more
profound basis the most appropriate imaging technique.
The second part of the introduction in this chapter discusses the promises of
the application of new molecular diagnostic techniques for the detection of
infection in orthopaedic patients. Current available microbiological tech-
niques like bacterial culture have shortcomings concerning speediness and
sensitivity. Some bacterial species encountered in orthopaedics require a con-
siderably prolonged culture time. In addition, some bacteria require specific
growth conditions. Furthermore, other aspects of musculoskeletal infections
can make them more difficult to culture. These include the fact that for the
treatment of orthopaedic infections often multiple and prolonged courses of
antibiotics are needed. Prior or concurrent antibiotic treatment may negative-
ly influence the outcome of culture. Phenotypically reduced growth rates can
also be found in bacteria embedded in biofilms on orthopaedic hardware like
prostheses and fixators, or may be induced by local release of antibiotics from
bone cement. New DNA based detection and identification methods have
been developed, which show promising features that might strengthen our
ability to detect bacterial infections. These tests can be run independently
from specific growth requirements. These tools might also detect pathogens
in a sensitive manner, since the number of copies of bacterial DNA can be
amplified exponentially using the polymerase chain reaction technique.
The diagnosis of musculoskeletal infection will evolve when it can be shown
that new techniques for detection and imaging appear to be useful tools for
this indication. Eventually, some of the dilemmas that one can be confronted
with every now and then in orthopaedics might be solved.
A study on the clinical use of a promising new agent for the imaging of infec-
tion and inflammation is presented in Chapter 3. A retrospective study on
the performance of In-111-labeled human nonspecific IgG (In-111-IgG) was
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performed involving over 200 patients with 232 possible foci of muscu-
loskeletal infection or inflammation. After intravenous administration of a
dose of 75 MBq In-111 labeled to 2 mg IgG (MacroScint), imaging was per-
formed 4, 24, and 48 hours postinjection. The results were verified by cul-
ture, obtained either surgically (42%) or via puncture (19%), and long-term
clinical and roentgenological follow-up (39%). Follow-up data were used in
patients of whom the vast majority had a negative work-up, including nega-
tive In-111-IgG scintigraphy. All infected total hip (THA) and total knee
(TKA) arthroplasties, focal osteomyelitis, diabetic foot infections, septic
arthritis, and soft-tissue infections were detected (61 foci). Only one patient
with early, low-grade spondylodiscitis was false-negative with In-111-IgG.
Since In-111-IgG scintigraphy does not discriminate between infectious and
sterile inflammation, careful interpretation is necessary in cementless THA up
to one year after insertion. Uptake only around the neck of the femoral com-
ponent of a THA, in recent fractures, and in pseudarthrosis are other pitfalls,
since this may be caused by sterile inflammation. The overall specificity for
infection of In-111-IgG scintigraphy is 77%. However, this study indicates
that it might be possible to increase this specificity when the scintigrams are
read in conjunction with radiographs and when particular patterns of
increased uptake caused by sterile inflammatory processes are identified. It
could be concluded that In-111-IgG scintigraphy is a very sensitive tool for
detection of infectious bone and joint disease. Although uptake in inflamma-
tory processes may decrease specificity of In-111-IgG scintigraphy for infec-
tion, specificity for most types of musculoskeletal infection was shown to be
considerable.
In Chapter 4 the performance of two new radiopharmaceuticals, Tc-99m-
PEG-liposomes and Tc-99m-HYNIC-IgG, were evaluated in an experimental
model of chronic osteomyelitis. For comparison, also Tc-99m-MDP, In-111-
granulocytes and Ga-67-citrate were used. Chronic osteomyelitis was induced
in rabbits by inserting S. aureus into the right reamed and washed femoral
canal. The canal was closed with cement. A sham operation was performed
on the left femur. Routine x-rays were obtained immediately after surgery
and prior to scintigraphy. Four weeks after surgery, each rabbit was injected
with 37 MBq Tc-99m-PEG-liposomes, Tc-99m-HYNIC-IgG and Tc-99m-MDP
on three consecutive days, and imaged up to 4 (MDP) or 22 (liposomes and
IgG) hours postinjection. On the fourth day, rabbit received either 18 MBq In-
111-granulocytes or Ga-67-citrate and were imaged up to 44 hours postinjec-
tion. Uptake in the infected femur was determined by drawing regions of
interest. Ratios of infected-to-sham-operated femur were calculated. After the
162
hoofdstuk 12  07-05-2001  13:43  Pagina 162
last image, the rabbits were killed and the left and right femur were scored
for microbiological and histopathological evidence of osteomyelitis. The
results showed that Tc-99m-PEG-liposomes and Tc-99m-HYNIC-IgG correctly
identified all 6 rabbits with osteomyelitis. In-111-granulocytes and Ga-67-cit-
rate gave equivocal results in one infected rabbit. Tc-99m-MDP missed one
case of osteomyelitis. The uptake in the affected region did not differ signifi-
cantly between the agents, although Tc-99m-MDP tended to have somewhat
higher values (MDP 4.75 – 1.23 %ID, Ga-67 2.05 – 0.54 %ID, granulocytes
1.56 – 0.83 %ID, liposomes 1.75 – 0.76 %ID and IgG 1.96 – 0.27 %ID).
The ratios of infected-to-normal femur were also not significantly different
for the respective radiopharmaceuticals. Radiography only visualized severe
osteomyelitis. It could be concluded that in this rabbit model, Tc-99m-PEG-
liposomes and Tc-99m-HYNIC-IgG performed at least as well as In-111-gran-
ulocytes and Ga-67-citrate in the localization of chronic osteomyelitis. The
ease of preparation, the better image quality and the lower radiation dose
suggest that Tc-99m-PEG-liposomes and Tc-99m-HYNIC-IgG might be suit-
able alternatives for Ga-67-citrate and In-111-granulocytes in the scintigraph-
ic evaluation of osteomyelitis.
In Chapter 5, a new DNA based technique for identification of bacterial
pathogens of musculoskeletal infection was explored. This technique, reverse
line blot hybridization (RLB), uses different oligonucleotide probes attached
on a membrane to screen for reactivity on clinical specimens after a broad-
range PCR on the 16S-rRNA gene, present in all bacteria. Species-, genus-
and group-specific oligonucleotide probes were designed that were specific to
bacteria frequently encountered in orthopaedic infections, based on informa-
tion available from public database on the internet. An additional eubacterial
probes screens for other, not specifically identified bacterial species in the
specimen. The aim of this study was to design these oligonucleotide probes,
and, subsequently, to test these for accuracy and clinical feasibility to detect
bacterial PCR products. Amplified DNA from bacterial lysates and from
patient material was used in this study. Correct hybridization signals were
found for most probes, and preliminary tests in patients, mostly with implant
related infections or septic arthritis, indicated promising results of the reverse
line blot technique. Further studies are employed to improve design of some
probes and to optimize hybridization conditions.
Improvement in diagnosis is only one feature involved in the optimization of
patient care in musculoskeletal infection. The evaluation of techniques and
products for use in prevention and treatment of musculoskeletal infection is
an equally important approach for this matter. Chapter 6 introduces Part II
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of this thesis, in which a new tobramycin-containing bone cement is evaluat-
ed for its release of tobramycin in vivo and its efficacy in the prevention and
treatment of prosthesis-related infection in rabbits. Since the introduction of
gentamicin-containing bone cement in the late sixties by Buchholz and subse-
quent other combination of antibiotic and bone cements, the incidence of
total hip prosthesis infection has decreased to a level below 1% and some-
what higher for infection of total knee prostheses. The high and increasing
number of primary joint arthroplasties performed annually (e.g. approxi-
mately 17,000 total hip prostheses in The Netherlands and up to a million
worldwide) makes that continuously effort is warranted to decrease this per-
centage. In numerous hospitals, especially in the United States, tobramycin
powder is hand-mixed with bone cement for the preparation of antibiotic
containing bone cement. The heat-stability of the aminoglycoside tobramycin
favors its use to incorporate it in polymethylmethacrylate (PMMA). The
antimicrobial spectrum of tobramycin includes pathogens like staphylococci
and aerobic Gram-negative bacilli, which are most frequently cultured from
orthopaedic implant infection. Figures in literature on the release of
tobramycin from hand-mixed tobramycin bone cement and the efficacy of
this cement in prosthesis infection underscore the applicability of tobramycin
to add as the antibiotic in bone cement. However, these data are not derived
from uniform studies in which only the same amount of tobramycin is mixed
similarly in one type of bone cement. Pre-mixed tobramycin-containing bone
cement might allow for a standardized preparation with a consistent and con-
trollable quality of the cement. Such a product enables the comparison of
future studies on its efficacy in orthopaedic infections and its biomechanical
behavior, as well as its outcome in in vitro, animal or clinical studies in rela-
tion with other antibiotic-containing bone cements. The second part of this
thesis reports from the first in vivo animal studies on the efficacy of this new
pre-mixed tobramycin-containing bone cement in the prevention and treat-
ment of prosthesis-related infections. This antibiotic-loaded carrier is one of
many local drug delivery systems, available for the management of muscu-
loskeletal infections. An overview is given in Chapter 7.
In the first of a series of studies on tobramycin-containing bone cement,
tobramycin release was evaluated in a rabbit model. After insertion of cement
into the right femur, tobramycin concentration as a function of time for up to
28 days was measured in serum and bone of rabbits. In Chapter 8, the
tobramycin release in the femoral cortex adjacent to the cement was shown
to be exceeding the minimal inhibitory concentration for S. aureus Wood 46.
Serum tobramycin concentrations were below the systemic toxicity threshold.
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The high local antibiotic levels in bone that can be achieved without compro-
mising systemic safety is an important advantage of delivering antibiotic
locally via bone cement. Such high tobramycin concentrations in bone might
also be beneficial considering its concentration dependent antimicrobial
killing, and might kill other pathogens that would be defined as resistant,
based serum susceptibility tests. However, the capacity of bacteria to pheno-
typically alter their growth characteristics with subsequent decreased suscep-
tibility to antimicrobial agents can counterbalance these benefits of antibiotic
bone cement derived antibiotics like tobramycin. Animal and clinical studies
are therefore necessary to assess the value of the use of this new pre-mixed
tobramycin-containing bone cement in orthopaedic implant-related infection.
To perform such an animal study, we evaluated in Chapter 9 the efficacy in
a rabbit model on the performance of the pre-mixed tobramycin-containing
bone cement to prevent prosthesis-related osteomyelitis. After intramedullary
injection with staphylococci, either standard or tobramycin-containing
Simplex-P bone cement was injected in the right femur of 120 rabbits.
Development of infection was examined by culture of femoral bone after 7 or
28 days. Loss of body weight and elevated erythrocyte sedimentation rate in
the control rabbits inoculated with S. aureus were seen in the first post-opera-
tive week, returning to normal in 28 days. Inoculation with S. epidermidis
only resulted in a low-grade infection. All rabbits receiving tobramycin-con-
taining bone cement were free of signs of infection and all their cultures were
negative. Culture yield from S. aureus controls increased with time and inocu-
lum dose. S. epidermidis controls needed higher inoculum doses to establish
an infection, whereas culture yield decreased in time. The results of the study
presented in this chapter showed that pre-mixed tobramycin-containing bone
cement could prevent in this rabbit model osteomyelitis caused by two repre-
sentatives of frequently encountered pathogens in orthopaedic implant-relat-
ed infection. Pre-clinical trials will be needed to ensure that these results will
be translatable to the use of this cement in human. Further studies are also
needed to see whether the use of this or other antibiotic-containing bone
cements are indicated and cost-effective in the prevention of prosthesis infec-
tions, especially in primary arthroplasties.
Currently, a much-preferred mode of antibiotic prophylaxis for orthopaedic
implant surgery is the administration of systemic antibiotics. Cephalosporins
are used widely for this indication. The goal of Chapter 10 was to see
whether systemic cefazolin could demonstrate a similar efficacy as compared
to pre-mixed tobramycin-containing bone cement in the previously presented
prevention model using a high inoculum dose. For this study, we used S.
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aureus in a dose of 106 colony-forming units to inoculate the femur in 18 rab-
bits prior to injection of bone cement. The first group of six rabbits received
tobramycin-containing Simplex-P bone cement. Two other groups of six rab-
bits received plain Simplex-P bone cement. Preoperatively, in one of the two
latter groups cefazolin was administered intravenously. The other group
served as untreated controls. The rabbits were monitored for clinical signs of
infection. At 7 days follow-up, the femora were harvested and cultures from
the bone adjacent to the cement plug were quantified. The reverse line blot
technique, as described in Chapter 5, was used as an additional control to
evaluate the outcome of this study. Cultures from the rabbits which received
antibiotic prophylaxis (either cefazolin systemically or tobramycin-containing
bone cement) were all negative. In contrast, all rabbits in the untreated con-
trol group had positive cultures. These rabbits also had other signs of infec-
tion such as an elevated erythrocyte sedimentation rate and loss of body
weight. Culture results were confirmed by the absence of bacterial DNA in the
PCR hybridization assay. In conclusion, we found that both tobramycin-con-
taining bone cement and systemic cefazolin are effective in preventing
implant bed infection in rabbits up to 7 days after contamination with S.
aureus.
Another major indication for the use of pre-mixed tobramycin-containing
bone cement can be expected to be its use for the treatment of an already
established osteomyelitis, e.g. after revision of an infected prosthesis. A revi-
sion arthroplasty can be performed in a one- or two-stage procedure. The lat-
ter involves an additional period in which the implant bed is allowed to
recover from the infection under antibiotic treatment. Whereas the one-stage
procedure certainly has some advantages like less morbidity and initial lower
costs, a higher risk of re-infection may decrease its cost-effectiveness in the
long term. Thus, the indications for a one-stage procedure have yet to be
refined, but this procedure seems to be a good option for evaluating new
antimicrobial treatments in animal studies. Not only may it require a higher
treatment efficacy of the treatment under investigation, but it is also limited
by fewer confounding factors when compared with the two-stage procedure.
Therefore, a one-stage revision model was used in Chapter 11 to study the
efficacy of tobramycin-containing bone cement as compared to that of sys-
temic cefazolin for treatment of an infected implant. In addition, the value of
detecting bacterial DNA after antibiotic treatment was investigated. An
implant was inserted into the right tibia of rabbits after inoculation with
S.aureus. At 28 days, the implant was removed. Subsequently, either plain
bone cement with or without systemic administration of cefazolin, or
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tobramycin-containing bone cement was injected into the medullary canal.
The tibiae were cultured fourteen days after revision (day 42) and showed a
significant decrease in bacterial counts for both antibiotic groups compared
with the control group (p†0.05). The rate of infection in the tobramycin-
cement group was slightly higher (2/9) than in the cefazolin group (0/8)
although the difference was not significant. Persistence of bacterial DNA after
antibiotic treatment may be the result of delayed clearance of DNA and not a
sign of active infection. This animal model shows that in a one-stage revision
tobramycin-containing bone cement can reduce size and rate of infection,
although systemic cefazolin may be more efficacious. Therefore, the use of
antibiotic-containing bone cement combined with systemic antibiotic might
provide optimal treatment.
The clinical entity of musculoskeletal infection cannot be approached unidi-
rectionally. The consequence of the multifactorial aspect of osteomyelitis and
related infections is that the problems it confronts the orthopaedic surgeon
and his colleagues with should be tackled from different directions. An early
recognition of the development and extent of musculoskeletal infection is
vital to its outcome and the prevention of subsequent complications. New
techniques and products aiming for improvements in diagnosis, prevention
and treatment of musculoskeletal infections are directed to provide standard-
ized efficacious tools available for patient care in this clinical setting. Because
of the complex nature of this infectious disorder, single studies like those pre-
sented in this thesis will not be sufficient to prove the efficacy of the new
developments in all its facets. Continuous efforts in the evaluation of such
new tools and those that are already in clinical use will be needed. Thus, a
decrease in incidence and consequences of musculoskeletal infections is and
should be an ongoing strive for both clinicians and researches involved in this
subject.
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Samenvatting en conclusies
Osteomyelitis en andere infecties van het steun- en bewegingsapparaat kun-
nen het klinisch beloop na trauma en chirurgie in belangrijke mate be nvloe-
den. Deze infecties resulteren soms in een lange periode van ziek zijn, zieken-
huisopname en lichamelijk ongemak. Beperkte diagnostische en
therapeutische mogelijkheden kunnen de behandeling van deze infecties tot
een opgave maken voor de (orthopaedisch) chirurg. Daarbij komt dat deze
complicatie ook een zware financi le last is voor de huidige gezondheidszorg
en een aanslag vormt op het ziekenhuisbudget. Onderzoek naar nieuwe tech-
nieken en middelen om te komen tot optimalisatie van de preventie en
behandeling van infecties van het steun- en bewegingsapparaat blijft noodza-
kelijk. Hierbij is een multifactori le aanpak vereist die rekening houdt met de
verschillende aspecten van deze klinische entiteit. Deze benadering houdt
onder andere in het identificeren van de verschillende risicofactoren die
bepalend zijn voor het ontstaan van infectie en de daaruit volgende adequate
prophylactische maatregelen. Effici nte opsporing- en afbeeldingstechnieken
van genoemde infecties faciliteren een vroege diagnose en behandeling. De
(orthopaedisch) chirurg zal moeten kiezen uit een breed scala aan producten
en technieken om te komen tot een optimale behandelingsstrategie. Kennis
van de mogelijkheden en effectiviteit van elk van deze draagt bij tot het vin-
den van de meest geschikte strategie voor de specifieke pati nt, lokalisatie en
type van de infectie. Bestaande en nieuwe technieken dienen te worden ge -
valueerd in klinische studies, dierexperimenten en in vitro studies. Dit proef-
schrift beschrijft studies naar de toepassing van recent ontwikkelde tech-
nieken voor het opsporen en afbeelden van infecties van het steun- en
bewegingsapparaat in Deel I, en een nieuw tobramycine-houdend botcement
voor de preventie en behandeling van prothese-gerelateerde infecties in Deel II.
Hoofdstuk 2 is een inleiding op het eerste deel van dit proefschrift over
nieuwe technieken in de diagnostiek van infecties van het steun- en beweg-
ingsapparaat. Verschillende conventionele en nucleaire technieken waarmee
deze infecties kunnen worden afgebeeld worden hier besproken.
Conventionele technieken, zoals radiografie, CT en MRI kunnen anatomische
veranderingen of waterverplaatsing door infectie afbeelden. De accuratesse
waarmee osteomyelitis kan worden afgebeeld hangt af van de duur van de
infectie en de eventuele verstoorde anatomie ten gevolge van trauma,
implantaat-chirurgie of eerdere infectie. Ook de interpretatie van skeletscinti-
grafie kan worden belemmerd indien het bot voorafgaand aan de infectie
reeds aangetast was, omdat een toegenomen technetium-99m-methylene
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diphosphonaat stapeling ten gevolge van een verhoogd botmetabolisme
bijvoorbeeld ook wordt gezien in/na een niet-ge nfecteerde fractuur.
Nucleaire technieken zoals 67Ga-citraat scintigrafie en radiogelabelde leuko-
cyten, antilichamen, of liposomen laten een meer functioneel dan anatomis-
che bepaalde verhoogde stapeling zien. Daarom is het met deze technieken,
beter dan met de conventionele, mogelijk om de uitgebreidheid van infec-
tieuze processen aan te tonen. Elke scintigrafische techniek heeft zijn eigen
specifieke voor- en nadelen in deze, afhankelijk van het mechanisme van
stapeling van de tracer, en van de lokalisatie en eigenschappen van de infec-
tie. In de laatste decennia zijn er verschillende radiofarmaca ontwikkeld om
te komen tot verbeterde diagnostiek van infecties. Deze radiofarmaca moeten
zowel klinisch als pre-klinisch ge valueerd worden om te komen tot gefun-
deerde inzichten in de mogelijkheden en beperking van elke middel, op basis
waarvan de (orthopaedisch) chirurg en nucleair geneeskundige de meest
ge igende afbeeldingstechniek kunnen aanwenden.
Het tweede deel van de introductie in hoofdstuk 2 behandelt de toepass-
ingsmogelijkheden van nieuwe moleculair diagnostische technieken voor het
opsporen van orthopaedische infecties. Huidige conventionele technieken
zoals het kweken van bacteri n zijn niet optimaal, met name wat betreft snel-
heid en sensitiviteit. De groei van sommige bacterie-species die genoemde
infecties kunnen veroorzaken is langzaam of stelt bijzondere eisen aan de
kweekcondities. Ook door andere factoren kan het moeilijk zijn de verwekker
van orthopaedische infecties aan te tonen door middel van kweek, zoals het
feit dat voor de behandeling van deze infecties vaak meerdere en langdurige
antibioticakuren nodig blijken te zijn. Dit kan de uitkomst van latere kweken
negatief be nvloeden. Een fenotypisch verminderde groeiactiviteit wordt ook
gezien in bacteri n die zich hebben ingenesteld in een biofilm op
orthopaedische prothesen of osteosynthesemateriaal, maar kan ook zijn ge n-
duceerd door lokaal afgifte van antibiotica uit botcement. Er zijn nieuwe
DNA-technieken voor het aantonen en identificeren van bacteri le infecties
beschikbaar die de diagnostiek in deze mogelijk kunnen verbeteren. Een
belangrijk aspect hierbij is dat deze technieken niet afhankelijk zijn van speci-
fieke groeicondities. Mogelijk kan de sensitiviteit van de diagnostiek ook
toenemen omdat middels de polymerase ketting reactie eventueel aanwezig
bacterieel DNA exponentieel kan toenemen. 
De diagnostiek van infecties van het steun- en bewegingsapparaat zal ver-
beteren indien door middel van onderzoek kan worden aangetoond dat
nieuwe detectie- en afbeeldingstechnieken hiervoor bruikbare instrumenten
blijken te zijn. 
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In Hoofdstuk 3 wordt een studie beschreven van een recent ontwikkeld
radiofarmacon voor het scintigrafisch afbeelden infectie- en ontstekingshaar-
den. Hiertoe werd een retrospectieve studie verricht naar de performance
van In-111-labeled human nonspecific IgG (In-111-IgG) in meer dan 200
pati nten met 232 mogelijke infectie- of ontstekingshaarden. Na intra-
veneuze toediening van 75 MBq In-111 gelabeld aan 2 mg IgG werden op 4,
12 en 48 uur na injectie opnames gemaakt. De resultaten hiervan werden
geverifieerd aan de hand van kweekuitslagen van peroperatief (42%) of via
punctie (19%) afgenomen weefsel, en door lange klinische en r ntgenologis-
che follow-up (39%). Deze laatste gegevens werden gebruikt in pati nten
waarvan in het merendeel geen infectie werd afgebeeld, ook niet middels In-
111-IgG scintigrafie. Alle ge nfecteerde totale heup of knieprothesen, focale
osteomyelitiden, diabetische voet infecties, septische arthritiden en weke
delen infecties werden scintigrafisch afgebeeld. E n pati nt met een laaggra-
dige spondylodiscitis had een vals-negatief resultaat na In-111-IgG scinti-
grafie. Het is belangrijk om de uitkomst van de In-111-IgG scintigrafie goed
te interpreteren bij niet-gecementeerde heuparthroplastieken, vooral tot n
jaar na plaatsing, omdat met deze techniek discriminatie tussen infectie en
ontsteking in principe niet mogelijk is. Verhoogde stapeling rond de hals van
een totale heupprothese, in recente fracturen en pseudarthrosen is een
andere valkuil, omdat dit ook veroorzaakt kan zijn door steriele ontsteking.
De specificiteit van In-111-IgG scintigrafie is 77% voor de totale groep pati n-
ten. Deze studie wijst echter aan dat het mogelijk is deze specificiteit te ver-
hogen wanneer de scintigrafische afbeeldingen wordt gelezen in samenhang
met de r ntgenologische en wanneer bepaalde patronen van verhoogde
stapeling worden ge dentificeerd als specifiek voor steriele ontsteking.
Geconcludeerd kon worden dat In-111-scintigrafie een sensitieve techniek is
voor het opsporen van bot- en gewrichtsinfecties. Hoewel stapeling in inflam-
matoire processen de specificiteit van In-111-IgG voor infectie kan verlagen,
was de specificiteit voor de meest typen van infecties van het steun- en
bewegingsapparaat aanzienlijk. 
In Hoofdstuk 4 worden twee nieuwe radiofarmaca, te weten Tc-99m-PEG-
liposomen and Tc-99m-HYNIC-IgG, ge valueerd in een experimenteel model
van chronische osteomyelitis. Ter vergelijking werden ook Tc-99m-MDP, In-
111-granulocyten en Ga-67-citraat gebruikt. Chronische osteomyelitis werd
opgewekt in konijnen door S. aureus te injecteren in de mergholte van het
rechter femur, en deze holte te sluiten met cement. Het linker femur werd
gebruikt als controle (geen inoculatie). Standaard r ntgenfoto s werden
gemaakt aansluitend aan de operatie en voorafgaand aan de scintigrafie
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opnames. Vier weken na de operatie kreeg elk konijn 37 MBq Tc-99m-PEG-
liposomen, Tc-99m-HYNIC-IgG en Tc-99m-MDP toegediend op drie
achtereenvolgende dagen, waarna afbeeldingen werden vervaardigd tot 44
uur na de injectie van de radiofarmaca. Stapeling in het ge nfecteerde femur
werd vergeleken met die in het controle femur. Na de laatste opname werden
de konijnen gedood en beide femora gescoord op microbiologische en histol-
ogische tekenen van osteomyelitis. Tc-99m-PEG-liposomen en Tc-99m-
HYNIC-IgG identificeerden alle zes konijnen met osteomyelitis correct. De
afbeeldingen vervaardigd met In-111-granulocyten en Ga-67-citraat waren
moeilijk te interpreteren in n ge nfecteerd konijn. Tc-99m-MDP miste n
geval van osteomyelitis. De stapeling in het aangedane gebied verschilde niet
significant tussen de radiofarmaca, hoewel Tc-99m-MDP meestal wat hogere
opname liet zien (MDP 4,75 – 1,23 %ID, Ga-67 2,05 – 0,54 %ID, granulo-
cyten 1,56 – 0,83 %ID, liposomen 1,75 – 0,76 %ID en IgG 1,96 – 0,27
%ID). De ratio s van opname in ge nfecteerde femora ten opzichte van con-
troles verschilden ook niet significant voor de respectievelijke radiofarmaca.
Alleen ernstige infecties waren zichtbaar op r ntgenfoto s. Geconcludeerd
werd dat in dit konijnenmodel Tc-99m-PEG-liposomen en Tc-99m-HYNIC-IgG
op zijn minst net zo goed presteerden als In-111-granulocyten en Ga-67-cit-
raat in het localiseren van chronische osteomyelitis. Het gemak van de
preparatie van het radiofarmacon, de betere afbeeldingskwaliteit en de lagere
stralingsdosis suggereren dat Tc-99m-PEG-liposomen en Tc-99m-HYNIC-IgG
goede alternatieven zijn voor Ga-67-citraat en In-111-granulocyten om
osteomyelitis scintigrafisch te evalueren. 
In Hoofdstuk 5 wordt een nieuwe DNA-techniek voor het identificeren van
bacteri le pathogenen van infecties van het steun- en bewegingsapparaat
beschreven. Deze techniek, de zogenaamde reverse line blot hybridisatie
(RLB), maakt gebruikt van verschillende oligonucleotide probes die gekop-
peld zijn aan een membraan. Eventuele reactiviteit met geamplificeerd DNA,
na een algemene 16S PCR gericht op het 16S-rRNA gen dat aanwezig is in
alle bacteri n, wordt hiermee getest. Species- genus- en groep-specifieke
oligonucleotide probes, gericht op veel voorkomende bacteri n in
orthopaedische infecties, werden ontworpen. Hiertoe werd gebruik gemaakt
van informatie uit publieke databases op het internet. Een extra eubacteri le
probe screent ook op andere, niet specifiek ge dentificeerde bacteri n in het
preparaat. Het doel van deze studie was het testen op accuratesse van deze
techniek en de mogelijkheid om dit toe te passen op klinische monsters.
Geamplificeerd DNA van bacteri le lysaten en van pati nten monsters wer-
den hiertoe gebruikt. De meest probes gaven een juist hybridisatie signaal en
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eerste klinische resultaten in pati nten met vooral implantaat-gerelateerde
infecties of septische arthritis zijn veelbelovend. Nadere studies worden
opgezet om te komen tot een verbeterd ontwerp van sommige probes en een
optimalisatie van hybridisatie condities.
Verbetering van de mogelijkheden tot het stellen van de diagnose is slechts
n aspect van het optimaliseren van de zorg voor de pati nt met een infectie
van het steun- of bewegingsapparaat. Net zo belangrijk is het evalueren van
technieken en producten gebruikt in de preventie en behandeling van deze
infecties. 
Hoofdstuk 6 introduceert Deel II van dit proefschrift, waarin een nieuw
tobramycine-houdend botcement wordt ge valueerd op de afgifte van
tobramycine in vivo en zijn werkzaamheid in de preventie en behandeling
van prothese-gerelateerde infecties in konijnen. Sinds de invoering van gen-
tamicine-houdend botcement eind jaren zestig (Buchholz) en andere antibi-
oticum-botcement combinaties, is de incidentie van totale heupprothese
infecties gedaald tot onder de 1%. Voor totale knieprothese infecties ligt de
incidentie iets hoger. Het grote en toenemende aantal primaire heuparthro-
plastieken dat jaarlijks wordt uitgevoerd (jaarlijks ongeveer 17.000 totale
heupprotheses in Nederland en tot een miljoen wereldwijd) noopt tot een
continue aandacht voor het terugdringen van infecties. In een groot aantal
ziekenhuizen, met name in de V.S., wordt tobramycine-poeder met de hand
vermengd met botcement om een antibioticum-houdend botcement te
maken. Het aminoglycoside tobramycine is hittebestendig, waardoor het
geschikt is om te gebruiken in polymethylmethacrylaat (PMMA). Het antimi-
crobi le spectrum van tobramycine omvat pathogenen als staphylococcen en
aerobe Gram-negatieve bacillen, welke de meest frequente verwekkers zijn
van orthopaedische implantaat infecties. Cijfers in de literatuur over de
afgifte van tobramycine uit handmatig gemengd tobramycine-houdend botce-
ment en de werkzaamheid van dit cement in prothese infecties onderschri-
jven de toepassingsmogelijkheid van het toevoegen van tobramycine in
botcement. Deze cijfers komen echter niet van uniforme studies waarin een
gelijke hoeveelheid tobramycine is vermengd met n type botcement. Een
gestandaardiseerd product van een consistente kwaliteit zou kunnen worden
verkregen door een voor-vermengd tobramycine-houdend cement van een
constante en controleerbare kwaliteit. Zo n product laat vergelijkingen toe
van toekomstige studies naar de werkzaamheid van dit cement in
orthopaedische infecties en zijn biomechanische gedrag, en bovendien van
uitkomsten uit in vitro, dier- of klinische studies in relatie tot andere antibi-
oticum-botcement combinaties. Deel II van dit proefschrift beschrijft de
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eerste in vivo dierexperimenten naar de werkzaamheid van dit nieuwe voor-
vermengde tobramycine-houdend botcement in de preventie en behandeling
van prothese-gerelateerde infecties. 
Antibioticum-houdend botcement is een van de vele systemen die voor de
behandeling van infecties van het steun- en bewegingsapparaat beschikbaar
zijn, waarmee lokaal antimicrobi le middelen kunnen worden afgegeven.
Hoofdstuk 7 geeft hiervan een overzicht.
In de eerste van een serie studies omtrent tobramycine-houdend botcement
werd de afgifte van tobramycine ge valueerd in een diermodel. Na het
inspuiten van tobramycine-houdend botcement werd de tobramycineconcen-
tratie als functie van tijd tot en met 28 dagen gemeten in serum en bot.
Hoofdstuk 8 laat zien dat de afgifte van tobramycine in de cortex van het
femur de MIC waarde voor S. aureus Wood 46 overstijgt. De tobramycine-
concentraties in het serum lagen onder de systemische toxiciteitsdrempel. De
hoge locale antibioticum-concentratie die kan worden bereikt in bot, zonder
de systemische toxiciteitsdrempel te overschrijden, vormt een belangrijk
voordeel van de locale toediening van antibiotica via botcement. Zulke hoge
tobramycine-concentraties in het bot kunnen ook een gunstig effect hebben
op de antimicrobi le werking, aangezien deze dosis afhankelijk is. Mogelijk is
het antibioticum dan ook werkzaam tegen resistente (gebaseerd op serum-
concentraties) bacteri n.  Echter, het vermogen van bacteri n om fenotypisch
hun groei aan te passen, resulterend in een verlaagde gevoeligheid antibioti-
ca, kan de voordelen van het antibioticum-houdend botcement tenietdoen.
Klinische studies en dierexperimenten zijn daarom nodig om de waarde van
het gebruik van het nieuwe voor-vermengde tobramycine-houdende botce-
ment in orthopedische, implantaatgerelateerde infecties te bepalen.
Door middel van dierexperimenteel onderzoek is in Hoofdstuk 9 de werking
van het nieuwe tobramycine-houdend botcement ten aanzien van prothese-
gerelateerde osteomyelitis ge valueerd. Na intramedullaire injectie met stafy-
lococcen, werd zowel standaard botcement als tobramycine-houdend
Simplex-P botcement ge njecteerd in de rechter femur van 120 konijnen.  Na
zeven of 28 dagen werd door middel van kweken onderzocht of er een infec-
tie was ontstaan in het femur-bot. In de eerste week na de operatie werd in
de S. aureus controlegroep gewichtsverlies en een verhoogde bezinkingssnel-
heid van erythrocyten gemeten. Na 28 dagen was de toestand bij deze groep
weer normaal. Inoculatie met S. epidermidis leidde slechts tot een geringe
infectie. Geen van de konijnen die tobramycine-houdend botcement kregen,
toonde tekenen van infectie. Ook hun kweken bleven negatief. Kweken van
de S. aureus controlegroep namen toe in de tijd en waren afhankelijk van de
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toegediende dosis. Konijnen uit de S. epidermidis groep hadden hogere doses
nodig om een infectie tot stand te brengen en kweken van deze groep namen
af in de tijd. De resultaten in hoofdstuk 9 laten zien dat tobramycine-
houdend botcement in dit diermodel osteomyelitis kan voorkomen wanneer
sprake is van S. aureus of S. epidermidis, ziektekiemen die regelmatig
voorkomen bij implantaat-gerelateerde infecties. Toekomstige studies moeten
aantonen of deze resultaten ook gelden bij gebruik van dit cement in de klin-
iek. Nadere evaluatie is ook gewenst om na te gaan of antibioticum-houdend
botcement doeltreffend en kosteneffectief is ten aanzien van de preventie van
prothese-infecties, met name bij primaire arthroplastieken.
Een veelgebruikte methode van infectiepreventie bij orthopedische implan-
taatchirurgie is de toediening van systemische antibiotica, zoals cefalospori-
nen. Het doel van de studie in Hoofdstuk 10 was na te gaan of systemisch
cefazolin, eenzelfde effect ten toon kon spreiden als tobramycine-houdend
botcement in het eerder gepresenteerde diermodel, wanneer een hoge inocu-
lum dosis (S. aureus, 106 cfu) werd gebruikt. S. aureus werd voorafgaand
aan de toediening van cement ingebracht in het femur van 18 konijnen. De
eerste groep van zes konijnen kreeg tobramycine-houdend Simplex P-botce-
ment. Twee andere groepen van zes konijnen kregen gewoon Simplex-P
botcement. Pre-operatief werd in een van de twee laatste groepen cefazolin
intraveneus toegediend. De andere groep gold als onbehandelde controle-
groep. De konijnen werden onderzocht op klinische verschijnselen van infec-
tie. Na zeven dagen werden de femora verwijderd en de cortex rond de
cementplug gekweekt, waarna de groei werd gekwantificeerd. De reverse line
blot techniek, zoals beschreven in hoofdstuk 5, werd ingezet als extra con-
trolemiddel bij de evaluatie van de resultaten van deze studie. De kweken
van konijnen die antibiotische profylaxe kregen (systemisch cefazolin of
tobramycine-houdend botcement), waren allemaal negatief. Daarentegen
waren de kweken van alle konijnen uit de onbehandelde groep positief. Deze
konijnen vertoonden ook andere tekenen van infectie, zoals gewichtsverlies
en een verhoogde bezinkingssnelheid van de erythrocyten. De kweekresultat-
en werden bevestigd door de afwezigheid van DNA in de PCR-hybridisatie
assay. Dus zowel tobramycine-houdend botcement als systemisch cefazolin is
effectief in het voorkomen van implantaatbed infecties in konijnen tot zeven
dagen na besmetting met S. aureus.
Een andere belangrijke indicatie voor het gebruik van tobramycine-houdend
botcement kan een reeds ontstane osteomyelitis zijn, bijvoorbeeld na revisie
van een ge nfecteerde prothese.  Een prothese kan gereviseerd worden in een
of twee fases. Een revisie in twee fases omvat een extra periode waarin het
175
CHAPTER 12  I  SUMMARY AND CONCLUSIONS
hoofdstuk 12  07-05-2001  13:43  Pagina 175
implantaatbed de tijd krijgt om te herstellen van de infectie door behandeling
met antibiotica. Hoewel directe revisie duidelijke voordelen heeft, zoals een
lagere morbiditeit en lagere kosten op de korte termijn, is er een hogere kans
op hernieuwde infectie en daarmee hogere kosten op de langere termijn.
Indicaties voor deze procedure moeten dus worden verfijnd. Deze techniek,
toegepast in een proefdiermodel, lijkt een goede optie om nieuwe antimicro-
bi le behandelingen te bestuderen. Dit zou een goede werkzaamheid van de
te onderzoeken behandeling vergen. Een voordeel is dat het model,
vergeleken met een revisie in twee fasen, minder wordt belemmerd door
storende variabelen. Daarom is in Hoofdstuk 11 een revisie in een fase
gekozen als opzet van een studie naar de effectiviteit van tobramycine-
houdend botcement in vergelijking tot systemische cefazolin bij de behandel-
ing van ge nfecteerde implantaten. Tevens werd  de waarde van de detectie
van bacterieel DNA na behandeling met antibiotica onderzocht. In de rechter
tibia van konijnen werd, na inoculatie met S. aureus, een implantaat inge-
bracht. Na 28 dagen werd het implantaat verwijderd. Vervolgens werd zowel
normaal botcement, met of zonder systemische toediening van cefazolin, of
tobramycine-houdend botcement ingebracht in de mergholte.  De tibiae wer-
den veertien dagen na de revisie (dag 42) gekweekt. De kweken toonden
voor beide antibiotische groepen een significante afname in bacteriegroei
vergeleken met de controlegroep (p<0,05). De mate van infectie in de
tobramycine-cement groep was enigszins, maar niet significant, hoger (2/9)
dan in de cefazolin groep (0/8). De aanwezigheid van bacterieel DNA na
behandeling met antibiotica zou kunnen duiden op een vertraagde opruiming
van DNA in plaats van op een actieve infectie. Dit diermodel laat zien dat
tobramycine-houdend botcement de grootte en mate van infectie kan reduc-
eren na een revisie in n fase, hoewel systemisch cefazolin mogelijk effec-
tiever is. Het gebruik van antibioticumhoudend botcement gecombineerd met
systemische antibiotica zou mogelijk aangewezen kunnen zijn indien een vir-
ulente infectie wordt behandeld met deze techniek.
De klinische entiteit van infecties van het steun- en bewegingsapparaat kan
niet eenzijdig worden benaderd. Omdat osteomyelitis en gerelateerde infec-
ties multifactorieel zijn, moeten de problemen die het schept voor de
orthopaedisch chirurg en zijn collegae vanuit verschillende invalshoeken wor-
den benaderd. Een vroegtijdige herkenning van de ontwikkeling en de uit-
breiding van een infectie van het steun- en bewegingsapparaat is van cruciaal
belang voor het verloop van de infectie en ter voorkoming van eventuele
complicaties. Nieuwe middelen en technieken gericht op het verbeteren van
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de diagnose, preventie en behandeling van infecties van het steun- en beweg-
ingsapparaat worden ontwikkeld om te voorzien in gestandaardiseerde doel-
treffende instrumenten voor de zorg van pati nten met deze aandoening.
Vanwege de complexe aard van deze infecties zijn de afzonderlijke studies,
zoals beschreven in dit proefschrift, niet afdoende om de doeltreffendheid
van nieuwe ontwikkelingen in alle facetten te bewijzen. De evaluatie van
dergelijke nieuwe middelen vergt continu nader onderzoek. Een afname van
het aantal infecties van het steun- en bewegingsapparaat en de gevolgen
daarvan is en zal dan ook een voortdurend streven moeten zijn van eenieder
betrokken bij dit onderwerp.
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